Economic Evaluations publications

2019

2019

  • Alexander H, Jabbar-Lopez Z, Patton T, Manca A, Flohr C. Novel systemic therapies in atopic dermatitis: are we getting excited too early? F1000Research 2019;8(F1000 Faculty Rev):132. Download from F1000
  • Arnold MGriffin SOchalek JRevill PWalker S. A one stop shop for cost-effectiveness evidence? Recommendations for improving Disease Control Priorities. Cost Effectiveness and Resource Allocation 2019;17:7. Download from BMC 
  • Arnold M, Pfeifer K, Quante AS. Is risk-stratified breast cancer screening economically efficient in Germany? PLoS ONE 2019;14(5):e0217213. Download from plosone
  • Barbosa E, Cookson R. Multiple inequity in health care: An example from Brazil. Social Science & Medicine 2019 May;228:1-8. Download from ScienceDirect
  • Beresford B, Mann R, Parker G, Kanaan M, Faria R, Rabiee P, Weatherly H, Clarke S, Mayhew E, Duarte A, Laver-Fawcett A, Aspinal F. Reablement services for people at risk of needing social care: the MoRe mixed-methods evaluation. Health Services and Delivery Research 2019;7(16). Download from NIHR
  • Bórquez A, Guanira JV, Revill P, Caballero P, Silva-Santisteban A, Kelly S et al. The impact and cost-effectiveness of combined HIV prevention scenarios among transgender women sex-workers in Lima, Peru: a mathematical modelling study. The Lancet Public Health 2019;4(3):e127-e136. Download from The Lancet
  • Cambiano V, Johnson C, Hatzold K, Terris-Prestholt F, Haheswaran H, Thirumurthy H, Figueroa C, Cowan F, Sibanda E, Ncube G, Revill P et al. The impact and cost-effectiveness of community-based HIV self-testing in sub-Saharan Africa. A health economic and modelling analysis. Journal of the International Aids Society 2019;22(S1):e25243. Download from Wiley
  • Chetter I, Oswald A, McGinnis E, Stubbs N, Arundel C, Buckley H, Bell K, Dumville J, Cullum N, Soares MSaramago P. Patients with surgical wounds healing by secondary intention: A prospective, cohort study. International Journal of Nursing Studies 2019;89:62-71. Download from ScienceDirect
  • Claxton K, Asaria M, Chansa C, Jamison J, Lomas JOchalek J, Paulden M. Accounting for timing when assessing health-related policies. Journal of Benefit-Cost Analysis 2019;10(S1):73-105. Download from Cambridge UP
  • Conner M, Grogan S, West R, Simms-Ellis R, Scholtens K, Sykes-Muskett B, Cowap L, Lawton R, Armitage C, Meads D, Schmitt L, Togerson C, Siddiqi, K. Effectiveness and cost-effectiveness of repeated implementation intention formation on adolescent smoking initiation: A cluster randomized controlled trial. Journal of Consulting and Clinical Psychology 2019;87(5):422-432. Download from APA    
  • Cox E, Wade R, Peron M, Dietz KC, Eastwood A, Palmer S, Griffin S. The clinical and cost-effectiveness of Inotuzumab Ozogamicin for the treatment of adult relapsed or refractory B-cell acute lymphoblastic Leukaemia: An evidence review group evaluation of a NICE single technology appraisal. PharmacoEconomics 2019;doi:10.1007/s40273-019-00779-4. Download from Springer
  • Drummond MF, Neumann P, Sullivan S, Fricke FU, Tunis S et al. Analytic considerations in applying a general economic evaluation reference case to gene therapy. Value in Health 2019;22(6):661-668. Download from Elsevier
  • Drummond MF, Towse A. Is rate of return pricing a useful approach when value-based pricing is not appropriate? European Journal of Health Economics 2019;doi:10.1007/s10198-019-01032-7. Download from Springer 
  • Emerson J, Panzer A, Cohen JT, Chalkidou K, Teerawattananon Y, Sculpher M et al. Adherence to the iDSI reference case among published cost-per-DALY averted studies. PLoS ONE 2019;14(5):e0205633. Download from Plosone
  • Franklin M, Lomas JWalker S, Young T. An educational review about using cost data for the purpose of cost-effectiveness analysis. PharmacoEconomics 2019:37(5):631-643. Download from Springer
  • Gabrio A, Baio G, Manca A. Bayesian statistical economic evaluation methods for Health Technology Assessment. In Jones AM, editor. Oxford Research Encyclopedia of Economics and Finance. Oxford: Oxford University Press. 2019. Download from OUP
  • Garrison LP, Jansen J, Devlin N, Griffin S. Novel approaches to value assessment within the cost-effectiveness framework. Value in Health 2019;22(6):S12-S17. Download from Value in Health
  • Gc VS, Alshurafa M, Sturgess DJ, Ting J, Gregory K, Oliveira Gonçalves AS et al. Cost-minimisation analysis alongside a pilot study of early Tissue Doppler Evaluation of Diastolic Dysfunction in Emergency Department Non-ST Elevation Acute Coronary Syndromes (TEDDy-NSTEACS). BMJ Open 2019;9(5):e023920. Download from BMJ
  • Gridley K, Aspinal F, Parker G, Weatherly HFaria RLongo F, van den Berg B. Specialist nursing support for unpaid carers of people with dementia: a mixed-methods feasibility study. Health Serv Deliv Res 2019;7(12). Download from NIHR
  • Griffin SLove-Koh J, Pennington B, Owen L. Evaluation of intervention impact on health inequality for resource allocation. Medical Decision Making 2019;39(3):171-182. Download from Sage
  • Hinde SBojke L, Harrison AS, Doherty PJ. Improving cardiac rehabilitation uptake: Potential health gains by socioeconomic status. European Journal of Preventive Cardiology 2019;doi:10.1177/2047487319848533. Download from Sagepub
  • Hinde S, Setters J, Bojke L, Hex N, Richardson G. Does the integration of response services lead to meaningful change in healthcare activity? A Case Study Evaluation. Journal of Integrated Care 2019;27(3):193-203. Download from Emeraldinsight  
  • Hinde S, Theriou C, May S, Matthews L, Arbon A, Fallowfield L, Bloomfield D. The cost-effectiveness of EndoPredict to inform adjuvant chemotherapy decisions in early breast cancer. Health Policy and Technology 2019;8(1):75-83. Download from ScienceDirect
  • Howdon D, Lomas J, Paulden M. Implications of non-marginal budgetary impacts in health technology assessment: a conceptual model. Value in Health 2019;doi:10.1016/j.jval.2019.04.001. Downlaod from Sciencedirect
  • Justo N, Espinoza M, Ratto B, Nicholson M, Rosselli D, Ovcinnikova O, Ovcinnikova O, Martí SG, Ferraz MB, Langsam M, Drummond MF. Real-World Evidence in healthcare decision-making: Global trends and case studies from Latin America. Value in Health 2019;22(6):739-749. Download from Elsevier
  • Kanavos P, Angelis A, Drummond M. An EU-wide approach to HTA: An irrelevant development or an opportunity not to be missed? European Journal of Health Economics 2019;20(3):329-332. Download from Springer
  • Kristensen FB, Husereau D, Huic M, Drummond MF, Berger M, Bond K et al. Identifying the need for good practices in Health Technology Assessment: summary of the ISPOR HTA Council Working Group Report on Good Practices in HTA. Value in Health 2019;22(1):13-20. Download from Value in Health
  • Lim M, Beyer T, Babayan A, Bergmann M, Brehme M, Buyx A, Czernin J, Egger G, Elenitoba-Johnson K, Gückel B, Jačan A, Haslacher H, Hicks R, Kenner L, Langanke M, Mitterhauser M, Pichler B, Salih H, Schibl R, Schulz S, Simecek J, Simon J, Soares M et al. Advancing biomarker development through convergent engagement: Summary report of the 2nd International Danube Symposium on Biomarker Development, Molecular Imaging and Applied Diagnostics; March 14–16, 2018; Vienna, Austria. Molecular Imaging and Biology 2019;doi:10.1007/s11307-019-01361-2. Download from Springer
  • Lomas J. Incorporating affordability concerns within cost-effectiveness analysis for health technology assessment. Value in Health 2019;doi:10.1016/j.jval.2019.05.003. Download from Value in Health  
  • Lomas J, Martin S, Claxton K. Estimating the marginal productivity of the English National Health Service from 2003/04 to 2012/13. Value in Health 2019;doi:10.1016/j.jval.2019.04.1926. Download from Value in Health
  • Longo FFaria R, Parker G, Gridley K, Aspinal F, Van Den Berg B, Weatherly H. Investigating the economic case of a service to support carers of people with dementia: a cross-sectional survey-based feasibility study in England. Health and Social Care in the Community 2019;doi:10.1111/hsc.12799. Download from Wiley  
  • Love-Koh JCookson R, Gutacker N, Patton T, Griffin S. Aggregate distributional cost-effectiveness analysis of health technologies. Value in Health 2019;22(5):518-526. Download from Sciencedirect
  • Love-Koh JGriffin S, Kataika E, Revill P, Sibandze S, Walker SIncorporating concerns for equity into health resource allocation. A guide for practitioners. Centre for Health Economics, University of York;CHE Research Paper 160 (PDF , 2,070kb)‌ 2019.
  • Love-Koh J, Walker S, Kataika E, Sibandze S, Arnold M, Ochalek J, Griffin S, Revill P, Sculpher M. Economic analysis for health benefits package design. Centre for Health Economics, University of York;CHE Research Paper 165 (PDF , 2,216kb) 2019.  
  • Martin S, Lomas J, Claxton KIs an ounce of prevention worth a pound of cure? Estimates of the impact of English public health grant on mortality and morbidity. Centre for Health Economics, University of York;CHE Research Paper 166 (PDF , 2,275kb)
  • Ochalek J, Asaria M, Chuar P, Lomas J, Mazumdar S, Claxton KAssessing health opportunity costs for the Indian health care systems. Centre for Health Economics, University of York;CHE Research Paper 161 (PDF , 2,097kb) 2019.
  • Peden C, Stephens T, Martin G, Kahan B, Thomson A, Rivette K, Wells D, Richardson G  et al, on behalf of the Enhanced Peri-Operative Care for High-risk patients (EPOCH) trial group. Effectiveness of a national quality improvement programme to improve survival after emergency abdominal surgery (EPOCH): a stepped-wedge cluster-randomised trial. The Lancet 2019; 393(10187):2213-2221. Download from ScienceDirect
  • Phillips A, Cambiano V, Nakagawa F, Bansi-Matharu L, Wilson D, Jani I, Apollo T, Sculpher M, Hallett T, Kerr C, van Oosterhout J, Eaton J, Estill J, Williams B, Doi N, Cowan F, Keiser O, Ford D, Hatzold K, Barnabas R, Ayles H, Meyer‐Rath G, Nelson L, Johnson C, Baggaley R, Fakoya A, Jahn A, Revill P. Cost-per-diagnosis as a metric for monitoring cost-effectiveness of HIV testing programmes in low-income settings in Southern Africa: Health economic and modelling analysis. Journal of the International Aids Society 2019;22(7):e25325. Download from Wiley
  • Phillips A, Venter F, Havlir D, Pozniak A, Kuritzkes D, Wensing A, Lundgren J, De Luca A, Pillay D, Mellors J, Cambiano V, Bansi-Matharu L, Nakagawa F, Kalua T, Jahn A, Apollo T, Mugurungi O, Clayden P, Gupta R, Barnabas R, Revill P, Cohn J, Bertagnolio S, Calmy A. Risks and benefits for use of dolutegravir-based antiretroviral drug regimens in sub Saharan Africa: a modelling study. The Lancet HIV 2019;6(2):e116-e127. Download from Sciencedirect
  • Regan J, Frison E, Collin F, Dawes P, Hann M, Himmelsbach I, Hooper E, Reeves D, Simkin Z, Thodi C, Yang F, Leroi I for the SENSE-Cog Trial Development Team. Individualised sensory intervention to improve quality of life in people with dementia and their companions (SENSE-Cog trial): study protocol for a randomised controlled trial. Trials 2019;20(80):1-15. Download from BMC
  • Sandhu H, Abraham C, Alleyne S, Balasubramanian S, Betteley L, Booth K, Carnes D, Furlan A, Haywood K, Iglesias Urrutia C, Lall R, Manca A, et al. Testing a support programme for opioid reduction for people with chronic non-malignant pain: The I-WOTCH randomised controlled trial protocol. BMJ Open 2019;9(8):e028937. Download from BMJ     
  • Saramago P, Espinoza MA, Sutton AJ, Manca A, Claxton K. The value of further research: The added value of individual-participant level data. Applied Health Economics and Health Policy 2019;17(3):273-284. Download from Springer
  • Selinger C, Bershteyn A, Dimitrov DT, Adamson BJS, Revill P, Hallett T et al. Targeting and vaccine durability are key for population-level impact and cost-effectiveness of a pox-protein HIV vaccine regimen in South Africa. Vaccine 2019;37(16):2258-2267. Download from ScienceDirect
  • South E, Cox E, Meader N, Woolacott N, Griffin S. Strimvelis® for treating severe combined immunodeficiency caused by adenosine deaminase deficiency: An evidence review group perspective of a NICE highly specialised technology evaluation. Pharmacoeconomics - Open 2019;3(2):151-161. Download from Springer
  • Taraldsen K, Mikolaizak AS, Maier A, Boulton E, Aminian K, Ancum J, Bandinelli S, Becker C, Bergquist R, Chiari L, Clemson L, French D, Gannon B, Hawley-Hague H, Jonkman N, Mellone S, Paraschiv-Ionescu A, Pijnappels M, Schwenk M, Todd C, Yang F et al. Protocol for the PreventIT feasibility randomised controlled trial of a lifestyle-integrated exercise intervention in young older adults. BMJ Open 2019;9(3);e023526. Download from BMJ
  • Vermeulen F, Gerbens L, Bosma A, Apfelbacher C, Irvine A, Arents B, Barbarot S, Deleuran M, Eichenfield L, Manca A et al on behalf of the international TREAT Registry Taskforce. TREatment of ATopic eczema (TREAT) Registry Taskforce: consensus on how and when to measure the core data set for atopic eczema research registries. British Journal of Dermatology 2019;doi:10.1111/bjd.17715. Download from Wiley
  • Wade R, Grosso A, South E, Rothery CSaramago PSchmitt L, Wright K, Palmer S. Brodalumab for the treatment of moderate to severe plaque psoriasis: an Evidence Review Group evaluation of a NICE Single Technology Appraisal. Pharmacoeconomics 2019;37(2):131-139. Download from Springer
  • Walker SGriffin S, Asaria M, Tsuchiya A, Sculpher M. Striving for a societal perspective: A framework for economic evaluations when costs and effects fall on multiple sectors and decision makers. Applied Health Economics and Health Policy 2019;doi:10.1007/s40258-019-00481-8. Download from Springer
  • Weir S, Tzu-Chun K, Samnaliev M, Tierney T, Manca A et al. Reoperation following lumbar spinal surgery: costs and outcomes in a UK population cohort study using the Clinical Practice Research Datalink (CPRD) and Hospital Episode Statistics (HES). European Spine Journal 2019;28(4):863-871. Download from Springer
  • Yang F, Devlin N, Luo N. Cost-utility analysis using EQ-5D-5L data: does how the utilities are derived matter? Value in Health 2019;22(1):45-49. Download from ScienceDirect
  • Yang F, Devlin N, Luo N. Impact of mapped EQ-5D utilities on cost effectiveness analysis: in the case of dialysis treatments. European Journal of Health Economics 2019;20(1):99-105. Download from Springer
  • Yang F, Wong C, Luo N, Piercy J, Moon R, Jackson J. Mapping the kidney disease quality of life 36-item short form survey (KDQOL-36) to the EQ-5D-3L and the EQ-5D-5L in patients undergoing dialysis. European Journal of Health Economics 2019;doi:10.1007/s10198-019-01088-5. Download from Springer
  • Yang H, Llewellyn A, Walker R, Harden M, Saramago Goncalves P, Griffin S et al. High-throughput, non-invasive prenatal testing for fetal rhesus D status in RhD- negative women: a systematic review and meta-analysis. BMC Medicine 2019;17:37. Download from BMC

2018

2018

  • Arundel C, Fairhurst C, Corbacho Martin M, Buckley H, et al, Saramago Goncalves PSoares M et al. Pilot feasibility randomized clinical trial of negative-pressure wound therapy versus usual care in patients with surgical wounds healing by secondary intention. BJS Open 2018;2(3):99-111. Download from Wiley
  • Asaria M, Dhami S, van Ree R, Gerth van Wijk R, Muraro A, Roberts G, Sheikh A. Health economic analysis of Allergen Immunotherapy (AIT) for the management of allergic rhinitis, asthma, food allergy and venom allergy: A systematic overview. Allergy 2018;73(2):269-283. Download from Wiley 
  • Banks H, Torbica A, Valzania C, Varabyova Y, Prevolnik Rupel V, Taylor RS, Hunger T, Walker S, Boriani G, Fattore G. For the MedtecHTA group. Five year trends (2008-2012) in cardiac implantable electrical device utilization in five European nations: a case study in cross-country comparisons using administrative databases. EP Europace 2018;20(4):643-653. Download from OUP
  • Barbieri M, Richardson G, Paisley S. The cost-effectiveness of follow-up strategies after cancer treatment: a systematic literature review. British Medical Bulletin 2018;126(1):85-100. Download from OUP
  • Bee P, Pedley R, Rithalia A, Richardson G, Pryjmachuk S, Kirk S, Bower P. Self-care support for children and adolescents with long-term conditions:the REfOCUS evidence synthesis. NIHR HS&DR Journal 2018;6(3). Download from NIHR
  • Bell K, Corbacho Martín B, Ronaldson S, Richardson G, Torgerson D, Robling M et al. The impact of pre and perinatal lifestyle factors on child long term health and social outcomes: a systematic review. Health Economics Review 2018;8:2. Download from Springer Open
  • Bojke LSchmitt LLomas JRichardson GWeatherly H. Economic evaluation of environmental interventions:reflections on methodological challenges and developments. International Journal of Environmental Research and Public Health 2018;15(11):2459. Download from IJERPH
  • Brealey S, Armstrong A, Brooksbank A, et al, Richardson G, et al. United Kingdom Frozen Shoulder Trial (UK FROST), multi-centre, randomised, 12 month, parallel group, superiority study to compare the clinical and cost-effectiveness of Early Structured Physiotherapy versus manipulation under anaesthesia versus arthroscopic capsular release for patients referred to secondary care with a primary frozen shoulder: study protocol for a randomised controlled trial. Trials.2017;18:614. Download from Trials
  • Brown LC, Ahmed HU, Faria R, El-Shater Bosaily A, Soares MScupher M et al. Multiparametric MRI to improve detection of prostate cancer compared with transrectal ultrasound-guided prostate biopsy alone: the PROMIS study. Health Technology Assessment 2018;22(39). Download from NIHR
  • Bywater T, Berry V, Blower SL, Cohen J, Gridley N, Kiernan K, Mandefield L, Mason-Jones A, McGilloway S, McKendrick K, Pickett K, Richardson G, Teare MD, Tracey L, Walker S, Whittaker K, Wright J. Enhancing Social-Emotional Health and Wellbeing in the Early Years (E-SEE): A study protocol of a community-based randomised controlled trial with process and economic evaluations of the incredible years infant and toddler parenting programmes, delivered in a proportionate universal model. BMJ Open 2018;8(12):e026906. Download from BMJ 
  • Chansa C, Mwase T, Matsebula T, Kandoole P, Revill P, Makumba J-B et al. Fresh money for health? The (false?) promise of “innovative financing” for health in Malawi. Health Systems & Reform 2018:4(4):324-335. Download from tandfonline
  • Ciani O, Epstein D, Rothery C, Taylor RS, Sculpher M. Decision uncertainty and value of further research: a case-study in fenestrated endovascular aneurysm repair for complex abdominal aortic aneurysms. Cost Effectiveness and Resource Allocation 2018;16:15. Download from BMC
  • Ciaranello A, Sohn AH, Collins IJ, Rothery C, Abrams EJ, Woods B et al. Simulation modeling and metamodeling to inform national and international HIV policies for children and adolescents. Jaids-Journal of Acquired Immune Deficiency Syndromes 2018;78(S1):S49-S57. Download from JAIDS
  • Ciani O, Torbica A, Lecci F, Morelli M, Drummond M, Tarricone R et al. Myth #5: Health care is rightly left to the private sector, for the sake of efficiency. In Adinolfi P, Borgonovi E (eds). The Myths of Health Care. Springer 2018; chapter 5: pp123-154. Download from Springer
  • Claxton KLomas J, Martin S. The impact of NHS expenditure on health outcomes in England: Alternative approaches to identification in all-cause and disease specific models of mortality. Health Economics 2018;27(6):1017-1023. Download from Wiley
  • Clemes S, Bingham D, Pearson N, Chen Y-L, Edwardson C, Mceachan R, Tolfrey K, Cale L, Richardson G et al. Stand out in class: restructuring the classroom environment to reduce sedentary behaviour in 9-10-year-olds- study protocol for a pilot cluster randomised controlled trial. Pilot and Feasibility Studies 2018;4;103. Download from Biomedcentral
  • Coelho T, Ines M, Conceicao I, Soares MFO, Carvalho M, Costa J. Natural history and survival in stage 1 Val30Met transthyretin familial amyloid polyneuropathy. Neurology 2018;91(21):e1999-e2009. Download from Neurology
  • Cookson R, Ali S, Tsuchiya A, Asaria M. E-learning and health inequality aversion: A questionnaire experiment. Health Economics 2018;27(11):1754-1771. Download from Wiley
  • Cookson R, Asaria M, Ali S, Shaw R, Doran T, Goldblatt P. Health equity monitoring for healthcare quality assurance. Social Science & Medicine 2018;198:148-156. Download from ScienceDirect
  • Danzon P, Drummond MF, Towse A, Pauly M. Objectives, budgets, thresholds, and opportunity costs—A health economics approach: An ISPOR special task force report [4]. Value in Health 2018;21(2):140-145. Download from ScienceDirect
  • Dodd P, Yuen CM, Becerra MC, Revill P, Jenkins HE, Seddon JA. The potential impact of household contact management on childhood tuberculosis: a mathematical modelling study. Lancet Global Health 2018;6(12):e1329-e1338. Download from ScienceDirect
  • Drummond MF, Tarricone R, Torbica A. Economic evaluation of medical devices. Oxford Research Encyclopedia of Economics and Finance, Economics and Finance March 2018;doi: 10.1093/acrefore/9780190625979.013.105. Download from OUP 
  • Duarte A, Bojke C, Cayton W, Salawu A, Case B, Bojke LRichardson G. Impact of specialist rehabilitation services on hospital length of stay and associated costs. The European Journal of Health Economics 2018;19(7):1-27-1034. Download from Springer
  • Edwardson C, Biddle S, Clarke-Cornwell A, Clemes S, Davies M, Richardson G et al. A three arm cluster randomised controlled trial to test the effectiveness and cost-effectiveness of the SMART Work & Life intervention for reducing daily sitting time in office workers: study protocol. BMC Public Health 2018;18:1120. Download from BMC
  • Elliott R, Camacho E, Campbell F, Jankovic D, Martyn-St James M, Kaltenthaler E, Wong R, Sculpher MFaria R. Prevalence and economic burden of medication errors in the NHS in England: Rapid evidence synthesis and economic analysis of the prevalence and burden of medication error in the UK. Policy Research Unit in Economic Evaluation of Health and Care Interventions (EEPRU) Report 2018;174p. Download from EEPRU
  • Espinoza MA, Manca AClaxton KSculpher M. Social value and individual choice: the value of a choice-based decision making process in a collectively funded health system. Health Economics 2018;27(2):e28-e40. Download from Wiley
  • Evans R, Brutsche M, Busca R, Deslee G, de Soyza A, Fellrath J-M, Franzen D, Hartman J, Mealing S, Morton T, Munavvar M, Sculpher M et al. Quantifying patient centered outcomes associated with the use of bilateral endobronchial coil treatment in patients with severe emphysema. Current Medical Research and Opinion 2018;34(11):1927-1932. Download from Taylor & Francis
  • Faria RSoares MO, Spackman E, Ahmed HU, Brown L, Kaplan R, Emberton M, Sculpher M. Optimising the diagnosis of prostate cancer in the era of multi-parametric magnetic resonance imaging: a cost-effectiveness analysis based on the Prostate MR Imaging Study (PROMIS). European Urology 2018;73(1):23-30. Download from European Urology
  • Faria RSoares M, Spackman E, Ahmed H, Brown L, Kaplan R, Emberton M, Sculpher M. Re: Jochen Walz. The "PROMIS" of magnetic resonance imaging cost effectiveness in prostate cancer diagnosis? Eur Urol 2018;73:31-2. European Urology 2018;73(6):e151-e152. Download from European Urology
  • Forster A, Hartley S, Bernard L, Ozer S, Schmitt L et al. An intervention to support stroke survivors and their carers in the longer term (LoTS2Care): study protocol for a cluster randomised controlled feasibility trial. Trials 2018;19:317. Download from Trials
  • Garrison L, Neumann P, Willke R, Basu A, Danzon P, Doshi J, Drummond M, Lakdawalla D, Pauly M, Phelps C, Ramsey SD, Towse A, Weinstein M. A health economics approach to US value assessment frameworks - Summary and recommendations of the ISPOR special task force report [7]. Value in Health 2018;21(2):161-165. Download from Value in health
  • Gridley K, Aspinal FJ, Parker GM, Weatherly HFaria RLongo F et al. Supporting Carers of People with Dementia: A mixed methods evaluation and feasibility study. Social Policy Research Unit, University of York, 2018. Download from SPRU
  • Haji Ali Afzali H, Bojke L, Karnon J. Model structuring for economic evaluations of new health technologies. Pharmacoeconomics 2018;36(11):1309-1319. Download from Springer
  • Hinde S, Crilly T, Balata H, Bartlett R, Crilly J, Barber P et al. The cost-effectiveness of The Manchester ‘Lung Health Checks’, a community-based lung cancer low-dose CT screening pilot. Lung Cancer 2018;126:119-124. Download from Lung cancer journal
  • Johannesen KM, Claxton KSculpher MJ, Wailoo AJ. How to design the cost-effectiveness appraisal process of new healthcare technologies to maximise population health: A conceptual framework. Health Economics 2018;27(2):e41-e54. Download from Wiley
  • Knuchel-Takano A, Hunt D, Jaccard A, Bhimjiyani A, Brown M, Retat L, Brown K, Hinde S, Selvarajah C, Bauld L, Webber L. Modelling the implications of reducing smoking prevalence: the benefits of increasing the UK tobacco duty escalator to public health and economic outcomes. Tobacco Control 2018;27:e124-e129. Download from BMJ
  • Kundu D, Sharma N, Chadha S, Laokri S, Awungafac G, Jiang L, Asaria M. Analysis of multi drug resistant tuberculosis (MDR-TB) financial protection policy: MDR-TB health insurance schemes, in Chhattisgarh state, India. Health Economics Review 2018;8:3. Download from Springer Open
  • Leurent B, Gomes M, Faria R, Morris S, Grieve R, Carpenter J. Sensitivity analysis for not-at-random missing data in trial-based cost-effectiveness analysis: A tutorial. PharmacoEconomics 2018;36(8):889-901. Download from Springer
  • Lomas J, Asaria MBojke L, Gale C, Richardson GWalker S. Which costs matter? Costs included in economic evaluation and their impact on decision uncertainty for stable coronary artery disease. PharmacoEconomics - Open 2018;2(4):403-413Download from Springer
  • Lomas JClaxton K, Martin S, Soares M. Resolving the ‘cost-effective but unaffordable’ ‘paradox’: estimating the health opportunity costs of non-marginal budget impacts. Value in Health 2018;21(3):266-275. Download from ScienceDirect
  • Lomas J, Martin S, Claxton K. Estimating the marginal productivity of the English National Health Service from 2003/04 to 2012/13. Centre for Health Economics, University of York; CHE Research Paper 158 (PDF , 4,475kb)‌ 2018.
  • Love-Koh J, Peel A, Rejon-Parilla JC, Ennis K, Lovett R, Manca A, Chalkidou A, Wood H, Taylor M. The future of precision medicine: Potential impacts for Health Technology Assessment. Pharmacoeconomics 2018;36(12):1439-1451. Download from Springer
  • Marsh KD, Sculpher M, Caro J, Tervonen T. The use of MCDA in HTA: great potential, but more effort needed. Value in Health 2018;21(4):394-97. Download from Value in health
  • Mauskopf J, Standaert B, Connolly MP, Culyer AJ, Garrison LP, Hutubessy R, Jit M, Pitman R, Revill P, Severens J. Economic analysis of vaccination programs: An ISPOR good practices for outcomes research task force report. Value in Health 2018;21(10):1133-1149. Download from ScienceDirect
  • McGuire F, Revill P, Twea P, Mohan S, Manthalu G, Smith P. Recommendations for the development of a health sector resource allocation formula in Malawi. Centre for Health Economics, University of York; CHE Research Paper 159 (PDF , 2,452kb) 2018.
  • Neumann PJ, Kim DD, Trikalinos TA, Sculpher MJ et al. Future directions in cost-effectiveness analyses in health and medicine. Medical Decision Making 2018;38(7):767-777. Download from Sagepub
  • Norman G, Westby M, Rithalia A, Stubbs N, Soares M, Dumville JC. Dressings and topical agents for treating venous leg ulcers. Cochrane Database of Systematic Reviews 2018;15(6):CD012583. Download from Cochrane
  • Ochalek J, Lomas JClaxton K. Estimating health opportunity costs in low- and middle-income countries: a novel approach and evidence from cross-country data. BMJ Global Health 2018;3(6):e000964. Download from BMJ
  • Ochalek JRevill P, Manthalu G, McGuire F, Nkhoma D, Rollinger ASculpher MClaxton K. Supporting the development of a health benefits package in Malawi. BMJ Global Health 2018;3(2):e000607. Download from BMJ
  • Pandya A, Doran T, Zhu J, Walker S, Arntson E, Ryan AM. Modeling the cost-effectiveness of pay-for-performance in primary care for the UK. BMC Medicine 2018;16:135. Download from BMC
  • Patton T, Hu H, Luan L, Yang K, Li S-C. Mapping between HAQ-DI and EQ-5D-5L in a Chinese patient population. Quality of Life Research 2018;27(11):2815-2822. Download from Springer
  • Perera D, Clayton T, Petrie M, Greenwood J, O'Kane P, Evans R, Sculpher M et al. Percutaneous revascularization for ischemic ventricular dysfunction: Rationale and design of the REVIVED-BCIS2 trial: Percutaneous coronary intervention for ischemic cardiomyopathy. JACC: Heart failure 2018;6(6):517-526. Download from Elsevier
  • Peron M, Llewellyn A, Moe-Byrne T, Walker S, Walton M, Harden M, Palmer S, Simmonds M. Adjunctive colposcopy technologies for assessing suspected cervical  abnormalities: Systematic reviews and economic evaluation. Health Technology Assessment 2018;22(54). Download from NIHR
  • Phelps C, Lakdawalla D, Basu A, Drummond MF, Towse A, Danzon P. Approaches to aggregation and decision making - A health economics approach: An ISPOR special task force report [5]. Value in Health 2018; 21(2):146-154. Download from Value in health
  • Phillippo D, Ades T, Dias S, Palmer S, Abrams K, Welton NJ. Methods for population-adjusted indirect comparisons in Health Technology Appraisal. Medical Decision Making 2018;38(2):200-211. Download from Sagepub
  • Pinho M, Pinto Borges A, Cookson R. Do healthcare professionals have different views about healthcare rationing than college students? A mixed methods study in Portugal. Public Health Ethics 2018;11(1):90-102. Download from Oxford oup 
  • Revill P, Dwyer E. Pre-exposure prophylaxis is cost-effective for HIV in the UK. Lancet Infectious Diseases 2018;18(1):10-11. Download from Sciencedirect
  • Revill PWalker S, Cambiano V, Phillips A, Sculpher M. Reflecting the real value of health care resources in modelling and cost-effectiveness studies-The example of viral load informed differentiated care. PloS One 2018;13(1):1-13e0190283. Download from Plosone
  • Rothery CWoods BSchmitt LClaxton KPalmer S,Sculpher M. Framework for value assessment
    of new antimicrobials: Implications of alternative funding arrangements for NICE Appraisal. Policy Research Unit in Economic Evaluation of Health and Care Interventions (EEPRU) Report 2018;178p. Download from EEPRU
  • Saramago P, Yang H, Llewellyn A, Walker R, Harden M, Palmer SGriffin S, Simmonds M.High-throughput non-invasive prenatal testing for fetal rhesus D status in RhD-negative women not known to be sensitised to the RhD antigen: a systematic review and economic evaluation. Health Technology Assessment 2018;22(13):1-172. Download from NIHR
  • Saramago Goncalves PR, Yang H, Llewellyn A, Palmer SJ, Simmonds MC, Griffin S. High-throughput, non-invasive prenatal testing for fetal RHD genotype to guide antenatal prophylaxis with anti-D immunoglobulin: a cost-effectiveness analysis. BJOG An International Journal of Obstetrics and Gynaecology 2018;125(11):1414-1422. Download from Wiley
  • Sculpher M. ISPOR’s initiative on US value assessment frameworks: seeking a role for health economics. Value in Health 2018;21(2):171-2. Download from Value in Health
  • Soares M, Bojke L. Expert elicitation to inform Health Technology Assessment. In Dias LC, Morton A, Quigley J (eds). Elicitation: The Science and Art of Structuring Judgement. Springer International Publishing 2018;Chapter 18:pp479-494. 
  • Soares MFO, Sharples L, Morton A, Claxton KP, Bojke L. Experiences of structured elicitation for model based cost-effectiveness analyses. Value in Health 2018;21(6):715-723. Download from ScienceDirect
  • Soares MO, Walker S, Palmer SJ, Sculpher MJ. Establishing the value of diagnostic and prognostic tests in Health Technology Assessment. Medical Decision Making 2018;38:495-508. Download from Sage Journals 
  • Sutton M, Garfield-Birkbeck S, Martin G, Meacock R, Morris S, Sculpher M, Street A, Watson SI, Lilford RJ. Economic analysis of service and interventions in health care.  Health Serv Deliv Res 2018;6(5). Download from NIHR
  • Tafesse W. The effect of mandatory iodine fortification on cognitive test scores in rural India. Health, Econometrics and Data Group (HEDG), University of York 2018; working paper 18/10. Download from HEDG
  • Thokala P, Ochalek J, Leech A, Tong T. Cost effectiveness thresholds: the past, the present and the future. PharmacoEconomics 2018;36(5):509-522. Download from Springer
  • Thompson DG, O'Brien S, Kennedy A, Rogers A, Whorwell P, Lovell K, Richardson G et al. A randomised controlled trial, cost-effectiveness and process evaluation of the implementation of self-management for chronic gastrointestinal disorders in primary care, and linked projects on identification and risk assessment. Programme Grants for Applied Research 2018;6(1). Download from NIHR
  • Thwaites GE, Scarborough M, Szubert A, Saramago P, Soares M, Bostock J et al. Adjunctive rifampicin to reduce early mortality from Staphylococcus aureus bacteraemia: the ARREST RCT. Health Technology Assessment 2018;22(59):1-148. Download from NIHR 
  • Tierrablanca L, Ochalek J, Ford D, Babiker A, Gibb D, Butler K, Turkova A, Griffin SRevill P. Economic evaluation of weekends-off antiretroviral therapy for young people in 11 countries. Medicine 2018;97(5):e9698. Download from Medicine
  • Torbica A, Tarricone R, Drummond M. Does the approach to economic evaluation in health care depend on culture, values, and institutional context? The European Journal of Health Economics 2018;19(6):769-774. Download from Springer
  • Woods BRothery C, Anderson S-J, Eaton JW, Revill P, Hallett TB, Claxton K. Appraising the value of evidence generation activities: An HIV Modelling Study. BMJ Global Health 2018;3(6):e000488. Download from BMJ
  • Woods BRothery CRevill P, Hallett T, Phillips A, Claxton K. Setting research priorities in Global Health: Appraising the value of evidence generation activities to support decision-making in health care. Centre for Health Economics, University of York; CHE Research Paper 155 (PDF , 2,544kb)‌ 2018.
  • Woods BS, Sideris E, Sydes MR, Gannon MR, Parmar MKB, Alzouebi M, Attard G, Birtle AJ, Brock S, Cathomas R, Chakraborti PR, Cook A, Cross WR, Dearnaley DP, Gale J, Gibbs S, Graham JD, Hughes R, Jones RJ, Laing R, Mason MD, Matheson D, McLaren DB, Millman R, O’Sullivan JM, Parikh O, Parker CC, Peedell C, Protheroe A, Ritchie AWS, Robinson A, Russell MJ, Simms MS, Srihari NN, Srinivasan R, Staffurth JN, Sundar S, Thalmann GN, Tolan S, Tran ATH, Tsang D, Wagstaff J, James ND, Sculpher MJ. Addition of docetaxel to first-line long-term hormone therapy in prostate cancer (STAMPEDE): Modelling to estimate long-term survival, quality-adjusted survival, and cost-effectiveness. Eur Urol Oncol 2018;1(6):449-458. Download from ScienceDirect 
  • Yang F, Devlin N, Luo N. Impact of mapped EQ-5D utilities on cost effectiveness analysis: in the case of dialysis treatments. European Journal of Health Economics 2018;doi:10.1007/s10198-018-0987-x. Download from Springer
  • Yang F, Gannon B, Weightman A. Public's willingness to pay towards a medical device for detecting foot ulceration in people with diabetes. Applied Health Economics and Health Policy 2018;16(4):559-567. Download from Springer

2017

2017

  • Ali S, Tsuchiya A, Asaria MCookson R. How robust are value judgments of health inequality aversion? Testing for framing and cognitive effects. Medical Decision Making 2017;37(6):635-646. Download from Sage journals
  • Al-Janabi H, Manca A, Coast J. Predicting carer health effects for use in economic evaluation. PLoS ONE 2017;12(9):e0184886. Download from plosone
  • Antioch K, Drummond MF, Niessen L, Vondeling H. International lessons in new methods for grading and integrating cost effectiveness evidence into clinical practice guidelines. Cost Effectiveness and Resource Allocation 2017;15(1). 
  • Asaria M. Health care costs in the English NHS: reference tables for average annual NHS spend by age, sex and deprivation group. Centre for Health Economics, University of York; CHE Research Paper 147 (PDF , 1,732kb)‌ 2017.
  • Asaria M. The economics of health inequality in the English NHS – the long view. Centre for Health Economics, University of York;CHE Research Paper 142 (PDF , 2,090kb) 2017.
  • Barratt H, Asaria M, Sheringham J, Stone P, Raine R, Cookson R. Dying in hospital: socioeconomic inequality trends in England. Journal of Health Services Research & Policy 2017;22(3):1490154.
  • Bojke L, Grigore B, Jankovic D, Peters J, Soares M, Stein K. Informing reimbursement decisions using cost-effectiveness modelling: a guide to the process of generating elicited priors to capture model uncertainties. Pharmacoeconomics 2017;35(9):867-877. Download from Springer
  • Bojke LManca AAsaria M, Mahon R, Shijie R, Palmer S. How to appropriately extrapolate costs and utilities in cost-effectiveness analysis. Pharmacoeconomics 2017;35(8):767-776. Download from Springer
  • Burgers LT, Redekop W, Al MJ, Lhachimi SK, Armstrong N, Walker SM, Rothery C, et al. Cost-effectiveness analysis of new generation coronary CT scanners for difficult-to-image patients. European Journal of Health Economics 2017;18(6):731-742. Download from Springer
  • Ciani O, Buyse M, Drummond MF, et al. Time to review the role of surrogate endpoints in health policy. Value in Health 2017;20(3):487-495. Download from Value in Health
  • Cookson RMirelman AGriffin SAsaria M, Dawkins B, Frithjof Norheim O, Verguet S, Culyer AJ. Using cost-effectiveness analysis to address health equity concerns. Value in Health 2017;20(2):206-212. Download from Value in Health
  • Cookson R, Mondor L, Asaria M, Kringos DS, Klazinga NS, Wodchis WP.  Primary care and health inequality: difference-in-difference study comparing England and Ontario. PLOS one 2017;doi:10.1371/journal.pone.0188560. Download from Plosone
  • Cookson R, Walden A. Inequality and the NHS hospital crisis: Why social disadvantage needs attention. British Journal of Hospital Medicine 2017;78(2):64-65. Download from Magonlinelibrary
  • Corbacho Martin MB, Bell KJ, Stamuli E, Richardson G, Ronaldson SJ, Hood K, Sanders J, Robling M, Torgerson DJ. Cost-effectiveness of the Family Nurse Partnership (FNP) programme in England: evidence from the Building Blocks Trial. Journal of Evaluation in Clinical Practice 2017;23(6):1367-1374. Download from Wiley
  • Corbett M, Chehadah F, Biswas M, Moe-Byrne T, Palmer SSoares M, Walton M, Harden M, Ho P, Woolacott N, Bojke L. Certolizumab pegol and secukinumab for treating active psoriatic arthritis following inadequate response to disease-modifying antirheumatic drugs: a systematic review and economic evaluation. Health Technology Assessment 2017;21(56):1-326. Download from NIHR
  • Dhami S, Zaman H, Varga E-M, et al. Asaria M, Netuveli G, Sheikh A, Allergen immunotherapy for insect venom allergy: a systematic review and meta-analysis. Allergy 2017;72(3):342-365. 
  • Dhami S, Kakourou A, Asamoah F, et al. Asaria M, Netuveli G, Zaman H, Akhlaq A, Sheikh A. Allergen immunotherapy for allergic asthma: a systematic review and meta-analysis. Allergy 2017;2017;72(12):1825-1848. Download from Wiley
  • Dhami S, Nurmatov U, Arasi S, Khan T, Asaria M, et al. Allergen immunotherapy for allergic rhinoconjunctivitis: a systematic review and meta-analysis. Allergy 2017;72(11):1597-1631. Download from Wiley  
  • Drummond MF, Houwing N, Slothuus U, Giangrande P. Making economic evaluations more helpful for treatment choices in haemophilia. Haemophilia Journal 2017;23(2):e58-e66.
  • Duarte A, Mebrahtu T, Goncalves PS, Harden M, Murphy R, Palmer S, Woolacott N, Rodgers M, Rothery C. Adalimumab, etanercept and ustekinumab for treating plaque psoriasis in children and young people: systematic review and economic evaluation. Health Technology Assessment 2017;21(64):1-244. Download from NIHR
  • Duarte AWalker S, Littlewood E, Brabyn S, Hewitt C, Gilbody S, Palmer S. Cost-effectiveness of computerized cognitive–behavioural therapy for the treatment of depression in primary care:: findings from the Randomised Evaluation of the Effectiveness and Acceptability of Computerised Therapy (REEACT) trial. Psychological Medicine 2017;47(10):1825-1835. Download from Cambridge university press 
  • Fleetcroft R, Asaria M, Ali S, Cookson R. Outcomes and inequalities in diabetes from 2004/2005 to 2011/2012: English longitudinal study. British Journal of General Practice 2017;67(654):e1-e9. Download from BJGP 
  • Gc VSuhrcke M, Hardeman W, Sutton S, Wilson EC. Cost-effectiveness and value of information analysis of brief interventions to promote physical activity in primary care. Value in Health 2017;doi:10.1016/j.jval.2017.07.005. Download from ScienceDirect
  • Graham H, Bland M, Cookson R, Kanaan M, White P. Do people favour policies that protect future generations? Evidence from a British survey of adults. Journal of Social Policy 2017;46(3):423-445.
  • Hakim J, Musiime V, Szubert A, Mallewa J, Siika A, Agutu C, Walker S, Pett SL, Bwakura-Dangarembizi M, Lugemwa A, Kaunda S, Karoney M, Musoro G, Kabahenda S, Nathoo K, Maitland K, Griffiths A, Thomason MJ, Kityo C, Mugyenyi P, Prendergast AJ, Walker AS, Gibb DM for the REALITY Trial Team. Enhanced prophylaxis with antiretroviral therapy for advanced HIV in Africa. New England Journal of Medicine 2017;377:233-245. Download from NEJM  
  • Hettle R, Corbett M, Hinde S, Hodgson R, Jones-Diette J, Woolacott N, Palmer S. The assessment and appraisal of regenerative medicines and cell therapy products: an exploration of methods for review, economic evaluation and appraisal. Health Technology Assessment 2017;21(7):1-238. Download from NIHR 
  • Hinde S, Allgar VL, Richardson G, Spiers G, Parker GM, Birks YF. An evaluation of the costs and consequences of Children Community Nursing teams. Journal of Evaluation in Clinical Practice 2017;23(4):767-772. Download from Wiley
  • Hinde SBojke LRichardson G, Retat L, Webber L. The cost-effectiveness of population health checks: have the NHS health checks been unfairly maligned? Journal of Public Health 2017;25(4):425-431. Download from Springer
  • Hinde S, Wiyani A, Griffin SWalker SM. Who bears the cost of NICE public health recommendations? British Medical Bulletin 2017;124(1):113-120. Download from OUP
  • Howdon D, Lomas J. Pricing implications of non-marginal budgetary impacts in health technology assessment: a conceptual model. Centre for Health Economics, University of York; CHE Research Paper 148 (PDF , 1,223kb) 2017.
  • Jackson C, Stevens J, Latimer N, Bojke LManca A, Sharples L. Extrapolating survival from randomised trials using external data: a review of methods. Medical Decision Making 2017;37(4):377-390. Download from Sage
  • Joyce VR, Sun H, Barnett PG, Bansback N, Griffin SC, Bayoumi AM, Anis AH, Sculpher M, Cameron W, Brown ST, Holodniy M, Owens DK. Mapping MOS-HIV to HUI3 and EQ-5D-3L in patients with HIV. MDM Policy & Practice 2017;2(2). Download from Sage
  • Kendrick D, Ablewhite J, Achana F, Benford P, Clacy R, Coffey F, Cooper N, Coupland C, Deave T, Goodenough T, Hawkins A, Hayes M, Hindmarch P, Hubbard S, Kay B, Kumar A, Majsak-Newman G, McColl E, McDaid L, Miller P, Mulvaney C, Peel I, Pitchforth E, Reading R,  Saramago P, Stewart J, Sutton A, Timblin C, Towner E, Watson M, Wynn P, Young B, Zou K. Keeping children safe: a multicentre programme of research to increase the evidence base for preventing unintentional injuries in the home in the under-fives. Programme Grants for Applied Research 2017;5(14). Download fromNCBI
  • Longo F, Siciliani L, Gravelle HSantos R. Do hospitals respond to rivals’ quality and efficiency? A spatial panel econometric analysis. Health Economics 2017;26(S2);38-62. Download from Wiley 
  • Longo F, Siciliani L, Moscelli G, Gravelle H. Does hospital competition improve efficiency? The effect of the patient choice reform in England. Centre for Health Economics, University of York; CHE Research Paper 149 (PDF , 1,874kb) 2017.
  • Longo F, Siciliani L, Street AD. Are costs differences between specialist and general hospitals compensated by the prospective payment system? European Journal of Health Economics 2017;doi:10.1007/s10198-017-0935-1 Oct 26. Download from Springer
  • MacPherson H, Vickers A, Bland M, Torgerson D, Corbett M, Spackman E, Saramago PWoods BWeatherly HSculpher MManca A, Richmond S, Hopeton A, Eldred J, Watt I. Acupuncture for chronic pain and depression in primary care:  a programme of research. Programme Grants for Applied Research 2017;5(3). Download from NIHR 
  • Manthalu G, Nkhoma D, Ochalek JM, Phillips A, Revill P. Confronting tight fiscal, human resource, and evidence constraints, Malawi revises its benefits package. In Glassman A, Giedion U, Smith PC, (eds) What's In, What's Out: Designing Benefits for Universal Health Coverage 2017. Washington D.C.;Center for Global Development:pp247-252. Download from CGD
  • Ochalek JRevill P, van den Berg B. Causal effects of HIV on employment status in low-income settings. Economics and Human Biology 2017;27(Pt A):248-260. Download from Elsevier
  • Patton TBojke L, Walton M, Manca A, Helliwell P. Evaluating the cost-effectiveness of biologic treatments for psoriatic arthritis: can we make better use of patient data registries? Clinical Rheumatology 2017;36(8):1803-1810. Download from Springer
  • Regan J, Dawes P, Pye A, Armitage C, Hann M, Himmelsbach I, Reeves D, Simkin Z, Yang F, Leroi I. Improving hearing and vision in dementia: Protocol for a field trial of a new intervention. BMJ Open 2017;7(11):e018744. Download from BMJ
  • Robson M, Asaria MCookson R, Tsuchiya A, Ali S. Eliciting the Level of Health Inequality Aversion in England. Health Economics 2017;26(10):1328-1334. Download from Wiley
  • Rothery CClaxton KPalmer S, Epstein D, Tarricone R, Sculpher M. Characterising uncertainty in the assessment of medical devices and determining future research needs. Health Economics 2017;26(S1):109-123.  
  • Santos J, Palumbo F, Molsen-David E, Willke RJ, Binder L, Drummond M et al. ISPOR Code of Ethics 2017 (4th Edition). Value in Health 2017;20(10):1227-1242. Download from Elsevier
  • Saramago PDuarte ARothery CPalmer S. Tackling network meta-analysis methodological challenges: a case study on biologic treatments for moderate to severe plaque psoriasis in children and young people. Value in Health 2017;20(9):A756. Download from Value in Health
  • Saramago PPalmer SGriffin S. Cost-effectiveness of high-throughput, non-invasive prenatal testing for fetal rhesus D status. Value in Health 2017;20(9):A588. Download from Value in Health
  • Sculpher MClaxton K, Pearson SD. Developing a value framework: the need to reflect the opportunity costs of funding decisions. Value in Health 2017;20(2):234-9. Download from Value in Health
  • Sculpher MJRevill POchalek JMClaxton KP. How much health for the money? Using cost-effectiveness analysis to support benefits plan decisions. In Glassman A, Giedion U, Smith PC, (eds) What's In, What's Out: Designing Benefits for Universal Health Coverage 2017. Washington D.C.;Center for Global Development: Chapter 4. Download from CGD
  • Sheringham J, Asaria M, Barratt H, Raine R, Cookson RA. Are some areas more equal than others? Socioeconomic inequality in potentially avoidable emergency hospital admissions within English local authority areas. Journal of Health Services Research & Policy 2017;22(2):83-90. Download from Sage
  • Spackman E, Hinde SBojke L, Payne K, Sculpher M. Using cost-effectiveness analysis to quantify the value of genomic-based diagnostic tests: recommendations for practice and research. Genetic Testing and Molecular Biomarkers 2017;21(12):705-716.
  • Tarricone R, Torbica A, Drummond MF. Challenges in the assessment of medical devices: the MedtecHTA project. Health Economics 2017;26(Suppl 1):5-12. Download from Wiley
  • Tarricone R, Torbica A, Drummond M for the MedtecHTA Project Group. Key recommendations from the MedtecHTA project. Health Economics 2017;26(Suppl 1):145-152. Download from Wiley
  • Wailoo AJ, Hernandez-Alava M, Manca A, Mejia A, Ray J, Crawford B, Botteman M, Busschbach J. Mapping to estimate health-state utility from non–preference outcome measures: an ISPOR good practices for outcomes research task force report. Value in Health 2017;20:130-139.
  • Walker SM, Spackman E, Conrad N, Edmin CA, Griffin E, Rahimi K, Sculpher M. Impact of missed treatment opportunities on outcomes in hospitalised patients with heart failure. Open Heart 2017;4(2):e000726. Download from BMJ
  • Weatherly H, Faria R, Van den Berg B, Sculpher M, O’Neill P, Nolan K, Glanville J, Isojarvi J, Baragula E, Edwards M. Scoping review on social care economic evaluation methods. Centre for Health Economics, University of York; CHE Research Paper 150 (PDF , 1,676kb)‌ 2017.
  • Weir S, Samnaliev M, Kuo T-C, Choitir CN, Tierney TS, Cumming D, Bruce J, Manca A, Taylor RS, Eldabe S. The incidence and healthcare costs of persistent postoperative pain following lumbar spine surgery in the UK: A cohort study using the Clinical Practice Research Datalink (CPRD) and Hospital Episode Statistics (HES). BMJ Open 2017;7(9):e017585. Download from BMJ
  • Woods BManca AWeatherly HSaramago PSideris E, Giannopoulou C, Rice S, Corbett M, Vickers A, Bowes M, MacPhersonH, Sculpher M. Cost-effectiveness of adjunct non-pharmacological interventions for osteoarthritis of the knee. PLoS ONE 2017;12(3):e0172749. Download from Plosone 

2016/2015

2016

  • Allen R, Bryden P, Grotzinger K, Stapelkamp C, Woods BS. Cost-effectiveness of Eltrombopag versus Romiplostim for the treatment of chronic immune thrombocytopenia in England and Wales. Value in Health 2016;19(5):614-622. 
  • Asaria MAli S, Doran T, Ferguson B, Fleetcroft R, Goddard M, Goldblatt P, Laudicella M, Raine R, Cookson R. How a universal health system reduces inequalities – Lessons from England. Journal of Epidemiology and Community Health 2016;70:637-643. Download from BMJ
  • Asaria MCookson R, Fleetcroft R, Ali S. Unequal socioeconomic distribution of the primary care workforce: whole-population small area longitudinal study. BMJ Open 2016;6(1):e8783. Download from BMJ
  • Asaria M, Doran T, Cookson R. The costs of inequality: whole-population modelling study of lifetime inpatient hospital costs in the English National Health Service by level of neighbourhood deprivation. Journal of Epidemiology and Community Health 2016;70(10):990-996. 
  • Asaria MGrasic KWalker S. Using linked electronic health records to estimate healthcare costs: key challenges and opportunities. PharmacoEconomics 2016;34(2):155-160.
  • Asaria MGriffin SCookson R. Distributional cost-effectiveness analysis: A tutorial. Medical Decision Making 2016;36(1):8-19.
  • Asaria MWalker SPalmer S, Gale C, Shah A, Abrams K, Crowther M, Manca A, Timmis A, Hemingway H, Sculpher M. Using electronic health records to predict costs and outcomes in stable coronary artery disease. Heart 2016;102(10):755-762. Download from BMJ and Associated model code
  • Barber S, Jackson C, Hewitt C, Ainsworth H, Buckley H, Akhtar S, Bingham D, Routen A, Summerbell C, Richardson G, Moore H, Pickett K, O’Malley C, Brierley S, Wright J. Assessing the feasibility of evaluating and delivering a physical activity intervention for pre-school children: a pilot randomised controlled trial. Pilot and Feasibility Studies 2016;2(12).
  • Becker D, Chit A, DiazGranados C, Maschio M, Yau E, Drummond M. High-dose inactivated influenza vaccine is associated with cost savings and better outcomes compared to standard-dose inactivated influenza vaccine in Canadian seniors. Human Vaccines & Immunotherapeutics 2016;doi: 10.1080/21645515.2016.1215395. 
  • Brabyn S, Araya R, Barkham M, Bower P, Cooper C, Duarte A, Kessler D, Knowles S, Lovell K, Littlewood E, Mattock RPalmer S, Pervin J, Richards D, Tallon D, White D, Walker S, Worthy G, Gilbody S. The second Randomised Evaluation of the Effectiveness, cost-effectiveness and Acceptability of Computerised Therapy (REEACT-2) trial: does the provision of telephone support enhance the effectiveness of computer-delivered cognitive behaviour therapy? A randomised controlled trial. Health Technol Assess 2016;20(89). Download from NIHR
  • Chiwaula L, Revill P, Ford D, Nkhata MJ, Mabugu T, Hakim J ,  Kityo C, Chan AK, Cataldo F, Gibb D, van den Berg B, for the Lablite Project Team. Measuring and valuing informal care for economic evaluations of HIV/AIDS interventions: methods and application in Malawi. Value in Health Regional Issues 2016;doi.org/10.1016/j.vhri.2016.08.002.
  • Ciani O, Buyse M, Drummond MF, Rasi G, Saad ED, Taylor RS. Use of surrogate endpoints in healthcare policy: proposal for consistent adoption of a validation framework. Nature Reviews Drug Discovery 2016;15(7):516. 
  • Claxton KPPalmer SJ, Longworth L, Bojke L, Griffin SSoares MFO, Spackman E, Rothery C.  A comprehensive algorithm for approval of health technologies with, without, or only in research: the key principles for informing coverage decisions. Value in Health 2016;19(6):885-891. Download from Value in Health
  • Cookson R, Asaria M, Ali S, Ferguson B, Fleetcroft R, Goddard M, Goldblatt P, Laudicella M, Raine R. Health equity indicators for the English NHS. Centre for Health Economics, University of York;CHE Research Paper 124 (PDF  , 11,583kb) 2016.
  • Cookson R, Cotton-Barrett O, Adler M, Asaria M, Ord T. Years of good life based on income and health: re-engineering cost-benefit analysis to examine policy impacts on wellbeing and distributive justice. Centre for Health Economics, University of York;CHE Research Paper 132 (PDF , 2,282kb)‌ 2016.
  • Cookson RMirelman AAsaria M, Dawkins B, Griffin S. Fairer decisions, better health for all: Health equity and cost-effectiveness analysis. Centre for Health Economics, University of York; CHE Research Paper 135 (PDF , 1,713kb)‌ 2016.
  • Cookson R, Propper C, Asaria M, Raine R. Socioeconomic inequalities in health care in England. Centre for Health Economics, University of York;‌ 2016.
  • Corbett M, Soares M, Jhuti G, Rice S, Spackman E, Sideris E, Moe-Byrne T, Fox D, Marzo-Ortega H, Kay L, Woolacott N, Palmer S. Tumour necrosis factor-inhibitors for ankylosing spondylitis and non-radiographic axial spondyloarthritis: a systematic review and economic evaluation. Health Technology Assessment 2016;20(9).
  • Corbacho Martin MB, Duarte A, Keding A, Handoll H, Chuang L-H, Torgerson DJ et al. Cost effectiveness of surgical versus non-surgical treatment of adults with displaced fractures of the proximal humerus: economic evaluation alongside the PROFHER trial. Bone and Joint Journal 2016;98B(2):152-159. 
  • Cullum N, Buckley H, Dumville J, Hall J, Lamb K, Madden M, Morley R, O’Meara S,  Saramago PSoares MO, Stubbs N. Wounds research for patient benefit programme. Programme Grants for Applied Research. NIHR Journals Library 2016;4(13). Download from NIHR
  • Dias J, Brealey S, Choudhary S, Cook L, Costa M, Fairhurst C, Hewitt C, Hodgson S, Jefferson L, Jeyapalan K, Keding A, Leighton P, Rangan A, Richardson GRothery C, Taub N, Thompson J, Torgerson D. Scaphoid Waist Internal Fixation for Fractures Trial (SWIFFT) protocol: a pragmatic multi-centre randomised controlled trial of cast treatment versus surgical fixation for the treatment of bi-cortical, minimally displaced fractures of the scaphoid waist in adults. BMC Musculoskeletal Disorders 2016;17(248):1-15.    
  • Drummond MF. Clinical Guidelines: a NICE way to introduce cost-effectiveness considerations? Value in Health 2016;19(5):525-530. 
  • Drummond MF, Augustovski F, Kalo Z, Yang B-M, Pichon-Riviere A, Bae E-Y, Kamal-Bahl S. Challenges faced in transferring economic evaluations to middle income countries. International Journal of Technology Assessment in Health Care 2016;31(6):442-448. 
  • Drummond MF, Tarricone R, Torbica A. Incentivizing research into the effectiveness of medical devices. European Journal of Health Economics 2016;17(9)1055-1058. 
  • Faria R, Kiss N, Aspinal F, Harden M, Weatherly H.  Economic evaluation of social care interventions: Lessons drawn from a systematic review of the methods used to evaluate reablement. Health Economics & Outcome Research: Open Access 2016;doi:10.4172/heor.1000107.
  • Faria RWalker S, Whyte S, Dixon S, Palmer SSculpher M. How to invest in getting cost-effective technologies into practice? A framework for value of implementation analysis applied to novel oral anticoagulants. Medical Decision Making 2016;37(2):148-161.
  • Faria RWoods BGriffin SPalmer SSculpher M, Ryder SD. Prevention of progression to cirrhosis in hepatitis C with fibrosis: effectiveness and cost effectiveness of sequential therapy with new direct-acting anti-virals. Alimentary Pharmacology & Therapeutics 2016;44(8):866-876. Download from Wiley
  • Farrar D, Simmonds M, Griffin SDuarte A, Lawlor DA, Sculpher M et al. The identification and treatment of women with hyperglycaemia in pregnancy: an analysis of individual participant data, systematic reviews, meta-analyses and an economic evaluation. Health Technology Assessment 2016;20(86):1-382. 
  • Fazio L, Rosner A, Drummond MF. How do U.S. payers use economic models submitted by Life Sciences Organizations? Value & Outcomes Spotlight 2016;2(2):18-21. 
  • Greenwood JP, Ripley DP, Berry C, McCann GP, Plein S, Bucciarelli-Ducci C, Dall’Armellina E, Prasad A, Bijsterveld P, Foley JR, Mangion K, Sculpher MWalker S, Everett CC, Cairns DA, Sharples LD, Brown JM, for the CE-MARC 2 Investigators. Effect of care guided by cardiovascular magnetic resonance, myocardial perfusion scintigraphy, or NICE guidelines on subsequent unnecessary angiography rates - The CE-MARC 2 Randomized Clinical Trial.  JAMA 2016;316(10):1051-1060. Download from JAMA
  • Grieve R, Abrams K, Claxton K, Goldacre B, James N, Nicholl J, Parmar M, Parker C, Sekhon JS, Smeeth L, Spiegelhalter D, Sculpher M.  Cancer Drugs Fund requires further reform: Reliance on “real world” observational data undermines evidence base for clinical practice. BMJ 2016;354:i5090. Download from BMJ
  • Hawkins N, Scott DA, Woods B, ‘Arm-based’ parameterization for network meta-analysis. Research Synthesis Methods 2016;7(3):306-313. Download from Wiley
  • Hinde SBojke LRichardson G. Have the NHS health checks been unfairly maligned? Value in Health 2016;19(7):A613. 
  • Hinde S, Epstein D, Cook A, Embleton A, Perren TJ, Sculpher MJ. The cost-effectiveness of Bevacizumab in advanced ovarian cancer using evidence from the ICON7 trial. Value in Health 2016;19(4):431-439. 
  • Hinde S, Wade R, Palmer S, Woolacott N, Spackman E. Apremilast for the treatment of moderate to severe plaque psoriasis: A critique of the evidence. PharmacoEconomics 2016;doi:10.1007/s40273-016-0382-3.
  • Jull J, Whitehead M, Petticrew M, Kristjansson E, Gough D, Petkovic J, Volmink J, Weijer C, Taljaard M, Edwards S, Mbuagbaw L, Cookson R, et al. When is a randomised controlled trial health equity relevant? Development and validation of a conceptual framework. BMJ Open 2017;7(9):1-9.e015815. Download from BMJ
  • Llewellyn A, Faria RWoods B, Simmonds M, Lomas J, Woolacott N, Griffin S. Daclatasvir for the treatment of chronic hepatitis C: A critique of the clinical and economic evidence. PharmacoEconomics 2016;34(10):981-992. 
  • Lomas J, Llewellyn A, Soares M, Simmonds M, Wright K, Eastwood A, Palmer S. The clinical and cost effectiveness of Vortioxetine for the treatment of a major depressive episode in patients with failed prior antidepressant therapy: A critique of the evidence. PharmacoEconomics 2016;34(9):901-912.
  • Lomas J, Schmitt L, Jones S, McGeorge M, Bates E, Holland M, Cooper D, Crowther R, Ashmore M, Rojas Rueda D, Weatherly HRichardson GBojke L. A pharmacoeconomic approach to assessing the costs and benefits of air quality interventions that improve health: a case study. BMJ Open 2016;6(6):e010686. 
  • Malone DC, Berg NS, Claxton K, Garrison LP, IJzerman M, Marsh K, Neumann PJ, Sculpher M, Towse A, Uyl-de Groot C, Weinstein MC. International Society for Pharmacoeconomics and Outcomes Research comments on the American Society of Clinical Oncology value framework. Journal of Clinical Oncology 2016;doi:10.1200/JCO.2015.64.4328. 
  • Mann R, Beresford B, Parker G, Rabiee P, Weatherly HFaria R,  Kanaan M, Laver-Fawcett A, Pilkington G, Aspinall F. Models of reablement evaluation (MoRE): a study protocol of a quasi-experimental mixed methods evaluation of reablement services in England. BMC Health Services Research 2016;16:375. 
  • Masters R, Anwar E, Collins B, Cookson R, Capewell S. Return on investment of public health interventions: a systematic review. Journal of Epidemiology and Community Health 2017;71(8):827-834. Download from BMJ
  • Meltzer DO, Basu A, Sculpher MJ. Theoretical foundations of cost-effectiveness analysis in health and medicine.  In Neumann PJ, Sanders GD, Russell LB, Siegel JE, Ganiats TG (eds).  Cost-Effectiveness in Health and Medicine 2016, Oxford University Press, 2nd edition. 
  • McKenna CGriffin S, Koffijberg H, Claxton K. Methods to place a value on additional evidence are illustrated using a case study of corticosteroids after traumatic brain injury. Journal of Clinical Epidemiology 2016;70:183-190.
  • Mealing S, Woods B, Hawkins N, Cowie M, Plummer C, Abraham W, Beshai J, Klein H, Sculpher M. Cost-effectiveness of implantable cardiac devices in patients with systolic heart failure. Heart 2016;102(21):1742-1749. 
  • Oddershede L, Walker S, Stohr W, Dunn DT, Arenas-Pinto A,  Paton NI, Sculpher MJ for the Protease Inhibitor monotherapy Versus Ongoing Triple therapy (PIVOT) Trial Team. Cost effectiveness of protease inhibitor monotherapy versus standard triple therapy in the long-term management of HIV patients: analysis using evidence from the PIVOT Trial. Pharmacoeconomics 2016;34(8):795-804. Download from Springer
  • Owens DK, Siegel JE,  Sculpher MJ, Salomon JA.  Designing a cost-effectiveness analysis. In Neumann PJ, Sanders GD, Russell LB, Siegel JE, Ganiats TG (eds). Cost-Effectiveness in Health and Medicine 2016, Oxford University Press, 2nd edition. 
  • Paton N, Stöhr W, Oddershede L, Arenas-Pinto A, Walker SSculpher MJ, Dunn D. The Protease Inhibitor Monotherapy Versus Ongoing Triple Therapy (PIVOT) trial: a randomised controlled trial of a protease inhibitor monotherapy strategy for long-term management of human immunodeficiency virus infection. Health Technology Assessment 2016;20(21). Download from NIHR
  • Phillips A, Cambiano V, Nakagawa F, Ford D, Apollo T, Murungu J, Rousseau C, Garnett G, Ehrenkranz P, Bansi-Matharu L, Vojnov L, Katz Z, Peeling R, Revill P. Point-of-care viral load testing for sub-Saharan Africa: informing a target product profile. Open Forum Infectious Diseases 2016;doi:10.1093/ofid/ofw161. Download from Oxford Journals
  • Phillips A, Cambiano V, Revill P, Nakagawa F, Lundgren J, Bansi-Matharu L, Mabugu T, Sculpher M, Garnett G, Staprans S, Becker S, Murungu J, Lewin S, Deeks S, Hallett T. Identifying key drivers of the impact of an HIV cure intervention in sub-Saharan Africa. The Journal of Infectious Diseases 2016;3(3):214(1):73-79. 
  • Pletscher M, Walker S, Moschetti K, Pinget C, Wasserfallen J-B, Greenwood JP, Schwitter J, Girardin FR. Cost-effectiveness of functional cardiac imaging in the diagnostic work-up of coronary heart disease. European Heart Journal 2016;2(3):201-207. Download from Oxford University Press
  • Rencz F, Gulacsi L, Drummond M, Golicki D, Rupel V, Simon J, Stolk E, Brodszky V, Baji P, Zavada J, Petrova G, Rotar A, Pentek M. EQ-5D in Central and Eastern Europe: 2000-2015. Quality of Life Research 2016;25(11):2693-2710. 
  • Robson M, Asaria M, Tsuchiya A, Ali S, Cookson R. Eliciting the level of health inequality aversion in England. Centre for Health Economics, University of York; CHE Research Paper 125 (PDF , 2,174kb) 2016.
  • Sanders GD, Neumann PJ, Basu A, Brock DW, Feeny D, Krahn M, Kuntz KM, Meltzer DO, Owens DK, Prosser LA, Salomon JA, Sculpher MJ, Trikalinos TA, Russell LB, Siegel JE, Ganiats TG. Recommendations for conduct, methodological practices, and reporting of cost-effectiveness analyses: Second panel on cost effectiveness in health and medicine. JAMA2016;316(10):1093-1103. Download from JAMA
  • Saramago Goncalves PWoods BWeatherly HManca A, Sculpher M, Khan K, Vickers A, MacPherson H. Methods for network meta-analysis of continuous outcomes using individual patient data: a case study in acupuncture for chronic pain. BMC Medical Research Methodology 2016;6;16(131). 
  • Sideris E, Corbett M, Palmer S, Woolacott N, Bojke L. The clinical and cost effectiveness of Apremilast for treating active psoriatic arthritis: A critique of the evidence. Pharmacoeconomics 2016;34(11):1101-1110. 
  • Spiers GF, Allgar VL, Richardson G, Thurland K, Hinde S, Birks YF, Gridley K, Duncan H, Clarke SE, Cusworth LS, Parker GM. Transforming community health services for children and young people who are Ill: A quasi-experimental evaluation. Health Services and Delivery Research 2016;4(25). Download from NIHR
  • Walker SAsaria MManca A, Palmer S, Gale C, Shah A, Abrams K, Crowther M, Timmis A, Hemingway H, Sculpher M. Long term health care use and costs in patients with stable coronary artery disease: a population based cohort using linked electronic health records (CALIBER). European Heart Journal - Quality of Care & Clinical Outcomes 2016;2(2):125-140. Download from oxfordjournals
  • Weatherly HFaria R, van den Berg B. Quantifying informal care for economic evaluation in mental health. In Razzouk D (ed). Mental Health Economics: The Costs and Benefits of Psychiatric Care 1st edition. Springer 2017;Ch17:pp.267-280.
  • Westby M, Dumville JC, Soares M, Stubbs N, Norman G. Dressings and topical agents for treating pressure ulcers. Cochrane Database of Systematic Reviews 2017; Issue 6:CD011947. Download from Wiley
  • Whyte S, Dixon S, Faria RWalker SPalmer S, Sculpher M, Radford S. Estimating the cost-effectiveness of implementation: Is sufficient evidence available? Value in Health 2016;19(2):138-144. Download from ScienceDirect
  • Woods B, Faria R, Griffin S. Assessing the value of new treatments for Hepatitis C: Are international decision makers getting this right? PharmacoEconomics 2016;34(5):427-433. 
  • Woods BSideris EPalmer S, Latimer N, Soares M. NICE DSU technical support document 19: Partitioned survival analysis for decision modelling in health care: a critical review. 2 Jun 2017, NICE Decision Support Unit;72p. Download from SCHARR 

2015

  • Abongomera G, Kiwuwa-Muyingo S, Revill P, Chiwaula L, Mabugu T, Phillips A, Katabira E, Musiime V, Gilks C, Chan A, Hakim J, Colebunders R, Kityo C, Gibb DM, Seeley J, Ford D, for the Lablite Project Team. Population level usage of health services, and HIV testing and care, prior to decentralization of antiretroviral therapy in Agago District in rural Northern Uganda. BMC Health Services Research 2015;15:527. Download from biomedcentral
  • Alfonso Ross Terres J, Lozano-Ortega G, Kendall R, Sculpher M. Cost-effectiveness of fondaparinux versus enoxaparin in non-ST-elevation acute coronary syndrome in Canada (OASIS-5). BMC Cardiovascular Disorders 2015;15:180. Download from Springer
  • Asaria M, Griffin S, Cookson R, Whyte S, Tappenden P. Distributional cost-effectiveness analysis of health care programmes – a methodological case study of the UK bowel cancer screening programme. Health Economics 2015;24(6):742-754. Download from Wiley
  • Barber S, Akhtar S, Jackson C, Bingham D, Hewitt C, Routen A, Richardson G, Ainsworth H, Moore H, Summerbell C, Pickett K, O'Malley C, Brierley S, Wright J. Preschoolers in the Playground: a pilot cluster randomised controlled trial of a physical activity intervention for children aged 18 months to 4 years. Public Health Research 2015;3(5).
  • Barnabus RV, Bendavid E, Bershteyn A, Boulle A, Eaton JW, Ford N, Hallett TB, Hontelez JAC, Klein DJ, Olney JJ, Phillips AN, Reniers G, Revill P, Slaymaker E, Zaba B, Priorities for HIV care in sub-Saharan Africa: a population perspective. HIV Modelling Consortium. Report for the World Health Organization HIV Treatment Guidelines Development Committee 2015. Download from HIV modelling
  • Bubela T, McCabe C, Archibald P, Atkins H, Bradshaw S, Kefalas P, Mujoomdar M, Packer C, Piret J, Raxworthy M, Soares M, Viswanathan S. Bringing regenerative medicines to the clinic: the future for regulation and reimbursement. Regenerative Medicine 2015;10(7):897–911. Download from Futuremedicine
  • Cambiano V, Ford D, Mabugu T, Napierala Mavedzenge S, Miners A, Mugurungi O, Nakagawa F, Revill P, Phillips A. Assessment of the potential impact and cost-effectiveness of self-testing for HIV in low-income countries. The Journal of Infectious Diseases 2015;212(4):570-577. Download from Oxford journals
  • Campbell JD, McQueen RB, Libby AM, Spackman E, Carlson JJ, Briggs A. Cost-effectiveness uncertainty analysis methods: A comparison of one-way sensitivity, analysis of covariance, and expected value of partial perfect information. Medical Decision Making 2015;35(5):596-607.
  • Chit A, Becker DL, DiazGranados CA, Maschio M, Yau E, Drummond M. Cost-effectiveness of high-dose versus standard-dose inactivated influenza vaccine in adults aged 65 years and older: An economic evaluation of data from a randomised controlled trial. The Lancet Infectious Diseases 2015;15(12):1459-1466. 
  • Clark AL, Johnson M, Fairhurst C, Torgerson D, Cockayne S, Rodgers S, Griffin S, , Allgar V, Jones L, Nabb S, Harvey I, Squire I, Murphy J, Greenstone M. Does home oxygen therapy (HOT) in addition to standard care reduce disease severity and improve symptoms in people with chronic heart failure? A randomised trial of home oxygen therapy for patients with chronic heart failure. Health Technology Assessment 2015;19(75). 
  • Claxton KGriffin S, Koffijberg H, McKenna C. How to estimate the health benefits of additional research and changing clinical practice. BMJ 2015;351:h5987. Download from bmj
  • Claxton KP, Martin S, Soares MO, Rice N, Spackman E, Hinde S, Devlin N, Smith PC, Sculpher M. Methods for the estimation of the NICE cost effectiveness threshold. Health Technology Assessment 2015;19(14). Download fron NIHR
  • Claxton K, Sculpher M, Palmer S, Culyer AJ. Causes for concern: is NICE failing to uphold its responsibilities to all NHS patients? Health Economics 2015;24(1):1–7. Download from Wiley
  • Conigliani C, Manca A, Tancredi A. Prediction of patient reported outcome measures via multivariate ordered probit models. Journal of the Royal Statistical Society: Series A (Statistics in Society) 2015;178(3):567-591.
  • Cookson R. Justice and the NICE approach. Journal of Medical Ethics 2015;41(1):99-102.
  • Cookson R, Gutacker N, Garcia-Armesto, S, Angulo-Pueyo E, Christiansen T, Bloor K, Bernal-Delgado E. Socioeconomic inequality in hip replacement in four European countries from 2002 to 2009 – area level analysis of hospital data. European Journal of Public Health 2015;25(suppl1):21-27. Download from Oxford journals
  • Corbett M, Heirs M, Rose M, Smith A, Stirk L, Richardson G, Stark D, Swinson D, Craig D, Eastwood A. The delivery of chemotherapy at home: an evidence synthesis. Health Services and Delivery Research 2015;3:14. 
  • Culyer AJ. Efficiency, equity and equality in health and health care. Centre for Health Economics, University of York;CHE Research Paper 120 (PDF , 1,596kb)‌ 2015. 
  • Culyer AJ. Cost-effectiveness thresholds in health care: a bookshelf guide to their meaning and use. Centre for Health Economics, University of York;‌ 2015.
  • Delgadillo J, Asaria MAli S, Gilbody S. On poverty, politics and psychology: the socioeconomic gradient of mental healthcare utilisation and outcomes. The British Journal of Psychiatry 2015;doi:10.1192/bjp.bp.115.171017. 
  • Drummond M. When do performance-based risk-sharing arrangements make sense? The European Journal of Health Economics 2015;16(6):569-571. 
  • Drummond M, Husereau D. David Sackett 1934 – 2015. Value in Health 2015;18(5):549. 
  • Drummond MFSculpher MJClaxton K, Stoddart GL, Torrance GW. Methods For The Economic Evaluation of Health Care Programmes. Fourth Edition: Oxford: Oxford University Press;2015. Download from OUP
  • Duarte A, Walker J, Walker SRichardson G, Holm Hansen C, Martin P, Murray G, Sculpher M, Sharpe M. Cost-effectiveness of integrated collaborative care for comorbid major depression in patients with cancer. Journal of Psychosomatic Research 2015;79(6):465-70. Download from ScienceDirect
  • Faria R, Hernandez Alava M, Manca A, Wailoo A. The use of observational data to inform estimates of treatment effectiveness in technology appraisal: methods for comparative individual patient data. NICE DSU technical support document 17;2015. NICE. 
  • Faria RWeatherly HLA, Kiss N, Manca A, Parker GM, Beresford B A, Aspinal FJ. The challenges in evaluating the cost-effectiveness of complex interventions. Value in Health 2015;18(7):A727-A728.
  • Formby A, Cookson R, Halliday S. Cost analysis of the legal declaratory relief requirement for withdrawing Clinically Assisted Nutrition and Hydration (CANH) from patients in the Permanent Vegetative State (PVS) in England and Wales. Centre for Health Economics, University of York; 2015.
  • Galdas P, Darwin Z, Fell J, Kidd L, Bower P, Blickem C, McPherson K, Hunt K, Gilbody S, Richardson G. A systematic review and metaethnography to identify how effective, cost-effective, accessible and acceptable self-management support interventions are for men with long-term conditions (SELF-MAN). Health Services and Delivery Research 2015;3(34). 
  • Galdas P, Fell J, Bower P, Kidd L, Blickem C, McPherson K, Hunt K, Gilbody S, Richardson G. The effectiveness of self-management support interventions for men with long term conditions: a systematic review and meta-analysis. BMJ Open 2015;5(3):e006620. 
  • Giannopoulou C, Sideris E, Wade R, Moe-Byrne T, Eastwood A, McKenna C.  Ipilimumab for previously untreated unresectable malignant melanoma: a critique of the evidence. PharmacoEconomics 2015;33(12):1269-1279. 
  • Gutacker N, Bloor K, Cookson R. Comparing the performance of the Charlson/Deyo and Elixhauser co-morbidity indices across five European countries and three conditions. European Journal of Public Health 2015;(suppl1):15-20. Download from Oxford journals
  • Gutacker N, Bloor K, Cookson R, Garcia-Armesto S, Bernal-Delgado E. Comparing hospital performance within and across countries: an illustrative study of coronary artery bypass graft surgery in England and Spain. European Journal of Public Health 2015;25(suppl1):28-34. Download from Oxford journals
  • Halliday S, Formby A, Cookson R. An assessment of the court’s role in the withdrawal of clinically assisted nutrition and hydration from patients in the permanent vegetative state. Medical Law Review 2015;23(4):556-587.
  • Hernandez-Quevedo C, Weatherly H. Health promotion, disease prevention and health inequalities. In McDaid D, Sassi F, Merkur S (eds.). Promoting Health, Preventing Disease: The Economic Case. Chapter 12;pp:259-278. 2015. Open University Press, Maidenhead, UK. 
  • Hinde SMcKenna C, Whyte S, Peake M, Callister M, Rogers T, Sculpher M. Modelling the cost-effectiveness of public awareness campaigns for the early detection of non-small cell lung cancer. British Journal of Cancer2015;113(1):135-41.
  • Hinde SSpackman E. Bidirectional citation searching to completion: an exploration of literature searching methods. Pharmacoeconomics 2015;33(1):5-11.
  • Husereau D, Drummond M, Petrou S, Greenberg D, Mauskopf J, Augustovski F, Briggs A, Moher D, Loder E, Carswell C. Reply to Roberts et al.: CHEERS is sufficient for reporting cost-benefit analysis, but may require further elaboration. PharmacoEconomics 2015;33(5):535-536.
  • Ijzerman M, Manca A, Keizer J, Ramsey S. Implementation of comparative effectiveness research in personalized medicine applications in oncology: current and future perspectives. Comparative Effectiveness Research 2015;5:65-72. 
  • Johnson M, Kanaan M, Richardson G, Nabb S, Torgerson D, English A, Barton R, Booth S.  A randomised controlled trial of three or one breathing technique training sessions for breathlessness in people with malignant lung disease. BMC Medicine 2015;13:213. 
  • Jones AM, Lomas J, Moore PT, Rice N. A quasi-Monte-Carlo comparison of parametric and semiparametric regression methods for heavy-tailed and non-normal data: an application to healthcare costs. Journal of the Royal Statistical Society: Series A (Statistics in Society) 2015;doi:10.1111/rssa.12141. Download from wiley
  • Jones AM, Lomas J, Rice N. Healthcare cost regressions: going beyond the mean to estimate the full distribution. Health Economics 2015;24(9):1192-1212. Download from wiley
  • Kumar G, Woods B, Hess LM, Treat J, Boye ME, Bryden P, Winfree KB. Cost-effectiveness of first-line induction and maintenance treatment sequences in non-squamous non-small cell lung cancer (NSCLC) in the U.S. Lung Cancer 2015;89(3):294-300. Download from ScienceDirect
  • Lipton JH, Bryden P, Sidhu MK, Huang H, McGarry LJ, Lustgarten S, Mealing S, Woods B, Whelan J, Hawkins N. Comparative efficacy of tyrosine kinase inhibitor treatments in the third-line setting, for chronic-phase chronic myelogenous leukemia after failure of second-generation tyrosine kinase inhibitors. Leukemia Research 2015;39(1):58-64.
  • Littlewood E, Duarte A, Hewitt C, Knowles S, Palmer SWalker S, Andersen P, Araya R, Barkham M, Bower P, Brabyn S, Brierley G, Cooper C, Gask L, Kessler D, Lester H, Lovell K, Muhammad U, Parry G, Richards DA, Richardson R, Tallon D, Tharmanathan P, White D, Gilbody S on behalf of the REEACT Team. A randomised controlled trial of computerised cognitive behaviour therapy for the treatment of depression in primary care: the Randomised Evaluation of the Effectiveness and Acceptability of Computerised Therapy (REEACT) trial. Health Technology Assessment 2015;19(101). 
  • Love-Koh JAsaria MCookson RGriffin S. The social distribution of health: Estimating quality-adjusted life expectancy in England. Value in Health 2015;18(5):655-662.
  • McGuire A, Drummond MF, Martin M, Just N. End of life or end of the road? Are rising cancer costs sustainable? Is it time to consider alternative incentive and funding schemes?Expert Review of Pharmacoeconomics and Outcomes Research 2015;15(4): 599-605.
  • McKenna CSoares M, Claxton KBojke LGriffin SPalmer SSpackman E. Unifying research and reimbursement decisions: case studies demonstrating the sequence of assessment and judgments required. Value in Health 2015;18(6):865-875. Download from ScienceDirect
  • McMillan A, Bratton D, Faria R, Laskawiec-Szkonter M, Griffin S, Davies R, Nunn A, Stradling J, Riha R, Morrell M. A multicentre randomised controlled trial and economic evaluation of continuous positive airway pressure for the treatment of obstructive sleep apnoea syndrome in older people: PREDICT. Health Technology Assessment 2015;19(40). 
  • Montresor A, A Porta N, Albonico M, Gabrielli AF, Jankovic D, Fitzpatrick C, Vercruysse J, Levecke B. Soil-transmitted helminthiasis: the relationship between prevalence and classes of intensity of infection. Transactions of the Royal Society of Tropical Medicine and Hygiene 2015;109(4):262-267.
  • Ochalek JLomas JClaxton K. Cost per DALY averted thresholds for low- and middle-income countries: evidence from cross country data. Centre for Health Economics, University of York;CHE Research Paper 122 (PDF , 2,322kb)‌ 2015.
  • Pennington M, Baker R, Werner B, Mason H, Gyrd Hansen D, Robinson A, Donaldson C, Manca A, The EuroVaQ Team. Comparing WTP values of different types of QALY gain elicited from the general public. Health Economics 2015;24(3):280-293. 
  • Phillips A, et al, Revill P. (Working group on modelling of antiretroviral therapy monitoring strategies in sub-Saharan Africa). Sustainable HIV treatment in Africa through viral-load-informed differentiated care. Nature2015;528:7580:S68–S76. Download from nature
  • Pichon-Riviere A, Garay OU, Augustovski F, Vallejos C, Huayanay L, del Pilar Navia Bueno M, Rodriguez A, Coelho de Andrade CJ, Buendia JA, Drummond MF. Implications of global pricing policies on access to innovative drugs: the case of trastuzumab in seven Latin American countries. International Journal of Technology Assessment in Health Care 2015;31(1-2):2-11. 
  • Portrait F, Bakker M, Slootman B, Gafni A, van den Berg B. How do patients receiving radiotherapy in a Dutch hospital value their time? A contingent valuation study. Journal of Radiotherapy in Practice 2015;14(2):152-161. 
  • Portrait F, van der Galien O, van den Berg B. Measuring healthcare providers’ performances within managed competition using multidimensional quality and cost indicators. Health Economics 2015;doi:10.1002/hec.3158.
  • Revill P, Hallett T, Phillips A. The costs and benefits of alternatives approaches to monitoring patients on antiretroviral therapy: modelling and economic analysis, HIV Modelling Consortium report for the World Health Organization HIV Treatment Guidelines Development Committee 2015. Download from HIV modelling
  • Revill PWalker S, Mabugu T, Nathoo KJ, Mugyenyi P, Kekitinwa A, Munderi P, Bwakura-Dangarembizi M, Musiime V, Bakeera-Kitaka S, Nahirya-Ntege P, Walker AS, Sculpher M, Gibb DM. Opportunities for improving the efficiency of paediatric HIV treatment programmes. AIDS 2015;29(2):201-210.
  • Revill PWoods BSculpher M. Economic evaluation of healthcare programs and interventions: Applications to low- and middle-Income. In: Scheffler RM, (ed). World Scientific Handbook of Global Health Economics and Public Policy Volume 1 2015. More details
  • Ricciardi GW, Toumi M, Weil-Olivier C, Ruitenberg EJ, Dankó D, Duru G, Picazo J, Zollner Y, Poland G, Drummond M. Comparison of NITAG policies and working processes in selected developed countries. Vaccine 2015;33(1):3-11.
  • Richardson R, Trépel D, Perry A, Ali S, Duffy S, Gabe R, Gilbody S, Glanville J, Hewitt C, Manea L, Palmer S, Wright B, McMillan D. Screening for psychological and mental health difficulties in young people who offend: a systematic review and decision model. Health Technology Assessment 2015;19(1).
  • Ripley DP, Brown JM, Everett CC,  Bijsterveld P, Walker S, Sculpher M, McCann GP, Berry C, Plein S, Greenwood JP.  Rationale and design of the Clinical Evaluation of Magnetic Resonance Imaging in Coronary heart disease 2 trial (CE-MARC ): A prospective, multicenter, randomized trial of diagnostic strategies in suspected coronary heart disease. American Heart Journal 2015;169(1):17-24e1. Download from ahjonline
  • Robling M, Bekkers M-J, Bell K, Butler C, Cannings-John R, Channon S, Corbacho Martin B, Gregory J, Hood K, Kemp A, Kenkre J, Montgomery A, Moody G, Owen-Jones E, Pickett K, Richardson G, Roberts Z, Ronaldson S, Sanders J,Stamuli E ,Torgerson D. Effectiveness of a nurse-led intensive home-visitation programme for first-time teenage mothers (Building Blocks): a pragmatic randomised controlled trial. The Lancet 2015;387(10014):146-155. 
  • Rogowski W, Payne K, Schnell-Inderst P, Manca A, Rochau U, Jahn B, Alagoz O, Leidl R, Siebert U. Concepts of ‘personalization’ in personalized medicine: implications for economic evaluation. PharmacoEconomics 2015;33(1):49-59.
  • Ruggeri M, Manca A, Coretti S, Codella P, Iacopino V, Romano F, Mascia D, Orlando V, Cicchetti A. Investigating the generalizability of economic evaluations conducted in Italy: A critical review. Value in Health;2015:18(5):709-20.
  • Scott DA, Woods B, Thompson JC, Clark JF, Hawkins N, Chambers M, Celli BR, Calverley P.  Mortality and drug therapy in patients with chronic obstructive pulmonary disease: a network meta-analysis. BMC Pulmonary Medicine 2015;15:145. Download from biomedcentral
  • Sculpher M, Clinical trials provide essential evidence, but rarely offer a vehicle for cost-effectiveness analysis. Value in Health 2015;18(2):141-2.
  • Sculpher MJ, Basu A, Kuntz KM, Meltzer DO. Reflecting uncertainty in cost-effectiveness analysis. In Neumann PJ, Sanders GD, Russell LB, Siegel JE, Ganiats TG (eds).  Cost-Effectiveness in Health and Medicine 2016, Oxford University Press, 2nd edition. 
  • Shepherd K, Hubbard D, Fenton N, Claxton K, Luedeling E, de Leeuw J. Policy: Development goals should enable decision-making. Nature 2015;523(7559):152-154. 
  • Sorenson C, Drummond MF, Torbica A, Callea G, Mateus C. The role of hospital payments in the adoption of new medical technologies: an international survey of current practice. Health Economics, Policy and Law 2015;10(2):133-59.
  • Stamuli E, Richardson G, Duffy S, Robling M, Hood K. Systematic review of the economic evidence on home visitation programmes for vulnerable pregnant women. British Medical Bulletin 2015;115(1):19-44.
  • Threlfall AG, Meah S, Fischer AJ, Cookson R, Rutter H, Kelly MP. The appraisal of health interventions: The use of theory. Journal of Public Health 2015;37(1):166-171. Download from Oxford journals
  • Tsoi B, O’Reilly D, Masucci L, Drummond MF, Goeree R. Harmonization of HTA-based reimbursement and regulatory approval activities: a qualitative study. Journal of Population Therapeutics and Clinical Pharmacology 2015;22(1):e78-e89.
  • Waddell KM, Kagame K, Ndamira A, Twinamasiko A, Picton SV, Simmons IG, Revill P, Johnston T, Newton R. Improving survival of retinoblastoma in Uganda. British Journal of Ophthalmology 2015;99(7):937-942Download from bjo 
  • Wade R, Duarte A, Simmonds M, Rodriguez-Lopez R, Duffy S, Woolacott N, Spackman E. The clinical and cost effectiveness of aflibercept in combination with irinotecan and fluorouracil-based therapy (FOLFIRI) for the treatment of metastatic colorectal cancer which has progressed following prior oxaliplatin-based chemotherapy: a critique of the evidence. Pharmacoeconomics 2015;Jan 24:33(5):457-466.
  • Wade R, Sideris E, Paton F, Rice S, Palmer S, Fox D, Woolacott N, Spackman E. Graduated compression stockings for the prevention of deep-vein thrombosis in postoperative surgical patients: a systematic review and economic model with a value of information analysis. Health Technology Assessment 2015;19(98). 
  • Welton N J, Soares MOPalmer S, Ades AE, Harrison D, Shankar-Hari M, Rowan KM. Accounting for heterogeneity in relative treatment effects for use in cost-effectiveness models and value-of-information analyses. Medical Decision Making 2015;35(5):608-621.
  • Westby MJ, Dumville JC, Soares MO, Stubbs N, Norman G, Foley CN. Dressings and topical agents for treating pressure ulcers. Cochrane Database of Systematic Reviews 2015;Issue 11:Art No.:CD011947. 
  • Wilkinson G, Drummond MF. Alternative approaches for assessing the socioeconomic benefits of medical devices: a systematic review. Expert Review of Medical Devices 2015;12(5):629-648.
  • Woods B, Hawkins N, Mealing S, Sutton A, Abraham WT, Beshai JF, Klein H, Sculpher M, Plummer CJ, Cowie MR. Individual patient data network meta-analysis of mortality effects of implantable cardiac devices.  Heart 2015;101(22):1800-1806. Download from Heart
  • Woods B, Llewellyn A, Faria R, Simmonds M, Lomas J, Harden M, Woolacott N, Griffin S. Evidence Review Group's Report: Daclatasvir for treating chronic hepatitis C. TA364 Report to NICE. 2015.
  • Woods BRevill PSculpher M, Claxton K. Country-level cost-effectiveness thresholds: initial estimates and the need for further research. Centre for Health Economics, University of York;CHE Research Paper 109 (PDF , 2,894kb) 2015.
  • Wright B, Barry M, Hughes E, Trépel D, Ali S, Allgar V, Cottrill L, Duffy S, Fell J, Glanville J, Glaser D, Hackney L, Manea L, McMillan D, Palmer S, Prior V, Whitton C, Perry A, Gilbody S. Clinical effectiveness and cost-effectiveness of parenting interventions for children with severe attachment problems: a systematic review and meta-analysis. Health Technology Assessment 2015;19(52). 

2014 - 2012

2014

  • Allen T, Sutton M, Cookson R. How do economic incentive schemes influence rationing decisions by primary care physicians?  In: Danis M, Hurst SA, Fleck L, Forde R, Slowther A. (Eds).  Fair Resource Allocation and Rationing at the Bedside.Oxford University Press;2014:Ch7.
  • Ara R, Basarir H, Keetharuth A, Barbieri M, Weatherly HSculpher M, Ahmed H, Brown S. Are policy decisions on surgical procedures informed by robust economic evidence? A systematic review. International Journal of Technology Assessment in Health Care 2014;30(4):381-393. Download from Cambridge Journals
  • Asaria M, Cookson R, Griffin S. Incorporating health inequality impacts into cost-effectiveness analysis (PDF , 330kb). In: Culyer AJ (ed.) Encyclopedia of Health Economics, Vol 1. San Diego:Elsevier;2014. pp.22-26.
  • Ashby RL, Gabe R, Ali S, Adderley UJ, Bland M, Cullum N, Dumville J, Iglesias Urrutia CP, Kang'ombe AR, Soares MO, Stubbs N, Torgerson D. Clinical and cost-effectiveness of compression hosiery versus compression bandages in treatment of venous leg ulcers (Venous leg Ulcer Study IV, VenUS IV): a randomised controlled trial. Lancet 2014;383(9920):871-879.
  • Ashby RL, Gabe R, Ali SSaramago P, Chuang L-H, Adderley UJ, Bland M, Cullum N, Dumville J, Iglesias Urrutia CP, Kang'ombe A, Soares M, Stubbs N, Torgerson D.  VenUS IV (Venous leg Ulcer Study IV) - compression hosiery compared with compression bandaging in the treatment of venous leg ulcers: a randomised controlled trial, mixed-treatment comparison and decision-analytic model. Health Technology Assessment 2014;18(57). Download from NIHR
  • Barbieri M, Richardson G, Paisley S, Sculpher MRapid review of existing literature on the cost-effectiveness of alternative systems for diagnosis and referral of any cancer in primary care. Policy Research Unit in Economic Evaluation of Health and Care Interventions (EEPRU) 2014; Research Report 020. Download from EEPRU
  • Barbieri M, Richardson G, Paisley S, Sculpher MRapid review of existing literature on the cost-effectiveness of follow-up strategies after cancer treatment. Policy Research Unit in Economic Evaluation of Health and Care Interventions (EEPRU) Research Report 021. Download from EEPRU
  • Barbieri M, Weatherly HLA, Ara R, Basarir H, Sculpher M, Adams R, Ahmed H, Coles C, Guerrero-Urbano T, Nutting C, Powell M. What is the quality of economic evaluations of non-drug therapies? A systematic review and critical appraisal of economic evaluations of radiotherapy for cancer. Applied Health Economics and Health Policy 2014;12(5):497-510. Download from Springer
  • Barnett PG, Chow A, Joyce VR, Bayoumi AM, Griffin SC, Sun H, Holodniy M, Brown ST, Cameron DW, Sculpher M, Youle M, Anis AH, Owens DK.  Effect of management strategies and clinical status on costs of care for advanced HIV. American Journal of Managed Care 2014;20(5):129-137. Download from AJMC
  • Blakeman T, Blickem C, Kennedy A, Reeves D, Bower P, Gaffney H, Gardner C, Lee V, Jariwala P, Dawson S, Bossabir R, Brooks H, Richardson G, Spackman E, Vassilev I, Chew-Graham C, Rogers A. Effect of information and telephone-guided access to community support for people with chronic kidney disease: randomised controlled trial. PLoS ONE 2014;9(10):e109135.
  • Bojke L, Soares M. Decision analysis: Eliciting experts’ beliefs to characterise uncertainties. In:Culyer AJ (ed.) Encyclopedia of Health Economics, Vol 1. San Diego:Elsevier;2014. pp149-154.
  • Briggs A, Drummond MF. Reporting guidelines for health economic evaluation: BMJ guidelines for authors and peer reviewers of economic submissions. In:Moher D, Altman DG, Schulz KF, Simera I, Wager E (eds.) Guidelines for Reporting Health Research: A Users Manual. John Wiley & Sons;2014.
  • Buxton M, Longworth L, Raftery J, Sculpher M, Towse A.  Reforming the cancer drug fund: focus on drugs that might be shown to be cost effective. BMJ 2014;349:g7276. Download from BMJ
  • Cary M, Byford S, Faria R. Measurement and valuation of health outcomes for economic evaluation and decision-making in healthcare. In Faria R, Mejia A (eds). Guidelines for the economic evaluation of healthcare technologies in Colombia: technical support documents. Instituto de Evaluación Tecnológica en Salud. Bogotá D.C.:IETS;2014 pp. 5-14.
  • Chan AK, Ford D, Namata H, Muzambi M, Nkhata MJ, Abongomera G, Mambule I, South A, Revill P  et al and the Lablite Team. The Lablite project: A cross-sectional mapping survey of decentralized HIV service provision in Malawi, Uganda and Zimbabwe. BMC Health Services Research 2014;14:352.
  • Claxton K, Revill P, Sculpher M, Wilkinson T, Cairns J, Briggs A. The Gates Reference Case for Economic Evaluation. The Bill and Melinda Gates Foundation;2014. ‌
  • Cockayne S, Pattenden J, Worthy G, Richardson G, Lewin R. Nurse facilitated Self-management support for people with heart failure and their family carers (SEMAPHFOR): a randomised controlled trial. International Journal of Nursing Studies 2014;51(9);1207-1213. 
  • Cookson R, Griffin S, Nord E. Incorporation of concerns for fairness in economic evaluation of health programs: overview. In: Culyer AJ (ed.) Encyclopedia of Health Economics, Vol 1. San Diego:Elsevier;2014. Pp27-34.
  • Cookson RSuhrcke M. Public Health: Overview. In: Culyer AJ (ed.) Encyclopedia of Health Economics, Vol 1. San Diego:Elsevier;2014. pp. 210-217. 
  • Drummond M. Why has Sweden been so prominent in health economics? In: Culyer A, Kobelt G, (eds). Portrait of a Health Economist. Lund, Sweden. The Swedish Institute for Health Economics 2014;pp:39-44.
  • Drummond M, de Pouvourville G, Jones E, Haig J, Saba G, Cawston H. A comparative analysis of two contrasting European approaches for rewarding the value added by drugs for cancer: England versus France. Pharmacoeconomics 2014;32(5):509-20.
  • Drummond M, Towse A. Orphan drugs policies: a suitable case for treatment. European Journal of Health Economics 2014;15(4):335-340.
  • Duarte A. Discounting in economic valuation of healthcare interventions. In Faria R, Mejia A (eds). Guidelines for the economic evaluation of healthcare technologies in Colombia: technical support documents. Instituto de Evaluación Tecnológica en Salud. Bogotá D.C.:IETS;2014 pp. 15-24
  • Eaton J, Menzies NA, Stover J, Cambiano V, Chindelevitch L, Core A, Hontelez JAC, Humair S, Kerr CC, Klein DJ, Mishra S, Mitchell KM, Nichols BE, Vickerman P, Bakker R, Barnighausen T, Bershteyn A, Bloom DE, Boiley M-C, Chang ST, Cohen T, Dodd PJ, Fraser C, Gopalappa C, Lundgren J, Martin NK, Mikkelsen E, Mountain E, Pham QD, Pickles M, Phillips A, Platt L, Pretorius C, Prudden HJ, Salomon JA, can de Vijer DAMC, de Vlas SJ, Wagner BG, White RG, Wilson DP, Zhang L, Blandford J, Meyer-Rath G, Remme M, Revill P, Sangrujee N, Terris-Prestholt F, Vassell A, Doherty M, Shaffer N, Easterbrook P, Hirnschall G, Hallett TB. Health benefits, costs, and cost-effectiveness of earlier eligibility for adult antiretroviral therapy and expanded treatment coverage: a combined analysis of 12 mathematical models. Lancet Global Health 2014;2(1):e23-34. Download from the Lancet
  • Epstein D, Sculpher MJ, Powell JT, Thompson SG, Brown LC, Greenhalgh RM (2014).  Long-term cost-effectiveness analysis of endovascular versus open repair for abdominal aortic aneurysm based on four randomized clinical trials.  British Journal of Surgery 2014;101(6):623–631.
  • Espinoza MA, Manca A, Claxton K, Sculpher MJ.  The value of heterogeneity for cost-effectiveness subgroup analysis: conceptual framework and application. Medical Decision Making 2014;34(8):951-964. Download from sagepub
  • Espinoza MA, Sculpher MJ, Manca A, Basu A. Analysing heterogeneity to support decision making. In: Culyer AJ (ed.) Encyclopedia of Health Economics, Vol 1. San Diego:Elsevier;2014. pp.71-76.
  • Essat M, Faria R, Gomersall T, Grimm S, Keetharuth A, Walker S, Dixon S, Palmer S, Sculpher M. (2014). Getting cost-effective technologies into practice: the value of implementation. Initial scoping review for phase 1. Policy Research Unit in Economic Evaluation of Health and Care Interventions (EEPRU)2014; Research Report 023:pp172. Download from EEPRU
  • Faria R, Barbieri M, Light K, Elliott KA, Sculpher MJ. The economics of medicines optimization: policy developments, remaining challenges and research priorities. British Medical Bulletin 2014;111(1):45-61. Download from Oxfordjournals
  • Faria R, Barbieri M, Light K, Sculpher MEconomics of Medicines Optimisation: Report for the Department of Health. Policy Research Unit in Economic Evaluation of Health and Care Interventions (EEPRU) 2014;research report RR0005:pp38. Download from EEPRU
  • Faria R, Gomes M, Epstein D, White IR. A guide to handling missing data in cost-effectiveness analysis conducted within randomised controlled trials. PharmacoEconomics 2014;32(12):1157-1170. Download from springer
  • Faria R, McKenna C, Palmer S. Optimizing the position and use of omalizumab for severe persistent allergic asthma using cost-effectiveness analysis. Value in Health 2014;17(8): 772-782. 
  • Faria R, Mejia A (eds). Guidelines for the economic evaluation of healthcare technologies in Colombia: technical support documents. Instituto de Evaluación Tecnológica en Salud. Bogotá D.C.;IETS:2014.pp55. 
  • Faria RRevill P. Decision rules in economic evaluation of healthcare interventions. In Faria R, Mejia A (eds). Guidelines for the economic evaluation of healthcare technologies in Colombia: technical support documents. Instituto de Evaluación Tecnológica en Salud. Bogotá D.C.:IETS;2014 pp. 42-54. 
  • Faria RWalker S, Whyte S, Dixon S, Palmer SSculpher MGetting cost-effective technologies into practice: the value of implementation. An application to novel anticoagulants in the prevention of stroke and systemic embolism. Policy Research Unit in Economic Evaluation of Health and Care Interventions (EEPRU) 2014; Research Report 022:pp82. Download from EEPRU
  • Gavan S, Harrison M, Iglesias Urrutia CP, Barton A, Manca A, Payne K. Economics of stratified medicine in rheumatoid arthritis. Current Rheumatology Reports 2014;16:468.
  • Griffiths A, Paracha N, Davies A, Branscombe N, Cowie MR, Sculpher MJ.  The cost effectiveness of ivabradine in the treatment of chronic heart failure from the UK National Health Service perspective. Heart 2014;100:1031-1036. Download from BMJ
  • Haakma W, Steuten LM, Bojke L, IJzerman MJ. Belief elicitation to populate health economic models of medical diagnostic devices in development. Applied Health Economics and Health Policy 2014;12(3):327-34.
  • Hall J, Buckley HL, Lamb KA, Stubbs N, Saramago P, Dumville JC, Cullum NA. Point prevalence of complex wounds in a defined United Kingdom population. Wound Repair and Regeneration 2014;22(6):694-700. 
  • Hallett TB, Menzies NA, Revill P, Keebler D, Borquez A, McRobie R, Eaton JW, Using modeling to inform international guidelines for antiretroviral therapy. AIDS 2014;28(S1):S1-S4.
  • Hinde S, Soares M, Burch J, Marson A, Woolacott N, Palmer S. The added clinical and economic value of diagnostic testing for epilepsy surgery. Epilepsy Research 2014;108(4)775-781. Download from sciencedirect
  • Jönsson L, Sandin R, Ekman M, Ramsberg J, Charbonneau C, Huang X, Jönsson B, Weinstein M, Drummond MF. Analyzing overall survival in randomized controlled trials with cross-over and implications for economic evaluation. Value in Health 2014;17(6);707-713.
  • Keebler D, Revill P, (joint 1st authors) Braithwaite S, Phillips A, Blaser N, Borquez A, Cambiano V, Ciaranello A, Estill J, Gray R, Hill A, Keiser O, Kessler J, Menzies NA, Nucifora KA, Salazar- Vizcaya L, Walker S, Welte A, Easterbrook P, Doherty M, Hirnschall G, Hallett T.  Cost effectiveness of different strategies to monitor adults on antiretroviral treatment: a combined analysis of three mathematical models. Lancet Global Health 2014;2(1):e35-43.
  • Madan J, Ades AE, Price M, Maitland K, Jemutai J, Revill P, Welton NJ. Strategies for the efficient computation of the expected value of partial perfect information. Medical Decision Making 2014;34(3):327-342. Download from sagepub
  • McKenna C. Uncertainty and the value of additional evidence in health care decisions. In Faria R, Mejia A. (eds). Guidelines for the economic evaluation of healthcare technologies in Colombia: technical support documents. Instituto de Evaluación Tecnológica en Salud. Bogotá D.C.:IETS;2014 pp. 25-41. Download from IETS
  • McMillan A, Bratton DJ, Faria R, Laskawiec-Szkonter M, Griffin S, Davies RJ, Nunn AJ, Stradling JR, Riha RL, Morrell MJ. Continuous positive airway pressure in older people with obstructive sleep apnoea syndrome (PREDICT): a 12-month, multicentre, randomised trial. The Lancet, Respiratory Medicine 2014;2(10):804-812.
  • Mejia A, Richardson G, Pattenden J, Cockayne S, Lewin R. Cost-effectiveness of a nurse facilitated, cognitive behavioural self-management programme compared with usual care using CBT manual alone for patients with heart failure: secondary analysis of data from the SEMAPHFOR trial. International Journal of Nursing Studies 2014;51(9):1214-1220.
  • Norheim OF, Johri M, Chisholm D, Nord E, Baltussen R, Brock DW, Carlsson P, Cookson R, Daniels N, Danis M, Fleurbaey M, Johansson KA, Kapiriri, L, Littlejohns P, Mbeeli T, Rao KD, Tan-Torres Edejer T, Wikler D. Guidance on priority setting in health care (GPS-Health): the inclusion of equity criteria not captured by cost-effectiveness analysis. Cost Effectiveness and Resource Allocation 2014;12:18.
  • Panagioti M, Richardson G, Small N, Murray E, Rogers A, Kennedy A, Newman S, Bower P. Self-management support interventions to reduce health care utilisation without compromising outcomes: a systematic review and meta-analysis.  BMC Health Services Research 2014;14:356.
  • Penazzato M, Revill P, Prendergast AJ, Collins IJ, Walker S, Elyanu P, Sculpher M, Gibb D. Early infant diagnosis of HIV infection in low and middle income countries: Does one size fit all? Lancet Infectious Diseases 2014;14(7):650-655. Download from the lancet
  • Phillips A, Cambiano V, Miners A, Revill P, Pillay D, Lundgren J, Bennett D, Raizes E, Nakagawa F, De Luca A, Vitoria M, Barcarolo J, Perriens J, Jordan M, Bertagnolio S. Effectiveness and cost-effectiveness of potential responses to future high levels of transmitted HIV drug resistance in antiretroviral drug-naive populations beginning treatment: modelling study and economic analysisThe Lancet HIV 2014;1(2):e85-e93. Download from Elsevier
  • Phillips A, Cambiano V, Nakagawa F, Magubu T, Miners A, Ford D, Pillay D, De Luca A, Lundgren J, Revill P. Cost-effectiveness of HIV drug resistance testing to inform switching to second line antiretroviral therapy in low income settings. PLoS ONE 2014;9(10);e109148. Download from plosone
  • Phillips AN, Munderi P, Revill P, El-Sadr WM, Lundgren JD. Antiretroviral therapy recommendations for the global community: aspiration versus reality. AIDS 2014;28(7):939-941. Download from aidsonline
  • Reeves D, Blickem C, Vassilev I, Brooks H, Kennedy A, Richardson G, Rogers A. The contribution of social networks to the health and self-management of patients with long-term conditions: A longitudinal study. PLOS ONE 2014;9(6):e98340.
  • Reeves D, Hann M, Rick J, Rowe K, Small N, Burt J, Roland M, Protheroe J, Blakeman T, Richardson G, Kennedy A, Bower P.  Care plans and care planning in the management of long-term conditions in the UK: A controlled prospective cohort study.  British Journal of General Practice 2014;64(626):e568-e575.
  • Revill P, Asaria M, Phillips A, Gibb DM, Gilks CF. WHO decides what is fair? International HIV treatment guidelines, social value judgements and equitable provision of lifesaving antiretroviral therapy. Centre for Health Economics, University of York; 2014.
  • Revill P, Walker S, Madan J, Ciaranello A, Mwase T, Gibb DM, Claxton K, Sculpher M. Using cost-effectiveness thresholds to determine value for money in low- and middle-income country healthcare systems: are current international norms fit for purpose? Centre for Health Economics, University of York;CHE Research Paper 98 (PDF , 592kb) 2014.
  • Saramago P, Chuang L-H, Soares M. Network meta-analysis of (individual patient) time to event data alongside (aggregate) count data. Centre for Health Economics, University of York; 2014.
  • Saramago P, Chuang L-H, Soares MO. Network meta-analysis of (individual patient) time to event data alongside (aggregate) count data. BMC Medical Research Methodology 2014;14:105. Download from biomedcentral
  • Saramago P, Cooper NJ, Sutton AJ, Hayes M, Dunn K, Manca A, Kendrick D. Cost-effectiveness of interventions for increasing the possession of functioning smoke alarms in households with pre-school children: a modelling study. BMC Public Health 2014;14:459.
  • Sculpher M, Walker S, Hinde S, Claxton KResearch to inform resource allocation in health and social care. Results of a scoping study. Policy Research Unit in Economic Evaluation of Health and Care Interventions (EEPRU)2014; Research Report 017. Download from EEPRU
  • Seuring T, Goryakin Y, Suhrcke M. The impact of diabetes on employment in Mexico. Centre for Health Economics, University of York;CHE Research Paper 100 (PDF , 460kb) 2014.
  • Soares MO, Dumville J, Ades AE, Welton NJ. Treatment comparisons for decision making: facing the problems of sparse and few data. Journal of the Royal Statistical Society: Series A (Statistics in Society) 2014;177(1):259-279. Download from wiley
  • Soares MO, Welton NJ, Harrison DA, Peura P, Shankar-Hari M, Harvey SE, Madan J, Ades AE, Rowan KM, Palmer SJ. Intravenous immunoglobulin for severe sepsis and septic shock: clinical effectiveness, cost effectiveness and value of a further randomised controlled trial. Critical Care 2014;18(6):649.
  • Soárez PC, Soares MO, Novaes HM. Modelos de decisão para avaliações econômicas de tecnologias em saúde (Decision modeling for economic evaluation of health technologies). Ciência & Saúde Coletiva 2014;19(10):4209-4222. Download from scielo 
  • Sorenson C, Drummond M. Improving medical device regulation: the United States and Europe in perspective. The Milbank Quarterly 2014;92(1):114-50.
  • Spackman E, Richmond S, Sculpher M, Bland M, Brealey S, Gabe R, Hopton A, Keding A, Lansdown H, Perren S, Torgerson D, Watt I, MacPherson H. Cost-effectiveness analysis of acupuncture, counselling and usual care in treating patients with depression: The results of the ACUDep trial. PLoS ONE 2014;9(11):e113726.
  • Spackman ESculpher M, Howard J, Malfroy M, Llewelyn C, Choo L, Hodge R, Johnson T, Rees DC, Fijnvandraat K, Kirby-Allen M, Davies S, Williamson L. Cost effectiveness analysis of pre-operative transfusion in patients with Sickle Cell Disease using evidence from the TAPS trial. European Journal of Haematology 2014;92(3):249-55.
  • Tarricone R, Ferrè F, Torbica A, Drummond MF. Generating appropriate clinical data for value assessment of medical devices: what role does regulation play? Expert Review of Pharmacoeconomics & Outcomes Research 2014;14(5):707-718.
  • Tina Shih YC, Mullins Daniel C, Drummond M. The role of economic evaluation in meeting IOM's recommendations on delivering high-quality cancer care. Value in health 2014;17(5):497-500. 
  • van den Berg B, Fiebig D, Hall J. Well-being losses due to care-giving. Journal of Health Economics 2014;35:123-131.
  • Victoor A, Hansen J, van den Akker-van Marle M E, van den Berg B, van den Hout W B, de Jong J D. Choosing your health insurance package: A method for measuring the public's preferences for changes in the national health insurance plan. Health Policy 2014;117(2):257-165. 
  • Walker SFaria R, Whyte S, Dixon S, Palmer SSculpher MGetting cost-effective technologies into practice: the value of implementation. Report on framework for valuing implementation initiatives. Policy Research Unit in Economic Evaluation of Health and Care Interventions (EEPRU)2014;Research Report 024:pp26. Download from EEPRU
  • Walker S, Walker J, Richardson GPalmer S, Wu Q, Gilbody S, Martin P, Holm Hansen C, Sawhney A, Murray G, Sculpher M, Sharpe M. Cost-effectiveness of combining systematic identification and treatment of co-morbid major depression for people with chronic diseases: the example of cancer. Psychological Medicine 2014;44(7):1451-1460. Download from Cambridge journals 
  • Weatherly H, Cookson R, Drummond M. Economic evaluation of public health interventions: methodological challenges. In: Culyer AJ (ed.) Encyclopedia of Health Economics, Vol 1. San Diego: Elsevier; 2014. pp 217-223.
  • Weatherly H, Faria R, van den Berg B. Valuing informal care for economic evaluation. In: Culyer AJ (ed.) Encyclopedia of Health Economics, Vol 1. San Diego: Elsevier; 2014. pp459-467.
  • Whyte S, Dixon S, Faria RWalker SPalmer SSculpher MGetting cost-effective technologies into practice: the value of implementation. An application to B-type natriuretic peptide (BNP) testing in diagnosing chronic heart failure. Policy Research Unit in Economic Evaluation of Health and Care Interventions (EEPRU) 2014; Research Report 025:pp30. Download from EEPRU
  • Wilkinson G, Drummond M. Impact of reimbursement policies on the adoption of medical devices in an outpatient setting. Health Policy and Technology 2014;3(4):281-286.

2013

  • Asaria M, Griffin S, Cookson R, Whyte S, Tappenden P. Distributional cost-effectiveness of health care programmes. Centre for Health Economics, University of York;  CHE Research Paper 91 (PDF , 1,278kb) 2013.‌
  • Asaria M, Griffin S, Cookson R. Distributional cost-effectiveness analysis: a tutorial. Centre for Health Economics, University of York; CHE Research Paper 92 (PDF , 1,651kb) 2013.
  • Asaria M, Griffin S, Cookson R. Measuring health inequality in the context of cost-effectiveness analysis. In Rosa Dias P, O’Donnell O (eds.) Health and Inequality (Research on Economic Inequality, Volume 21), Emerald Group Publishing Limited.pp:491-507. 2013. Download from emeraldinsight
  • Ashworth M, Schofield P, Doran T, Cookson R, Sutton M, Seed P, et al. The Public Health Impact (PHI) score – a new measure of public health effectiveness for general practices in England. British Journal of General Practice. 2013;63(609):291-9.
  • Barber S, Jackson C, Akhtar S, Bingham D, Ainsworth H, Hewitt C, Richardson G, Summerbell C, Pickett K, Moore H, Routen A, O’ Malley C, Brierley S, Wright J. "Pre-schoolers in the Playground” an outdoor physical activity intervention for children aged 18 months to 4 years old: Study protocol for a randomised controlled trial. Trials 2013;14(326).
  • Bayoumi A, Barnett P, Joyce V, Griffin S, Sun H, Bansback N, Holodniy M, Sanders G, Brown S, Kyriakides T, Angus B, Cameron W, Anis A, Sculpher M, Owens D. Cost-effectiveness of newer antiretroviral drugs in treatment-experienced patients with multi-drug resistant HIV disease. Jaids-Journal of acquired immune deficiency syndromes 2013;doi:10.1097/QAI.0000000000000002.
  • Bes RE, Van den Berg B. Ranking sources of hospital quality information for orthopedic surgery patients: consequences for the system of managed competition. The Patient - Patient-Centered Outcomes Research 2013;6(2):75-80.
  • Blickem C, Blakeman T, Kennedy A, Bower P, Reeves D, Gardner C, Lee V, Chew-Graham C, Richardson G, Brooks H, Dawson, S, Mossabir R, Jariwala, P, Swallow A, Kontopantelis E, Gaffney H, Small N, Spackman E, Rogers A. The clinical and cost-effectiveness of the BRinging Information and Guided Help Together (BRIGHT) intervention for the self-management support of people with stage 3 chronic kidney disease in primary care: study protocol for a randomized controlled trial. Trials 2013;14(1):28.
  • Callery P, Kyle RG, Weatherly H, Banks M, Ewing C, Powell P, Kirk S. Substituting community children's nursing services for inpatient care: a case study of costs and effects. Emergency Medicine Journal 2013;doi:10.1136/emermed-2012-201926.
  • Christiansen T, Cookson RGutacker N, García-Armesto S, Angulo-Pueyo E, Bernal-Delgado E, on behalf of the ECHO consortium. Handbook on methodology: Measurement of socioeconomic equity; ECHO 2014: Apr 27. 
  • Claxton K, Griffin S, Koffijberg H, McKenna C. Expected health benefits of additional evidence: Principles, methods and applications. Centre for Health Economics, University of York; CHE Research Paper 83 (PDF , 1,068kb) 2013. PCORI Technical Appendix (PDF , 983kb)
  • Claxton K, Martin S, Soares M, Rice N, Spackman E, Hinde S, Devlin N, Smith PC, Sculpher M. Methods for the estimation of the NICE cost effectiveness threshold. Centre for Health Economics, University of York, CHE Research Paper 81 (PDF , 3,781kb) 2013.
  • Cookson R. Can money teach morality? Commentary on Disney, Le Grand and Atkinson. From irresponsible knaves to responsible knights for Just 5p: behavioural public policy and the environment. In Oliver A (ed). Behavioural Public Policy. Cambridge University Press 2013:pp 88-93.
  • Cookson, R. Can the NICE ‘‘end-of-life premium’’ be given a coherent ethical justification? Health Politics, Policy and Law 2013;38(6):1129-1148.
  • Cookson R, Laudicella M, Li Donni P. Does hospital competition harm equity? Evidence from the English National Health Service. Journal of Health Economics 2013;32(2):410-422.
  • Cookson R, Sainsbury R, Glendinning C. (eds.) Jonathan Bradshaw on Social Policy: Selected Writings 1972-2011, University of York, York, 2013.
  • Davies A, Bakhai A, Schmitt C, Barrett A, Graham-Clarke P, Sculpher M. Prasugrel vs clopidogrel in patients with acute coronary syndrome undergoing percutaneous coronary intervention: a model-based cost-effectiveness analysis for Germany, Sweden, the Netherlands, and Turkey. Journal of Medical Economics 2013;16(4):510–521.
  • Drummond MF. Twenty years of using economic evaluations for drug reimbursement decisions. What has been achieved? Journal of health politics policy and law 2013;38(6):1081-1102.
  • Drummond MF. Future prospects for pharmacoeconomics and outcomes research in the emerging regions. Value in Health Regional Issues May 2013;2(1):3-4.
  • Drummond MF, Daniel Mullins C. Improving the quality of papers published in pharmacoeconomics and outcomes research. Value in health: the journal of the International Society for Pharmacoeconomics and Outcomes Research 2013;16(2):229-30.
  • Drummond MF, Shemilt I, Vale L, On behalf of the Campbell and Cochrane Economic Methods group. Should the Cochrane Collaboration be producing reviews of efficiency? Cochrane Database Syst Rev 2013 October 24;10: ED000071.
  • Drummond MF, Tarricone R, Torbica A. Assessing the added value of health technologies: reconciling different perspectives. Value in Health 2013;16(1):S7-S13.
  • Eaton J, Menzies NA, Stover J, Cambiano V, Chindelevitch L, Core A, Hontelez JAC, Humair S, Kerr CC, Klein DJ, Mishra S, Mitchell KM, Nichols BE, Vickerman P, Bakker R, Barnighausen T, Bershteyn A, Bloom DE, Boiley M-C, Chang ST, Cohen T, Dodd PJ, Fraser C, Gopalappa C, Lundgren J, Martin NK, Mikkelsen E, Mountain E, Pham QD, Pickles M, Phillips A, Platt L, Pretorius C, Prudden HJ, Salomon JA, can de Vijer DAMC, de Vlas SJ, Wagner BG, White RG, Wilson DP, Zhang L, Blandford J, Meyer-Rath G, Remme M, Revill P, Sangrujee N, Terris-Prestholt F, Vassell A, Doherty M, Shaffer N, Easterbrook P, Hirnschall G, Hallett TB. How Should HIV Programmes Respond to Evidence for the Benefits of Earlier ART Initiation? A Combined Analysis of Twelve Mathematical Models. Report for the Consolidated Clinical and Programmatic ART Guidelines Committees, HIV Department of the World Health Organizations 2013;WHO/HIV:2013.56. Download from WHO
  • Edlin R, McCabe C, Round J, Wright J, Claxton K, Sculpher M, Cookson R. Understanding Harris’ understanding of CEA: is cost effective resource allocation undone? Journal of Health Services Research and Policy. 2013;18(1)(1):34-9.
  • Eldabe S, Raphael J, Thompson S, Manca A, deBelder M, Aggarwal R, Banks M, Morag B, Merotra S, Adeniba R, Davies E, Taylor R.S. The effectiveness and cost-effectiveness of spinal cord stimulation for refractory angina (RASCAL study): study protocol for a pilot randomised controlled trial. Trials 2013;14(57).
  • Epstein D, Mochón LG, Espín J, Soares MO. Use of multi-parameter evidence synthesis to assess the appropriateness of data and structure in decision models. Medical Decision Making 2013;33(5):715-730. Download from sagepub
  • Faria R, Bojke L, Epstein D, Corbacho B, Sculpher M, On the behalf of the REFLUX trial group. Cost-effectiveness of laparoscopic fundoplication versus continued medical management for the treatment of gastro-oesophageal reflux disease based on long-term follow-up of the REFLUX trial. British Journal of Surgery 2013;100(9):1205-1213.
  • Faria R, Manca A. Statistical analysis of clinical trial data for resource allocation decisions. In:Durlauf SN, Blume LE. (eds). The New Palgrave Dictionary of Economics Online. Palgrave Macmillan. 2013.
  • Faria R, McKenna C, Wade R, Yang H, Woolacott N, Sculpher M. The EOS 2D/3D X-ray imaging system: A cost-effectiveness analysis quantifying the health benefits from reduced radiation exposure. European Journal of Radiology 2013;82(8):e342-e349.
  • Faria R, Spackman E, Burch JA, Corbacho Martin MB, Todd D, Pepper C, Woolacott NF, Palmer S. Dabigatran for the prevention of stroke and systemic embolism in atrial fibrillation: a NICE single technology appraisal. Pharmacoeconomics 2013;31(7):551-562.
  • Favato G, Baio G, Capone A, Marcellusi A, Costa S, Garganese G, Picardo M, Drummond M, Jonsson B, Scambia G, Zweifel P, Mennini F. Transparency or proper study valuation procedures missed? Medical Care 2013;51(4):374-378.
  • Fischer A, Threlfall A, Meah S, Cookson R, Rutter R, Kelly M. The appraisal of public health interventions: Overview. Journal of Public Health 2013;35(4):488-494.
  • Grant A, Boachie C, Cotton S, Faria R, Bojke L, Epstein D, Ramsay C, Corbacho B, Sculpher M, Krukowski Zh, Heading R, Campbell M. Clinical and economic evaluation of laparoscopic surgery compared with medical management for gastro-oesophageal reflux disease: 5-year follow-up of multicentre randomised trial (the REFLUX trial). Health Technology Assessment 2013;17(22).
  • Grant A, Cotton SC, Boachie C, Ramsay C, Krukowski ZH, Headling RC, Campbell MK, The REFLUX Trial Group (CHE members Bojke L, Faria R, Sculpher M,) Minimal access surgery compared with medical management for gastro-oesophageal reflux disease: five year follow-up of a randomised controlled trial (REFLUX). BMJ 2013;346:f1908.
  • Gray R, Keebler D, Revill P, Braithwaite S, Phillips A, Blaser N, Cambiano V, Ciaranello A, Estill J, Gray R, Hill A, Keiser O, Salazar-Vizcaya L, Hallett T. The Cost and Impact of Alternative Strategies for Monitoring Child Patients on ART. Report for the Consolidated Clinical and Programmatic ART Guidelines Committees, the HIV Department of the World Health Organizations 2013;WHO/HIV:2013.60. Download from WHO.
  • Grutters JPC, Sculpher MJ, Briggs AH, Severens JL, Candel MJ, Stahl SE, De Ruyssche D, Boer A, Ramaekers BLT, Joore MA. Acknowledging patient heterogeneity in economic evaluation.  A systematic literature review. Pharmacoeconomics. 2013;31(2)(2):111-23.
  • Howard J, Malfroy M, Llewelyn C, Choo L, Hodge R, Johnson T, Purohit S, Rees D, Tillyer L, Walker I, Fijnvandraat K, Kirby-Allen M, Spackman E, Davies S, Williamson L.  The transfusion alternatives preoperatively in sickle cell disease (TAPS) study: a randomised controlled multi-centre clinical trial. The Lancet  2013;381(9870):930-938.
  • Husereau D, Drummond M, Petrou S, Carswell C, Mother D, Greenberg D, Augustovski  F, Briggs AH, Mauskopf  J, Loder E. Consolidated Health Economic Evaluation Reporting Standards (CHEERS) statement. British Medical Journal 2013;Mar25:346.f1049.
  • Husereau D, Drummond M, Petrou S, Carswell C, Mother D, Greenberg D, Augustovski F, Briggs AH, Mauskopf J, Loder E. Consolidated Health Economic Evaluation Reporting Standards (CHEERS) - explanation and elaboration: A report of the ISPOR health economic evaluation publication guidelines good reporting practices task force. Value in Health 2013;16(2):231-250.
  • Kearns B, Ara R, Wailoo A, Manca A, Hernandez Alava M, Abrams K, Campbell M. Good practice guidelines for the use of statistical regression models in economic evaluation. Pharmacoeconomics. 2013;31(8):643-652.
  • Keebler D, Revill P, Braithwaite S, Phillips A, Blaser N, Borquez A, Cambiano V, Ciaranello A, Estill J, Gray R, Hill A, Keiser O, Kessler J, Menzies NA, Nucifora KA, Salazar-Vizcaya L, Walker S, Welte A, Easterbrook P, Doherty M, Hirnschall G, Hallett T. How Should HIV Programmes Monitor Adults on ART? A Combined Analysis of Three Mathematical models. Report for the Consolidated Clinical and Programmatic ART Guidelines Committees, the HIV Department of the World Health Organizations. 2013;WHO/HIV:2013.61. Download from WHO
  • Kennedy A, Bower P, Reeves D, Blakeman T, Bowen R, Chew-Graham C, Eden M, Fullwood C, Gaffney H, Gardner C, Lee V, Morris R, Protheroe J, Richardson G, Sanders C, Swallow A, Thompson D, Rogers, A. Implementation of self management support for long term conditions in routine primary care settings: cluster randomised controlled trial. British Medical Journal 2013;346:f2882.
  • Lensberg B, Drummond MF, Danchenko N, Despiégel N, François C. Challenges in measuring and valuing productivity costs, and their relevance in mood disorders. ClinicoEconomics and Outcomes Research 2013;5:565-573.
  • Longworth L, Youn J, Bojke L, Palmer S, Griffin S, Spackman E, Claxton, K. When does NICE recommend the use of Health technologies within a programme of evidence development? : A systematic review of NICE guidance. Pharmacoeconomics 2013;31(2):137-49.
  • Mabugu T, Revill P, Van den Berg B. The methodological challenges for the estimation of quality of life in children for use in economic evaluation in low income countries. Value in Health Regional Issues 2013;2(2):231-239
  • MacPherson H, Richmond S, Bland M, Brealey S, Gabe R, Hopton A, Keding A, Lansdow H,  Perren S, Sculpher MSpackman E,  Torgerson D, Watt I.  Acupuncture and counselling for depression in primary care: a randomised controlled trial.  PLOS Medicine 2013;10(9):e1001518. Download from plosmedicine
  • Marks L, Weatherly HLA, Mason A. Prioritizing investment in public health and health equity: what can commissioners do? Public Health 2013;127(5):410-418.
  • Naci H, Spackman E. National approaches to comparative effectiveness research. In: Handbook of Health Services Research. Springer 2013.
  • Norman G, Faria R, Paton F, Llewellyn A, Fox D, Palmer S, Clifton I, Paton J, Woolacott N, McKenna C. Omalizumab for the treatment of severe persistent allergic asthma: a systematic review and economic evaluation. Health Technology Assessment 2013;17(52):1–342.
  • Norman R, Church J, van den Berg B, Goodall S. Australian health-related quality of life population norms derived from the SF-6D. Australian and New Zealand Journal of Public Health. 2013;37(1)(1):17-23.
  • Owen-Jones E, Bekkers MJ, Butler C, Cannings-John R, Channon S, Hood K, Gregory J, Kemp A, Kenkre J, Martin Corbacho B, Montgomery A, Moody G, Pickett K, Richardson G, Roberts Z, Ronaldson S, Sanders J, Stamuli E, Torgerson D, Robling M, The effectiveness and cost-effectiveness of the Family Nurse Partnership home visiting programme for first time teenage mothers in England: a protocol for the Building Blocks randomised controlled trial. BMC Pediatrics 2013;13(114).
  • Pitman R, Nagy LD, Sculpher MJ. Cost-effectiveness of childhood influenza vaccination in England and Wales: Results from a dynamic transmission model. Vaccine 2013;31(6):927-42.
  • Revill P, Ryan P, McNamara A, Normand C. A cost and outcomes analysis of alternative models of care for young children with severe disabilities in Ireland. ALTER The European Journal of Disability Research 2013;7(4):260-274.
  • Richardson G, Epstein D, Chew-Graham C, Dowrick C, Bentall RP, Morriss RK, Peters S, Riste L, Lovell K, Dunn G, Wearden AJ. Cost-effectiveness of supported self-management for CFS/ME patients in primary care. BMC Family Practice 2013;14(12).
  • Rudmik L, Drummond M. Health economic evaluation: Important principles and methodology. Laryngoscope 2013;123(6):1341-1347.
  • Schmitt LHM, Brugere C. Capturing ecosystem services, stakeholders’ preferences and trade-offs in coastal aquaculture decisions: a bayesian belief network application. PLoS ONE 2013;8(10):e75956.
  • Sculpher MJ. Methods development for health technology assessment: is it time to set priorities? Medical Decision Making 2013;33(3):313-5. Download from sagepub
  • Shah K, Cookson R, Culyer AJ, Littlejohns P. NICE’s social value judgements about equity in health and health care. Health Economics, Policy and Law 2012;8(2):145-65. Download from Cambridge journals
  • Shemilt I, McDaid D, Marsh K, Henderson C, Bertranou E, Mallander J, Drummond MF, Mugford M, Vale L. Issues in the incorporation of economic perspectives and evidence into Cochrane reviews. Systematic Reviews 2013 Sep 20;2(83):10.1186/2046-4053-2-83.
  • Soares MO, Dumville J, Ashby RL, Iglesias Urrutia CP, Bojke L, Adderley UJ, McGinnis E, Stubbs N, Torgerson D, Claxton K, Cullum N. Methods to assess cost effectiveness and value of further research when data are sparse: Negative-pressure wound therapy for severe pressure ulcers. Medical Decision Making 2013;33(3):415-36.
  • Sorenson C, Drummond MF, Bhuiyan Khan B. Medical technology as a key driver of rising health expenditures: disentangling the relationship. ClinicoEconomics and Outcomes Research 2013;5:223-234.
  • Sorenson C, Drummond MF, Burns LR. Evolving reimbursement and pricing policies for devices in Europe and the United States should encourage greater value. Health affairs (Project Hope) 2013 April;32(4):788-796.
  • Sorenson C, Drummond MF, Wilkinson G. Use of innovation payments to encourage the adoption of new medical technologies in the English NHS. Health Policy and Technology 2013;2(3):168-173.
  • Spackman DE. The significance and international influence of NICE.  The Economic Evaluation of Health technology and Public policy - the case from overseas and the course of Japan. Tokyo, Japan: Jiho; 2013.
  • Spackman E, Kadiyala S, Neumann PJ, Veenstra DL, Sullivan SD. The validity of dependence as a health outcome measure in Alzheimer disease.  American Journal of Alzheimer's Disease & Other Dementias 2013;28(3):245-252.
  • Spackman E, Rice S, Norman G, Suh D-C, Eastwood A, Palmer S. Trastuzumab for the treatment of HER2-positive metastatic gastric cancer: A NICE single technology appraisal. Pharmacoeconomics 2013; 31(3):185-194.
  • Spackman ESculpher M, Howard J, Malfroy M, Llewelyn C, Choo L,  Hodge R, Johnson T, Rees D, Fijnvandraat K, Kirby-Allen M, Davies S, Williamson L. Cost effectiveness analysis of pre-operative transfusion in patients with sickle cell disease using evidence from the TAPS trial. European Journal of Haematology  2013;doi:10.1111/ejh.12232.
  • Spinner D, Birt J, Walter J, Bowman LLB, Mauskopf J, Drummond M, Copley-Merriman C. Do different clinical evidence bases lead to discordant health-technology assessment decisions? An in-depth case series across three jurisdictions. ClinicoEconomics and Outcomes Research 2013;5:69-85.
  • Tsoi B, Masucci L, Campbell K, Drummond MF, O'Reilly D, Goeree R. Harmonization of reimbursement and regulatory approval processes: a systematic review of international experiences. Expert Review of Pharmacoeconomics and Outcomes Research 2013;13(4):497-511.
  • Van den Berg B, Gafni A, Portrait F. Attributing a monetary value to patients’ time: A contingent valuation approach. Centre for Health Economics, University of York; CHE Research Paper 90 (PDF , 1,074kb)‌ 2013.
  • Van Dijk CE, Van den Berg B, Verheij RA, Spreeuwenberg P, Groenewegen PP, De Bakker DH. Moral hazard and supplier-induced demand: empirical evidence in general practice. Health Economics 2013;22(3):340-352.
  • Wade R, Spackman E, Corbett M, Walker S, Light K, Naik R, Sculpher M, Eastwood A. Adjunctive colposcopy technologies for examination of the uterine cervix – DySIS, LuViva advanced cervical scan and niris imaging system. Health Technology Assessment 2013;17(8). Download from HTA.
  • Walker S, Girardin F, McKenna C, Ball SG, Nixon J, Plein S, Greenwood JP, Sculpher M. Cost-effectiveness of cardiovascular magnetic resonance in the diagnosis of coronary heart disease: an economic evaluation using data from the CE-MARC study. Heart 2013;99(12):873-81.
  • Weatherly H, Faria R, Van den Berg B. Valuing informal care for economic evaluation. In: Elsevier On-line Encyclopaedia of Health Economics; Forthcoming.

2012

  • Ashby R, Dumville J, Soares M, McGinnis E, Stubbs N, Torgerson D, Cullum N. A pilot randomised controlled trial of negative pressure wound therapy (NPWT) to treat grade III/IV pressure ulcers. Trials 2012;13(119). Download from trialsjournal
  • Basu A, Manca A. Regression estimators for generic health-related quality of life and quality-adjusted life years. Medical Decision Making 2012;32(1):56-69.
  • Bojke L, Spackman E, Hinde S, Helliwell P. Capturing all of the costs in NICE appraisals: the impact of inflammatory rheumatic diseases on productivity. Rheumatology 2012;51(2):210-15.
  • Bower P, Kennedy A, Reeves D, Richardson G. A cluster randomised controlled trial of the clinical and cost-effectiveness of a “whole-systems” model of self management support for the management of long term conditions in primary care:trial protocol. Implementation Science 2012;7:7(January).
  • Briggs AH, Drummond MF. Reporting guidelines for health economic evaluation: BMJ guidelines for authors and peer reviewers of economic submissions. In: BMJ User's Manual; forthcoming.
  • Briggs AH, Weinstein MC, Fenwick E, Karnon J, Sculpher MJ, Paltiel AD. Model parameter estimation and uncertainty: A report of the ISPOR-SMDM Modelling Good Research Practices Task Force Working Group-6. Medical Decision Making 2012;32(5):722-32.
  • Briggs AH, Weinstein MC, Fenwick EAL, Karnon J, Sculpher MJ, Paltiel AD. on behalf of the ISPOR-SMDMK Modelling Good Research Practices Task Force (2012).  Model parameter estimation and uncertainty: a report of the ISPOR-SMDM Modelling Good Research Practices Task Force-6. Value in Health 2012;15(6):835-42.
  • Burch J, Griffin S, McKenna C, Walker S, Paton J, Wright K, Woolacott N. Omalizumab for the treatment of severe persistent allergic asthma in children Aged 6-11 years: a NICE single technology appraisal. Pharmacoeconomics 2012;30(11):991-1004. Download from adisonline
  • Burch J, Hinde S, Palmer S, Beyer F, Minton J, Marson A, Wieshmann U, Woolacott N, Soares M. The clinical and cost-effectiveness of technologies used to visualise the seizure focus in people with refractory epilepsy being considered for surgery: a systematic review and decision-analytical model. Health Technology Assessment 2012;16(34). Download from hta
  • Burch J, Marson A, Beyer F, Soares M, Hinde S, Wieshmann U, Woolacott N. Dilemmas in the interpretation of diagnostic accuracy studies on presurgical workup for epilepsy surgery. Epilepsia 2012;53(8):1294-302. Download from wiley 
  • Burton C, Richardson G, Sharpe M. Healthcare costs incurred by repeated referral of patients with medically unexplained symptoms to secondary medical care. Journal of Psychosomatic Research 2012;72(3):242-247.
  • Cabieses B, Espinoza M. The power of chameleonic ideas in the policy decision-making process: the case of the 'students' revolution' in Chile. Journal of Education for Teaching: International research and pedagogy 2012;38(4):509-11.
  • Callery P, Kyle R, Weatherly H, Banks M, Ewing C, Powell P, Kirk S. Comparison of the costs of care during acute illness by two community children's nursing teams. Emergency Medicine 2012;doi:10.1136/emermed-2012-201930.
  • Chuang LH, Soares MO, Tilbrook H, Cox H, Hewitt CE, Aplin J, Semlyen A, Trewhela A, Watt I, Torgerson D. A pragmatic multi-centered randomised controlled trial of yoga for chronic low back pain: economic evaluation Spine 2012;37(18):1593-1601.
  • Claxton K, Palmer S, Longworth L, Bojke L, Griffin S, McKenna C, Soares M, Spackman DE, Youn J. Informing a decision framework for when NICE should recommend the use of health technologies only in the context of an appropriately designed programme of evidence development. Health Technology Assessment 2012;16. Download from hta
  • Conigliani C, Manca A, Tancredi A. Statistical methods for health care economic evaluation. In: Faltin F, Kenett R, Ruggeri F, editors. Statistical Methods in Healthcare:Wiley;2012:Chapter 18.
  • Cookson RClaxton KThe humble economist. Tony Culyer on health, health care and social decision making. Office of Health Economics, London and University of York, 2012. The humble economist
  • Cookson R, Dawson D. Hospital competition and patient choice in publicly funded health care. In: Jones AM, editor. The Elgar Companion to Health Economics (2 nd Edition) Cheltenham: Edward Elgar;2012.
  • Cookson R, Laudicella M, Li Donni P. Measuring change in health care equity using small area administrative data – evidence from the English NHS 2001-8. Social Science and Medicine 2012;75(8):1514-1522.
  • Cookson R, Laudicella M, Li Donni P, Dusheiko M. Effects of the Blair/Brown health reforms on socioeconomic equity in health care. Journal of Health Services Research and Policy 2012;17(Suppl1):55-63.
  • Cookson R, Nord E. Incorporating concern for fairness into economic evaluation of health programs: overview. In: Elsevier On-line Encyclopaedia of Health Economics; forthcoming.
  • Cooper NJ, Kendrick D, Achana F, Dhiman P, He Z, Wynn P, Le Cozannet E, Saramago P, Sutton A. Network meta-analysis to evaluate the effectiveness of interventions to increase the uptake of smoke alarms. Epidemiologic Reviews 2012;34(1):32-45.
  • Costa-Font J, Karlsson M, Van den Berg B. Redesigning long-term care finance and delivery. Applied Economic Perspectives and Policy 2012;34(2):215-19.
  • Culyer AJ. Hic sunt dracones: the future of Health Technology Assessment - one economist's perspective. Medical Decision Making 2012;32:E25-E32.
  • Drummond M. Twenty years of using economic evaluations for reimbursement decisions. What have we achieved? Centre for Health Economics, University of York; CHE Research Paper 75 (PDF , 765kb)‌‎‌‎ 2012.
  • Drummond MF. Economic evaluation and decision makers In: Jones AM, editor. The Elgar Companion to Health Economics. Cheltenham: Edward Elgar; 2012. p. 640.
  • Drummond M, Neumann P, Jonsson B, Luce B, Schwartz J, Siebert U, Sullivan S. Can we reliably benchmark health technology assessment organizations? International Journal of Technology Assessment in Health Care 2012;28(2):159-65.
  • Drummond MF, Towse A. Is it time to reconsider the role of patient co-payments for pharmaceuticals in Europe? European Journal of Health Economics 2012;13:1-5.
  • Dumville JC, Soares MO, O'Meara S, Cullum N. Systematic review and mixed treatment comparison: Dressings to heal diabetic foot ulcers. Diabetologia 2012;55:1902-1910. Download from springerlink
  • Faria R, Weatherly H, Van den Berg B. A review of approaches to measure and monetarily value informal careBerg. In: Curtis L, editor. Unit costs of health and social care 2012. Kent: PSSRU; 2012. p. 22-31.
  • Favato G, Baio G, Capone A, Marcellusi A, Costa S, Garganese G, Picardo M, Drummond MF, Jonsson B, Scambia G, Zweifel P, Mennini F. Novel health economic evaluation of a vaccination strategy to prevent HPV-related diseases. The BEST study. Medical Care 2012;50(12):1076-85.
  • Fleetcroft R, Steel N, Cookson RWalker S, Howe A. Incentive payments are not related to expected health gain in the pay for performance scheme for UK primary care: cross-sectional analysis. BMC Health Services Research 2012;12(94). Download from biomedcentral
  • Ford JA, Waugh N, Sharma P, Sculpher MJ, Walker A. NICE guidance: a comparative study of the introduction of the single technology appraisal process and comparison with guidance from Scottish Medicines Consortium. BMJ Open 2012;2(1)doi:10.1136/bmjopen-2011-000671. Download from bmjopen
  • Garber AM, Sculpher M. Cost-effectiveness and payment policy. In: Pauly MV, McGuire TG, Barros PP, editors. Handbook in Health Economics. Oxford: Elsevier; 2012.
  • Joyce VR, Barnett PG, Chow A, Bayoumi AM, Griffin S, Sun H, Holodniy M, Brown ST, Kyriakides TC, Cameron DW, Youle M, Sculpher M, Anis AH, Owens DK. Effect of treatment interruption and intensification of antiretroviral therapy on health related quality of life in patients with advanced HIV: a randomized, controlled trial. Medical Decision Making 2012;32(1):70-82. Download from sagepub
  • Laudicella M, Siciliani L, Cookson R. Waiting times and socioeconomic status: evidence from England. Social Science and Medicine 2012;74(9):1331-41.
  • Luce B, Drummond MF. Principles for the conduct of comparative effectiveness research. Journal of Comparative Effectiveness Research 2012;1(5):431-40.
  • Manca A, Asseburg C, Bravo-Vergel Y, Seymour MT, Meade A, Stephens R, Parmar M, Sculpher MJ. The cost-effectiveness of different chemotherapy strategies for patients with poor prognosis advanced colorectal cancer (MRC FOCUS). Value in Health 2012;15(1):22-31.
  • Maund E, Craig D, Suekarran S, Neilson AR, Wright K, Brealey S, Dennis L, Goodchild L, Hanchard N, Rangan A, Richardson G, Robertson J, McDaid C. Management of frozen shoulder: a systematic review and cost-effectiveness analysis. HTA Report 09/13/02 2012.
  • McKenna C, Maund E, Sarowar M, Fox D, Stevenson M, Pepper C, Woolacott N, Palmer S. Dronedarone for the treatment of atrial fibrillation. A NICE Single Technology Appraisal. Pharmacoeconomics 2012;30:35-46.
  • McKenna C, Wade R, Faria R, Yang H, Stirk L, Gummerson N, Sculpher M, Woolacott N. EOS 2D/3D X-ray imaging system: a systematic review and economic evaluation. Health Technology Assessment 2012;16(14):1-188. Download from HTA
  • McKenna CWalker S, Lorgelly P, Fenwick E, Burch J, Suekarran S, Bakhai A, Witte K, Harden M, Wright K, Woolacott N, Palmer S. Cost-effectiveness of aldosterone antagonists for the treatment of post-myocardial infarction heart failure. Value in Health 2012;15(3). More details  from Value in Health
  • Mujica-Mota RE, Tarricone R, Ciani O, Bridges JFP, Drummond MF. Determinants of demand for total hip and knee arthroplasty: a systematic literature review. BMC Health Services Research 2012;12(1).
  • Norman R, Church J, Van den Berg B, Goodall S. Australian health-related quality of life population norms derived from the SF-6D. Australian and New Zealand Journal of Public Health 2012;Forthcoming.
  • Pichon-Riviere A, Augustovski F, Marti SG, Sullivan SD, Drummond MF. Transferability of health technology assessment reports in Latin America: an exploratory survey of researchers and decision makers. International Journal of Technology Assessment in Health Care 2012;28(2):180-86.
  • Pitman RL, White LJ, Sculpher MJ. Estimating the clinical impact of introducing paediatric influenza vaccination in England and Wales. Vaccine 2012;30:1208-24.
  • Revill PSculpher MJ. Cost effectiveness of interventions to tackle non-communicable diseases. British Medical Journal 2012;344:d7883. Download from bmj
  • Rodgers M, Asaria M, Walker S, McMillan D, Lucock M, Harden M, Palmer S, Eastwood A. The clinical effectiveness and cost-effectiveness of low-intensity psychological interventions for the secondary prevention of relapse after depression: a systematic review. Health Technology Assessment 2012;16(28):1-129. Download from HTA
  • Ryan P, Revill P, Devane D, Normand C. An assessment of the cost-effectiveness of midwife-led care in the United Kingdom Midwifery 2012;In Press. Download from sciencedirect
  • Saramago PManca A, Sutton AJ. Deriving input parameters for cost-effectiveness modelling: taxonomy of data types and approaches to their statistical synthesis. Value in Health 2012;15(5):639-649.
  • Saramago P, Sutton A, Cooper NJ, Manca A. Mixed treatment comparisons using aggregate-and individual-participant level data statistics in medicine Statistics in Medicine 2012;doi:10.1002.sim.5442.
  • Schut FT, Van den Berg B. Long-term care insurance in the Netherlands. In: Costa-Font J, Courbage C, editors. Financing Long-Term Care in Europe: Palgrave; 2012.
  • Sculpher MJ, Claxton K. Real economics needs to reflect real decisions a response to Johnson. Pharmacoeconomics 2012;30(2):133-36. Download from Springer
  • Soares MO. Is the QALY blind, deaf and dumb to equity? NICE's considerations over equity. British Medical Bulletin 2012;101(1):17-31. Download from oxfordjournals
  • Soares MO, Canto e Castro L. Continuous time simulation and discretized models for cost-effectiveness analysis. Pharmacoeconomics 2012;30(12):1101-17. Download from adisonline
  • Soares MO, Dumville J, Ashby R, Iglesias C, Bojke L, Adderley U, McGinnis E, Stubbs N, Torgerson D, Claxton K, Cullum N. Methods to assess cost effectiveness and value of further research when data are sparse: negative pressure wound therapy for severe pressure ulcers. Medical Decision Making 2012;doi:10.1177/0272989X12451058. Download from sagepub
  • Soares MO, Welton NJ, Harrison DA, Peura P, Hari MS, Harvey SE, Madan JJ, Ades AE, Palmer SJ, Rowan KM. An evaluation of the feasibility, cost and value of information of a multicentre randomised controlled trial of intravenous immunoglobulin for sepsis (severe sepsis and septic shock): incorporating a systematic review, meta-analysis and value of information analysis. Health Technology Assessment 2012;16(7).
  • Sorenson C, Drummond MF. Socio-economic value of orthopedic devices: evidence and methodological challenges. Orthopedic Research and Reviews 2012;4:87-96.
  • Sorenson C, Drummond MF, Chalkidou K. Comparative effectiveness research: the NICE experience. Journal of Clinical Oncology 2012;30(34).
  • Spackman DE, Kadiyala S, Neumann PJ, Veenstra DL, Sullivan SD. Measuring alzheimer disease progression with transition probabilities: estimates from NACC-UDS. Current Alzheimer Research 2012;9(9):1050-58.
  • Thwaites G, Auckland C, Barlow G, Cunningham R, Davies G, Edgeworth J, Greig J, Hopkins S, Jeyaratnam D, Jenkins N, Llewelyn M, Meisner S, Nsutebu E, Planche T, Read RC, Scarborough M, Soares MO, Tilley R, Török ME, Williams J, Wilson P, Wyllie S, Walker AS. Adjunctive rifampicin to reduce early mortality from Staphylococcus aureus bacteraemia (ARREST): study protocol for a randomised controlled trial. Trials 2012;13(December):241. Download from pubmed
  • Towse A, Drummond MF, Sorenson C. Measuring value:pharmacoeconomics theory and practice. In: Danzon P, Nicholson S, editors. The Oxford Handbook of The Economics of the Biopharmaceutical Industry. Oxford: Oxford University Press;2012. p.394-437.
  • Van den Berg B. SF-6D population norms. Health Economics 2012;21(12):1508-1512.
  • Wade R, Yang H, McKenna C, Faria R, Gummerson N, Woolacott N. A systematic review of the clinical effectiveness of EOS 2D/3D X-ray imaging system. European Spine Journal 2012;DOI 10.1007/s00586-012-2469-7.
  • Wagstaff A, Culyer AJ. Four decades of Health Economics through a bibliometric lens. Journal of Health Economics 2012;31:406-39.
  • Walker S, Griffin S, Claxton K, Palmer S, Sculpher M. Guest editorial, Appropriate perspectives for health care decisions. In: Curtis L, editor. Unit costs of health and social care 2012. Kent: PSSRU; 2012. p. 8-11. Download from pssru
  • Walker S, Sculpher M, Claxton K, Palmer S. Coverage with evidence development, only in research, risk sharing or patient access scheme? A framework for coverage decisions. Centre for Health Economics, University of York; ‌‎‌‎ 2012.
  • Walker S, Sculpher M, Claxton K, Palmer S. Coverage with evidence development, only in research, risk sharing or patient access scheme? A framework for coverage decisions. Value in Health 2012;15(3):570-579. More details from Value in Health
  • Wasi N, Van den Berg B, Buchmueller T. Heterogeneous effects of child disability on maternal labor supply: evidence from the 2000 US census. Labour Economics 2012;19(1):139-154.
  • Weatherly H, Cookson R, Drummond M. Evaluation of public health interventions: methodological challenges. In:Elsevier On-line Encyclopaedia of Health Economics; Forthcoming.
  • Yang H, Craig D, Epstein D, Bojke L, Light K, Bruce I, Sculpher M, Woolacott N. Golimumab for the treatment of psoriatic arthritis: A NICE Single Technology Appraisal. Pharmacoeconomics 2012;30:257-70.

2011 - 2008

2011 

  • Asaria M, Norman G, Hinde S, O'Connor J, Palmer S, Light K, Soares M, Eastwood A. Fingolimod for the treatment of relapsing remitting multiple sclerosis. (PDF , 2,151kb). CRD/ CHE Technology Assessment Group, University of York, 2011.
  • Backhouse M, Wonder M, Hornby E, Kilburg A, Drummond MF, Mayer FK. Early dialogue between the developers of ew technologies and pricing and reimbursement agencies. Value in Health 2011;14:608-15.
  • Barnett PG, Chow A, Joyce VR, Bayoumi AM, Griffin S, Nosyk B, Holodniy M, Brown ST, Sculpher M, Anis AH, Owens DK. Determinants of the cost of health services used by veterans with HIV. Medical Care 2011;49(9):848-56. Download from pubmed
  • Bloudek LM, Spackman DE, Blankenburg M, Sullivan SD. Review and meta-analysis of biomarkers and diagnostic imaging in alzheimer's disease. J Alzheimers Dis 2011;26(4).
  • Bloudek LM, Spackman DE, Veenstra DL, Sullivan SD. CDR state transition probabilities in alzheimer's disease with and without cholinesterase inhibitor intervention in an observation cohort J Alzheimers Dis 2011;26(4).
  • Bojke L, Epstein D, Craig D, Rodgers M, Woolacott N, Yang H, Sculpher M. Modelling the cost-effectiveness of biologic treatments for psoriatic arthritis. Rheumatology 2011;50:iv39-iv47.
  • Campbell HE, Epstein D, Bloomfield D, Griffin SManca A, Yarnold J, Bliss J, Johnson L, Earl H, Poole C, Hiller L, Dunn J, Hopwood P, Barrett-Lee P, Ellis P, Cameron D, Harris AL, Gray AM, Sculpher MJ. The cost-effectiveness of adjuvant chemotherapy for early breast cancer: a comparison of no chemotherapy and first, second, and third generation regimens for patients with differing prognoses. European Journal of Cancer 2011;Nov 47(17):2517-30. Download from Sciencedirect
  • Chase R, Culyer AJ, Dobrow M, Coyte P, Sawka C, O'Reilly S, Laing K, Trudeau M, Smith S, Hoch J, Morgan S, Peacok S, Abbott R, Sullivan T. Access to Cancer Drugs in Canada: Looking Beyond Coverage Decisions. Healthcare Policy 2011;6:27-35.
  • Chuang LH, Soares MO, Watson JM, Bland JM, Cullum N, Iglesias C, Kang'ombe AR, Torgerson D, Nelson EA, on behalf of the VenUS III team. Economic evaluation of a randomized controlled trial of ultrasound therapy for hard-to-heal venous leg ulcers. British Journal of Surgery 2011;98(8):1099-1106. Download from Wiley
  • Claxton KPalmer S, Longworth L, Bojke LGriffin SMcKenna C, Soares MSpackman E, Youn J. Uncertainty, evidence and irrecoverable costs: Informing approval, pricing and research decisions for health technologies.Centre for Health Economics, University of York;‌‎‌‎ 2011.
  • Claxton K, Paulden M, Gravelle H, Brouwer W, Culyer AJ. Discounting and decision making in the economic evaluation of health care technologies. Health Economics 2011;20:2-15. Download from Wiley interscience
  • Claxton KSculpher M, Carroll S. Value-based pricing for pharmaceuticals: its role, specification and prospects in a newly devolved NHS. Centre for Health Economics, University of York; ‌‎ ,  2011.
  • Cookson R. The tough test for the NHS isn’t cost but care. Parliamentary Brief 2011;13(6).
  • Cookson R, Laudicella M, Li Donni P. Does hospital competition harm equity? evidence from the English National Health Service. Centre for Health Economics, University of York; ‌‎‌‎ 2011.
  • Cookson R, Laudicella M, Li Donni P. Measuring change in health care equity using small area administrative data - evidence from the English NHS 2001-8. Centre for Health Economics, University of York; CHE Research Paper 67 (PDF , 378kb)‌‎‌‎ 2011.
  • Culyer AJ. Maximising the odds. New Statesman (supplement: Competition in a New Society: National Health) 2011;15 December 6-8.
  • Culyer AJUK report: NHS 'reforms: Health Care Cost Monitor 1-2, The Hastings Center; 2011. Download from the Hastings Center
  • Culyer AJ, Bombard Y. An equity checklist: a framework for health technology assessments. Centre for Health Economics, University of York; ‌‎‌‎ 2011.
  • Culyer AJ, Bombard Y. An equity framework for health technology assessments. Medical Decision Making 2011;forthcoming DOI:10.1177/0272989X11426484.
  • Drummond MF, Augustovski F, Melendez G, Lemgruber A. Implementing pharmacoeconomic guidelines in Latin America: lessons learned. Value in Health 2011;14:S3-S7.
  • Drummond MF, Jönsson B, Rutten F, Stargardt T. Reimbursement of pharmaceuticals: reference pricing versus health technology assessment. The European Journal of Health Economics 2011;12:263-71.
  • Elston J, Santaniello-Newton A, Meigh J, Harmer D, Allgar V, Allison T, Richardson G, Meigh R, Palmer SR, Barlow G. Increasing incidence of invasive pneumococcal disease and pneumonia despite improved vaccination uptake- surveillance in Hull and East Yorkshire, United Kingdom, 2002-2009. Epidemiology and Infection 2011;DOI:10.1017/S0950268811001907.
  • Epstein D, Sutton A. Modelling correlated clinical outcomes in health technology appraisal. Value in Health 2011;14(6):793-99. Download from Value in Health
  • Felix J, Andreozzi V, Soares M, Borrego P, Gervasio H, Moreira A, Costa L, Marcelo F, Peralta F, Furtado I, Pina F, Albuquerque C, Santos A, Passos-Coelho JL. For the Portuguese Group for the Study of Bone Metastases. Hospital resource utilization and treatment cost of skeletal-related events in patients with metastatic breast or prostate cancer: An estimation for the Portuguese National Health System. Value in Health 2011;14(4). Download from ISPOR
  • Garau M, Shah K, Mason A, Wang Q, Towse A, Drummond M. Using QALYs in cancer: a review of the methodological limitations. Pharmacoeconomics 2011;29(8):673-85.
  • Griffin S, Claxton K. Analysing uncertainty in cost-effectiveness for decision making. In: Glied S, Smith PC, editors. Oxford Handbook of Health Economics. Oxford: Oxford University Press; 2011.
  • Griffin S, Claxton K, Palmer S, Sculpher M. Dangerous omissions: the consequences of ignoring decision uncertainty. Health Economics 2011;20:212-24.
  • Harrison M, Bansback N, Marra C, Drummond MF, Tugwell B. Valuing health for clinical and economic decisions: directions relevant for rheumatologists. The Journal of Rheumatology 2011;38(8):1770-75.
  • Hassink WHJ, Van den Berg B. Time-bound opportunity costs of informal care: Consequences for access to professional care, caregiver support, and labour supply estimates. Social Science and Medicine. 2011;73(10):1508-16.
  • Hastrup LH, Van den Berg B, Gyrd-Hansen D. Do informal caregivers in mental illness feel more burdened? A comparative study of mental versus somatic illnesses. Scandinavian Journal of Public Health 2011;39:598-607.
  • Hawkins N, Richardson G, Sutton A, Cooper N, Griffiths C, Rogers A, Bower P. Surrogates, meta-analysis and cost-effectiveness modelling: a combined analytic approach. Health Economics 2011;DOI:10.1002/hec.1741.
  • Jackson CH, Bokje L, Thompson SG, Claxton K, Sharples LD. A framework for addressing structural uncertainty in decision models. Medical Decision Making 2011;31(4):662-674. Download from sagepub
  • Kolosa K, Manca A, Schubert S. A review of Health Technology Assessment (HTA) recommendations for drug therapies issued between 2007 and 2009 and their impact on policy making processes in Poland. Health Policy 2011;102(2-3):145-151.
  • Longworth L, Sculpher MBokje L, Tosh J. Bridging the gap between methods research and the needs of policy makers: A review of the research priorities of the National Institute for Health and Clinical Excellence. International Journal of Technology Assessment in Health Care 2011;27(2):180-7. Download from pubmed
  • Marks L, Cave S, Wallace A, Mason A, Hunter DJ, Mason JM, Peckham S. Incentivising preventive services in primary care: perspectives on the use of Local Enhanced Services. Journal of Public Health 2011; 33 (4): 556-564.
  • Martin M, Lensberg B, Drummond MF, McGuire A. Relative efficacy - towards a new frontier? ISPOR Connections 2011;17(5):8-10.
  • Mauskopf JA, Walter J, Copley-Merriman K, Birt J, Bowman LLB, Drummond MF. Differences among formulary submission guidelines:implications for health technology assessment. International Journal of Technology Assessment in Health Care 2011;27(3):261-70.
  • McKenna C, Claxton K. Addressing adoption and research design decisions simultaneously: the role of value of sample information analysis. Medical Decision Making 2011;31:853-865. Download from Pubmed
  • McKenna C, Maund E, Sarowar M. Dronedarone for the treatment of atrial fibrillation. A NICE Single Technology Appraisal. Pharmacoeconomics 2011;In Press.
  • McKenna CWalker S, Lorgelly P, Fenwick E, Burch J, Suekarran S, Bakhai A, Witte K, Harden M, Wright K, Woolacott N, Palmer S. Cost-effectiveness of aldosterone antagonists for the treatment of post-myocardial infarction heart failure. Value in Health 2012;15(3). More details  from Value in Health
  • Norman G, Rice S, Spackman E, Stirk L, Danso-Appiah A, Suh D, Palmer S, Eastwood A. Trastuzumab for the treatment of HER2 positive metastatic adenocarcinoma of the stomach or gastro-oesophageal junction. Health Technol Assess 2011;15(Suppl 1):33-42.
  • Paulden M, Claxton K. Budget allocation and the revealed social rate of time preference for health. Health Economics 2011;doi:10.1002/hec.1730. Download from Wiley
  • Powdthavee N, Van den Berg B. Putting different price tags on the same health condition: Re-evaluating the well-being valuation approach. Journal of Health Economics 2011;30(5):1032-43.
  • Rodgers M, Epstein D, Bojke L, Yang H, Craig D, Fonseca T, Myers L, Bruce I, Chalmers R, Bujkiewicz S, Lai M, Cooper N, Abrams K, Spiegelhalter D, Sutton A, Sculpher M, Woolacott N. Etanercept, infliximab and adalimumab for the treatment of psoriatic arthritis: a systematic review and economic evaluation. Health Technol Assess 2011;15(10):1-329. Download from HTA
  • Rodgers M, Soares MEpstein D, Yang H, Fox D, Eastwood A. Bevacizumab in combination with a taxane for the first-line treatment of HER2-negative metastatic breast cancer. Health Technology Assessment 2011;15:Suppl.1. Download from HTA
  • Rogers A, Vassilev I, Sanders C, Kirk S, Chew-Graham C, Kennedy A, Protheroe J, Bower P, Blickem C, Reeves D, Kapadia D, Brooks H, Fullwood C, Richardson G. Social networks, work and network-based resources for the management of long-term conditions: a framework and study protocol for developing self-care support. Implementation Science 2011;6:56(May).
  • Sampat B, Drummond MF. Another special relationship? interactions between health technology policies and health care systems in the United States and the United Kingdom. Journal of Health Politics, Policy and Law 2011;36:119-39.
  • Shah K, Cookson RCulyer AJ, Littlejohns P. Nice's social value judgements about equity in health and health care. Centre for Health Economics, University of York; ‌‎‌‎ 2011.
  • Soares MO, Bojke L, Dumville J, Iglesias C, Callum N, Claxton K. Methods to elicit experts' beliefs over uncertain quantities: application to a cost effectiveness transition model of negative pressure wound therapy for severe pressure ulceration. Statistics in Medicine 2011;30(19):2363-2380. Download from Wiley
  • Soares MO, Canto E, Castro L. Continuous time simulation and discretized models for cost-effectiveness analysis. Pharmacoeconomics 2011;Accepted for publication.
  • Sorenson C, Tarricone R, Siebert M, Drummond MF. Applying health economics for policy decision making: do devices differ from drugs? Europace Spotlight Supplement 2011;13:ii54-ii58.
  • Star SM, Van den Berg B. Individual responsibility and health-risk behaviour: A contingent valuation study from the ex ante societal perspective. Health Policy 2011;101:300-311.
  • Sullivan PW, Slejko JF, Sculpher MJ. Catalogue of EQ-5D Scores for the United Kingdom. Medical Decision Making 201131(6):800-804.
  • Tarricone R, Drummond MF. Challenges in the clinical and economic evaluation of medical devices:The case of transcatheter aortic valve implantation. Journal of Medical Marketing 2011;11(3):221-29.
  • Towse A, Drummond MF, Sorenson C. Measuring value:pharmacoeconomics theory and practice. London: Office of Health Economics; 2011.
  • Tso P, Culyer AJ, Brouwers M, Dobrow MJ. Developing a decision aid to guide public sector health policy decisions: A study protocol. Implementation Science2011;6(46).
  • Wagstaff A, Culyer AJ. Four decades of Health Economics through a bibliometric lens. World Bank Policy Research Working Paper Series2011;5829.
  • Walker S, Burch J, McKenna C, Wright K, Griffin S, Woolacott N. Omalizumab for the treatment of severe persistent allergic asthma in children aged 6-11 years: Health Technology Assessment 2011;15:Suppl.1:13-21.
  • Walker SSculpher MDrummond MF. The methods of cost-effectiveness analysis to inform decisions about the use of health care interventions and programmes. In: Smith PC, Glied S, editors. Oxford Handbook of Health Economics. Oxford: Oxford University Press; 2011. p.733-58.
  • Watson JM, Kang'ombe AR, Soares MO, Chuang LH, Worthy G, Bland JM, Iglesias C, Cullum N, Torgerson D, Nelson EA on behalf of the VenUS III Team. Use of weekly,low dose, high frequency ultrasound for hard to heal venous leg ulcers: the VenUS III randomised controlled trial. BMJ 2011;342. Download from BMJ
  • Watson JM, Kang'ombe AR, Soares MO, Chuang LH, Worthy G, Bland JM, Iglesias C, Cullum N, Torgerson D, Nelson EA on behalf of the VenUS III team.VenUS III: a randomised controlled trial of therapeutic ultrasound in the management of venous leg ulcers. Health Technol Assess 2011;15(13):1-176. Download from HTA
  • Watt M, Mealing S, Eaton J, Piazza N, Moat N, Brasseur P, Palmer S, Busca R, Sculpher M. Cost-effectiveness of transcatheter aortic valve replacement in patients ineligible for conventional aortic valve replacement. Heart 2011;98:370-76.  Download from BMJ
  • Weatherly H, Kirk S, Kyle RG, Callery P. Comparison of costs of acute care by children's community nursing teams Archives of Disease in Childhood 2011;96(Suppl 1):A92.

2010 

  • Ashby R, Bland JM, Cullum N, Dumville J, Hall J, Kang'ombe A, Madden M, O'Meara S, Soares M, Torgerson D, Watson J. Reflections on the recommendations of the EWMA Patient Outcome Group Journal of Wound Care 2010;19(7):282-85. Download from Pubmed
  • Barbieri M, Drummond M, Rutten F, Cook J, Glick H, Lis J, Reed SD, Sculpher M, Severens J. on behalf of the ISPOR Good Research Practices Economic Data Transferability Task Force. What do international pharmacoeconomic guidelines say about economic data transferability? Value in Health 2010;13:1028-37.
  • Bloudek L, Spackman DE, Sullivan SD. A comparison of transitions between health states and institutionalization among alzheimer's disease patients versus non-alzheimer's disease dementia patients using the nacc-uds database. Value in Health 2010;13(3):108-9.
  • Bojke L, Claxton K, Bravo Vergel Y, Sculpher M, Palmer S, Abrams K. Eliciting distributions to populate decision analytic models. Value in Health 2010;13:557-64. Download from Wiley interscience
  • Campbell JD, Spackman DE. The costs and consequences of Omalizumab in uncontrolled Asthma from a USA payer perspective. Allergy 2010;10.111/j.1398-9995.2010.02336.x.
  • Chambers D, Worthy G, Myers L, Weatherly H, Elliott R, Hawkins N, Sculpher M, Eastwood A. Glycopeptide versus non-glycopeptide antibiotics for prophylaxis of surgical site infections: a systematic review. Surg Infect 2010;11(5):455-62.
  • Claxton K, Walker S, Palmer S, Sculpher M. Appropriate perspectives for health care decisions. Centre for Health Economics, University of York; CHE Research Paper 54 (PDF , 1,114kb)‌‎‌‎ 2010.
  • Elliot RA, Weatherly HLAHawkins NS, Cranny G, Chambers D, Myers L, Eastwood A, Sculpher MJ. An economic model for the prevention of MRSA infections after surgery: non-glycopeptide or glycopeptide antibiotic prophylaxis? European Journal of Health Economics 2010;11(1):57-66. Download from springerlink
  • Gohel MS, Epstein D, Davies AH. Cost-effectiveness of traditional and endovenous treatments for varicose veins. Br J Surg 2010;97(12):1815-23. Download from pubmed
  • Gomes M, Soares MO, Dumville J, Lewis SC, Torgerson D, A.R. B, Gough MJ, Warlow CP and the GALA collaborative group. Cost -effectiveness analysis of general anaesthesia versus local anaesthesia for carotid surgery (GALA Trial). British Journal of Surgery 2010;10.1002/bjs.7110. Download from BJS
  • Griffin S, Claxton K, Palmer S, Sculpher M. Dangerous omissions: the consequences of ignoring decision uncertainty. Health Economics, 2010;DOI:10.1002/hec.1586. Download from Wiley InterScience
  • Griffin SClaxton K, Welton N. Exploring the research decision space: the expected value of information for sequential research designs. Medical Decision Making 2010;30:155-62. Download from Sage journals
  • Luce B, Drummond M, Jonsson B, Neumann PJ, Schwartz JS, Siebert U, Sullivan SD. (The International Working Group for HTA Advancement ) EBM, HTA and CER: clearing the confusion. The Millbank Quarterly 2010;88:256-76.
  • Manca A, Eldabe S, Buchser E, Kumar K, Taylor RS. Relationship between health-related quality of life, pain, and functional disability in neuropathic pain patients with failed back surgery syndrome. Value in Health 2010;13(1):95-102.
  • Manca A, Sculpher M, Goeree R. The analysis of multinational cost effectiveness data for reimbursement decisions: a critical appraisal of recent methodological developments. Pharmacoeconomics 2010;28:1079-96.
  • Marks L, Cave S, Hunter DJ, Mason JM, Peckham S, Wallace A, Mason AWeatherly H, Melvin K. Public health governance and primary care delivery: a triangulated study. final report; NIHR Service Delivery and Organisation programme 2010. Full Report and Executive Summary
  • Mason A, Drummond M, Ramsey S, Campbell J, Raisch D. Comparison of anticancer drug coverage decisions in the United States and United Kingdom: does the evidence support the rhetoric? Journal of Clinical Oncology 2010;28(20):3234-38.
  • Maund E, McKenna C, Sarowar M. Dronedarone for the treatment of atrial fibrillation and atrial flutter. Health Technology Assessment 2010;14:Suppl.2. Download from pubmed
  • McCabe C, Chilcott J, Claxton K, Tappenden P, Cooper C, Roberts J, Cooper N, Abrams K. Continuing the multiple sclerosis risk sharing scheme is unjustified. British Medical Journal 2010;340 (C1786) Download from BMJ
  • McKenna C, Burch J, Suekarran S. Aldosterone antagonists for post-myocardial infarction heart failure. Health Technology Assessment 2010;14(24):161.
  • McKenna C, Chalabi Z, Epstein DClaxton K. Budgetary policies and available actions: a generalisation of decision rules for allocation and research decisions. Journal of Health Economics 2010; 29: 170–181. Download from Science Direct
  • McKenna C, Hawkins N, Claxton K, McDaid C, Suekarran S, Light K, Chester M, Cleland J, Woolacott N, Sculpher M. Cost-effectiveness of Enhanced External Counterpulsation (EECP) for the treatment of stable angina in the UK. International Journal of Technology Assessment in Health Care 2010;26(2):175-82. Download from Pubmed
  • McLaughlin T, Feldman H, Fillit H, Sano M, Schmitt F, Aisen P, Leibman C, Mucha L, Ryan JM, Sullivan SD, Spackman DE, Neumann PJ, Cohen J, Stern Y. Dependence as a unifying construct in defining Alzheimer disease severity. Alzheimer's & Dementia 2010;6(6):482-03.
  • Neumann PJ, Drummond MF, Jonsson B, Luce BR, Schwartz JS, Siebert U, Sullivan S. Are Key Principles for improved health technology assessment supported and used by health technology assessment organizations? International Journal of Technology Assessment in Health Care 2010;26:71-78.
  • Norman G, Rice S, Spackman E, Stirk L, Danso-Appiah A, Suh D, Palmer S, Eastwood A. Trastuzumab for the treatment of HER2 positive metastatic adenocarcinoma of the stomach or gastro-oesophageal junction. Health Technol Assess 2010, In Press.
  • Norman G, Soares M, Peura P, Rice S, Suh D, Wright K, Sculpher M, Eastwood A. Capecitabin for advanced gastric cancer. Health Technology Assessment 2010;14(s2). Download from  Pubmed
  • Paton F, Paulden M, Saramago P, Manca A, Misso K, Palmer S, Eastwood A. Topotecan for the treatment of recurrent and stage IVB carcinoma of the cervix. Health Technology Assessment, 2010;14(S1):55-62.
  • Paulden M, Rodgers M, Griffin S, Slack R, Duffy S, Ingram JR, Woolacott N, Sculpher M. Alitretinoin for the treatment of severe chronic hand eczema. Health Technology Assessment 2010;14(s1):39-46. Download from NIHR
  • Pichon-Riviere A, Augustovski F, Rubinstein A, Marti SG, Sullivan SD, Drummond M. Health technology assessment for resource allocation decisions: are key principles relevant for Latin America? . International Journal of Technology Assessment in Health Care 2010;26:421-27.
  • RESPECT Trial Team. Cost-effectiveness of shared pharmaceutical care for older patients: RESPECT trial findings. British Journal of General Practice. 2010;60:21-27.
  • Rodgers M, Griffin S, Paulden M, Slack R, Duffy S, Ingram JR, Wollacott N, Sculpher M. Alitretinoin for Severe Chronic Hand Eczema: A NICE Single Technology Appraisal. Pharmacoeconomics 2010;28(5):351-62. Download from Pubmed
  • Sculpher M, Claxton K. Sins of omission and obfuscation: IQWiG’s guidelines on economic evaluation methods. Health Economics 2010;19(10):1132-36.
  • Shemilt I, Mugford M, Vale L, Marsh K, Donaldson C, Drummond MF. Evidence synthesis, economics and public policy. Research Synthesis Methods 2010;1:126-135.
  • The United Kingdom EVAR Trial Investigators. Endovascular versus open repair of abdominal aortic aneurysm. New England Journal of Medicine 2010;362:1863-71. Download from NEJM
  • The United Kingdom EVAR Trial Investigators. Endovascular repair of aortic aneurysm in patients physically ineligible for open repair. New England Journal of Medicine 2010;362:1872-80. Download from NEJM
  • Wailoo AJ, Goodacre S, Sampson F, Hernandez M, Asseburg C, Palmer S, Sculpher M, Abrams K, de Belder MA, Gray H. Primary angioplasty versus thrombolysis for acute ST-elevation myocardial infarction: an economic analysis of the National Infarct Angioplasty Project. Heart. 2010;96:668-72.
  • Walker S, Mason A, Claxton K, Cookson R, Fenwick E, Fleetcroft R, Sculpher M. Value for money and the quality and outcomes framework in primary care in the NHS. British Journal of General Practice 2010;60(574):352-57. Download from Ingentaconnect
  • Walker D, Teerawattanonon Y, Anderson R, Richardson G. Generalisability, transferability, complexity and relevance. In: Shemilt I, Mugford M, Vale L, Marsh K, Donaldson C, editors. Evidence-based decisions and economics: health care, social welfare, education and criminal justice, 2nd Edition: Wiley-Blackwell; 2010.
  • Wearden AJ, Dowrick C, Chew-Graham C, Bentall RP, Morriss RK, Peters S, Riste L, Richardson G, Lovell K, Dunn G. A randomised controlled trial of a nurse-led home-based self-help treatment for patients in primary care with chronic fatigue syndrome - the FINE trail. BMJ 2010;340:C1777.

2009 

  • Augustovski F, Iglesias CManca A, Drummond M, Rubinstein A, Garcia Marti S. Barriers to generalizability of health economic evaluations in Latin America and the Caribbean region. Pharmacoeconomics 2009;27(11):919-29.
  • Austin PC, Manca A, Zwarenstein M, Juurlink DN, Stanbrook MB. A substantial and confusing variation exists in handling of baseline covariates in randomized controlled trials: a review of trials published in leading medical journals. Journal of Clinical Epidemiology. 2009. In Press.
  • Barbieri M, Hawkins NSculpher MJ. Who does the numbers? The role of third-party technology assessments to inform health systems' decision-making about the funding of health technologies. Value in Health. 2009;12:193-201.
  • Bojke L, Claxton K, Sculpher M, Palmer S. Characterizing structural uncertainty in decision-analytic models: a review and application of methods. Value in Health. 2009;12:739-49.
  • Burch J, Corbett M, Stock C, Nicholson K, Elliot AJ, Duffy S, Westwood M, Palmer S, Stewart L. Prescription of anti-influenza drugs for healthy adults: a systematic review and meta-analysis. Lancet Infect Dis. 2009;9(9):537-45.
  • Burch J, Epstein D, Baba-Akbari Sari A, Weatherly H, Jayne D, Fox D et al. Stapled haemorrhoidopexy for the treatment of haemorrhoids: a systematic review. Colorectal Disease. 2009;11:233-44.
  • Burch J, McKenna C, Palmer S, Norman G, Glanville J, Sculpher M, Woolacott N. Rimonabant for the treatment of overwieght and obese people. Health Technology Assessment: 13:Suppl.3; 2009. Download from HTA
  • Burch J, Paulden M, Conti S, Stock C, Corbett M, Welton N, Ades AE, Sutton A, Cooper N, Elliot A, Nicholson K, Duffy S, McKenna C, Stewart L, Westwood M, Palmer S. Antiviral drugs for the treatment of influenza: a systematic review and economic evaluation. Health Technol Assess. 2009;13(58):1-290. Download from HTA
  • Chambers D, Epstein D, Walker S, Fayter D, Paton F, Wright K, et al. Endovascular stents for abdominal aortic aneurysms: a systematic review and economic model. Health Technol Assess 2009;13(48). Download from HTA
  • Conti S, Claxton K. Dimensions of design space: a decision theoretic approach to optimal research portfolio design. Medical Decision Making 2009;29:643-60. Download from Sage Journals online
  • Cooke D, Hurel SJ, Casbard A, Steed L, Walker S, Meredith S, Nunn AJ, Manca ASculpher M et al. Randomized controlled trial to assess the impact of continuous glucose monitoring on HbA1c in insulin-treated diabetes (MITRE Study). Diabetic Medicine. 2009;26(5):540-7. Download from Wiley InterScience
  • Cookson R, Drummond M, Weatherly H. Explicit incorporation of equity considerations into economic evaluation of public health interventions. Health Economics Policy and Law. 2009;4:231-45.
  • Cookson R, Drummond M, Weatherly H. Explicit incorporation of equity considerations into economic evaluation of public health interventions. Reply to Richardson and Shiell. Health Economics Policy and Law. 2009;February 16.
  • Cox H, Tilbrook H, Aplin J, L-H. C, Hewitt C, Jayakody S, Semlyen A, Soares M, Torgerson DJ, Trewhela A, Watt I, Worthy G. A pragmatic multi-centred randomised controlled trial of yoga for chronic low back pain: trial protocol. Complementary Therapies for Clinical Practice 2009;In Press doi:10.1016/j.ctcp.2009.09.010. Download from Elsevier
  • Culyer AJHealth, distribution and fairness - sorting out the theory and matching it to future policy practice (notes for the Select Committee on Health) House of Commons Select Committee on Health, 3 rd Report: Health Inequalities; 2009.
  • Drummond M, Barbieri M, Cook J, Glick H, Lis J, Malik F, Reed S, Rutten F, Sculpher M, Severens J. Transferability of economic evaluations across jurisdictions: ISPOR Good Practices Task Force report. Value in Health. 2009;12:409-18
  • Dumville JC, Soares M. The economics of clinical decision making. In: Essential Decision Making and Clinical Judgement for Nurses. London: Churchill Livingstone; 2009.
  • Dumville JC, Worthy G, Bland JM, Cullum N, Dowson C, Iglesias C, Mitchell JL, Nelson EA, Soares M, Torgerson DJ. VenUS II team. Larval therapy for leg ulcers (VenUS II): randomised controlled trial. British Medical Journal 2009;Mar 19:338:b773. Download from BMJ
  • Dumville JC, Worthy G, Soares M, Bland JM, Cullum N, Dowson C, Iglesias C, McCaughan D, Mitchell JL, Nelson EA, Torgerson DJ. VenUS II: a randomised controlled trial of larval therapy in the management of leg ulcers: Health Technology Assessment. 2009 Nov;13(55):1-182, i-iv. Download from HTA
  • Elliot RA, Weatherly HLAHawkins NS, Cranny G, Chambers D, Myers L, Eastwood A, Sculpher MJ. An economic model for the prevention of MRSA infections after surgery: non-glycopeptide or glycopeptide antibiotic prophylaxis? . European Journal of Health Economics 2009;Epub ahead of print. Available from: Download from springerlink
  • Epstein D. Is EVAR worth the price difference? In: Greenhalgh R, editor. Vascular and Endovascular Controversies Update 31. London: Biba Medical; 2009.
  • Epstein D. Opportunity Cost. In: Encyclopedia of Medical Decision Making: Sage Publications; 2009.
  • Epstein D, Bojke L, Sculpher M & the REFLUX trial group. The cost-effectiveness of laparoscopic fundoplication versus medical management for gastro oesophageal reflux disease. British Medical Journal 2009;338:b2576.
  • Epstein D, Jimenez Rubio D, Smith PC, Suhrcke M. An economic framework for analysing the social determinants of health and health inequalities. Centre for Health Economics, University of York; ‌‎‌‎ 2009.
  • Epstein D, Jimenez Rubio D, Smith PC, Suhrcke M. Social determinants of health: an economic perspective. Health Economics 2009;18:495-502.
  • Gauthier A, Manca A, Anton S. Bayesian modelling of healthcare resource use in multinational randomised clinical trials. Pharmacoeconomics. 2009;In Press.
  • Greenwood JP, Maredia N, Radjenovic A, Brown JM, Nixon J, Farrin AJ, Dickinson C, Younger JF, Ridgeway JP, Sculpher M, Ball SG, Plain S. Clinical evaluation of magnetic resonance imaging in coronary heart disease: The CE-MARC study. Trials. 2009;10:p62 (doi:10.1186/745-6215-10-62).
  • Griffin S, Dunn G, Palmer S, Macfarlane S, Brent S, Dyker A, et al. The use of paclitaxel in the management of early stage breast cancer. Health Technology Assessment: 2009;13(s1):15-22.
  • Griffin S, Rice N, Sculpher M. Economic evaluation of public health interventions. In: Killoran A, Kelly M, editors. Evidence-based public health: effectiveness and efficiency. Oxford: Oxford University Press; 2009.
  • Griffin S, Walker S, Sculpher M, et al. Cetuximab plus radiotherapy for the treatment of locally advance squamous cell carcinmoa of the head and neck. Health Technology Assessment: 2009;13(s1):49-54. Download from HTA
  • Hewitt C, Gilbody S, Brealey S, Paulden M, Palmer S, Mann R, Green J, Morrell J, Barkham M, Light K, Richards D. Methods to identify postnatal depression in primary care: an integrated evidence synthesis and value of information analysis. Health Technol Assess 2009;13(36):1-145, 47-230. Download from HTA
  • Hoomans T, Fenwick E, Palmer S, Claxton K. Value of information and value of implementation: application of a framework to inform resource allocation decisions in metastatic hormone-refractory prostate cancer. Value in Health. 2009;12:315-24. Download from wiley InterScience
  • Iglesias CManca A, Torgerson D. The health related quality of life and cost implications of falls in elderly women Osteoporosis International 2009;Jun 20(6):869-78. Epub 2008 Oct 10.
  • Longworth L, Bojke L, Tosh J, Sculpher M. MRC-NICE scoping project: identifying the national institute for health and clinical excellence’s methodological research priorities and an initial set of priorities. Centre for Health Economics, University of York; ‌‎‌‎ 2009.
  • Manca A. Economic evaluation of medical devices and drugs - same or different? (Editorial). Value in Health. 2009;12(4):401.
  • Manca A. Task force report on good research practices on economic data transferability in HTA (Editorial). Value in Health. 2009;In Press.
  • Manca A, Eldabe S, Buchser E, Kumar K, Taylor RS. Relationship between health related quality of life, pain and functional disability in neuropathic pain patients with failed back surgery syndrome. Value in Health. In Press.
  • McDaid C, Duree KH, Griffin SC, Weatherly HLA, Stradling JR, Davies RJO, Sculpher MJ, Westwood ME. A systematic review of continuous positive airway pressure for obstructive sleep apnoea-hypopnoea syndrome.Sleep Medicine Reviews 2009;13(6):427-36. Details from Sleep Medicine Reviews
  • McDaid C, Griffin S, Weatherly H, Duree KH, Burgt van der M, Hout van S, Akers J, Davies RJO, Sculpher M, Westwood M. Continuous positive airway pressure devices for the treatment of obstructive sleep apnoea-hypopnoea syndrome: a systematic review and economic analysis. Health Technology Assessment. 2009; 13(4) pp1-142.
  • McKenna C, Bojke L, Manca A, et al. Shoulder acute pain in primary healthcare: Is retraining GP's effective (SAPPHIRE) randomised trial - cost effectiveness analysis. Rheumatology, a dvance access published on March 2009; doi:10.1093/rheumatology/kep008
  • McKenna C, McDaid C, Suekarran S, Hawkins NClaxton K, Light K, Chester M, Cleland J, Woolacott N, Sculpher M. Enhanced external counterpulsation (EECP) for the treatment of stable angina and heart failure: A systematic review and economic analysis. Health Technology Assessment. 2009;13(24):1-112. Download from HTA
  • McKenna C, Palmer S, Rodgers M, et al. Cost-effectiveness of radiofrequency catheter ablation for the treatment of atrial fibrillation in the UK. Heart. 2009;95:542-9. Download from BMJ
  • Newman SP, Cooke D, Casbard A, Walker S, Meredith S, Nunn A, Steed L, Manca ASculpher M, et al. A randomised controlled trial to compare minimally invasive glucose monitoring devices with conventional monitoring in the management of insulin-treated diabetes mellitus (MITRE). Health Technology Assess. 2009;May;13(28):iii-iv, ix-xi, 1-194. Download from HTA
  • Paulden M, Claxton K. Budget allocation and the revealed social rate of time preference for health. Centre for Health Economics, University of York; CHE Research Paper 53 (PDF , 314kb)‌‎‌‎ 2009.
  • Richardson G, Bloor K, Williams J, Russell I, Durai D, Cheung W-Y, et al. Cost-Effectiveness of Nurse-Delivered Endoscopy: findings from a randomised Multi-Institution Nurse Endoscopy Trial (MINuET) BMJ. 2009;338:b270, doi:10.1136/bmj.b270.
  • Richardson G, Bojke C, Kennedy A, Reeves D, Bower P, Lee V, et al. What outcomes are important to patients with long term conditions? A discrete choice experiment. Value in Health. 2009;12(2):331-9.
  • Rogowski W, Burch J, Palmer S, Craigs C, Golder S, Woolacott N. The effect of different treatment durations of clopidogrel in patients with non-ST-segment elevation acute coronary syndromes: a systematic review and value of information analysis. Health Technol Assess. 2009;13(31):1-77. Download from HTA
  • Sculpher MJ, Lozano-Ortaga G, Sambrook J, Palmer S, Ormanidhi O, Bakhai A, et al. Fondaparinux versus Enoxaparin in non-ST-elevation acute coronary syndromes: short-term cost and long-term cost-effectiveness using data from the Fifth Organization to Assess Strategies in Acute Ischemic Syndromes Investigators (OASIS-5) trial. American Heart Journal. 2009;157:845-52.
  • Soares M, Iglesias CP, Bland JM, Cullum N, Dumville JC, Nelson EA, Torgerson DJ, Worthy G. VenUS II team. Cost effectiveness analysis of larval therapy for leg ulcers British Medical Journal 2009 Mar;19:338:b825 doi: 10.1136/bmj.b825. Download from BMJ
  • Taylor RS, Iglesias CP. Assessing the clinical and cost-effectiveness of medical devices and drugs: are they that different? Value in Health 2009;Jun 12(4):404-6. Epub 2008 Nov 19.
  • Walker S, Palmer S, Erhorn S, Brent S, Dyker A, Ferrie L, Horsley W, Macfarlane S, White S, Thomas S. Fludarabine phosphate for the first-line treatment of chronic lymphocytic leukaemia. Health Technology Assessment 2009;13(sl):35-40. Download from HTA
  • Weatherly H, Drummond M, Claxton K, Cookson R, Ferguson B, Godfrey C, Sculpher M, et al. Methods for Assessing the Cost-Effectiveness of Public Health Interventions: Key Challenges and Recommendations. Health Policy 2009;93:85-92. Download from Elsevier
  • Weatherly HLA, Griffin S, McDaid C, Duree KH, Davies RJO, Stradling JR, Sculpher MJ et al. An economic analysis of continuous positive airway pressure for the treatment of obstructive sleep apnea-hypopnea syndrome. International Journal of Technology Assessment in Health Care. 2009;25(01):26-34.
  • Williams J, Russell I, Durai D, Cheung W-Y, Farrin A, Bloor K, Coulton S, Richardson G. Effectiveness of Nurse-Delivered Endoscopy: Findings from a Randomised Multi-Institution Nurse Endoscopy Trial (MINuET) British Medical Journal. 2009;338:b231, doi:10.1136/bmj.b231.

2008

  • Al-Ruzzeh S, Epstein D, George S, Bustami M, Wray J, Ilsley C, Sculpher M, Amrani M. Economic evaluation of coronary artery bypass grafting surgery with and without cardiopulmonary bypass: cost-effectiveness and quality-adjusted life years in a randomized controlled trial. Artificial Organs. 2008;32(11):891-7. Download from Wiley InterScience
  • Bansback N, Sun H, Guh D, Li X, Nosyk B, Griffin S, et al. The impact of using a recall period on the measurement of health utilities for acute events. Health Economics. 2008;Forthcoming
  • Bojke L, Claxton K, Sculpher M, Palmer S, Philips Z. The cost-effectiveness and value for information associated with repeat screening for age related macular degeneration. Medical Decision Making. 2008;28:33-43. Download from Sage Journals Online
  • Bravo Vergel Y, Sculpher M. Quality-adjusted life years. Practical Neurology. 2008;8:175-82. Download from BMJ
  • Burch J, Epstein D, Baba-Akbari A, Weatherly H, Fox D, Golder S, Jayne D, Drummond M, Wolacott N. Stapled haemorrhoidectomy (haemorrhoidopexy) for the treatment of haemorrhoids: a systematic review and economic evaluation. Health Technology Assessment 2008;12(8). Download from HTA
  • Chalabi Z, Epstein D, McKenna C, Claxton K. Uncertainty and value of information when allocating resources within and between healthcare programmes. European Journal of Operational Research. 2008;191(2):530-9. Download from Science Direct
  • Claxton K. Exploring uncertainty in cost-effectiveness analysis. Pharmacoeconomics. 2008;9:781-98.
  • Claxton K, Briggs A, Buxton M, Culyer A, McCabe C, Walker S, Sculpher M. Value based pricing for NHS drugs: an opportunity not to be missed? BMJ. 2008;336:251-4. Download from BMJ
  • Claxton K, Culyer A. Not a NICE fallacy: A reply to Dr Quigley. Journal of Medical Ethics. 2008;34:598-601.
  • Conti S, Claxton K. Dimensions of design space: a decision-theoretic approach to optimal research design. Centre for Health Economics, University of York; 2008.
  • Cranny G, Elliott R, Weatherly H, Chambers D, Hawkins N, Myers L, Sculpher M, Eastwood A.  A systematic review and economic model of switching from non-glycopeptide to glycopeptide antibiotic prophylaxis for surgery.  Health Technology Assessment 2008;12:1-168.
  • Culyer A, Sculpher M. Lessons from health technology assessment. In: Tompa E, Culyer A, Dolinschi R, eds. Economic Evaluation of Interventions for Occupational Health and Safety. Oxford: Oxford University Press 2008.
  • Drummond M, Iglesias C, Cooper NJ. Systematic reviews and economic evaluations conducted for the National Institute for Health and Clinical Excellance in the United Kingdom: A game of two halves? International Journal of Technology Assessment in Health Care. 2008;24:146-50. Download from Cambridge Journals
  • Drummond MF, Schwartz JS, Jönsson B, Luce BR, Neumann PJ. Key principles for the improved conduct of health technology assessments for resource allocation decisions. International Journal of Technology Assessment in Health Care 2008;24(3):244-58.
  • Drummond M, Weatherly H, Ferguson B. Economic evaluation of health interventions: a broader perspective is needed that include potential cost and benefits for all stakeholders. British Medical Journal. 2008;337:a1204.
  • Epstein D, Mason A, Manca A. The hospital costs of care for stroke in nine european countries. Health Economics. 2008;17 (S1):S21-S31. Download from Wiley InterScience
  • Epstein DM, Garcia Mochon L. The accuracy of telemedicine compared with conventional methods in the diagnosis of malignant melanoma of the skin. Revista Espanola de Economia de la Salud. 2008;7:193-6.
  • Epstein D, Sculpher M, Clayton T, Henderson R, Pocock SJ, Buxton M, et al. Costs of an early intervention versus a conservative strategy in acute coronary syndrome. International Journal of Cardiology. 2008;127(2):240-6. Download from ScienceDirect
  • Epstein D, Sculpher M, Manca A, Michaels J, Thompson SG, Brown LC, et al. Modelling the long-term cost-effectiveness of endovascular or open repair for abdominal aortic aneurysm. British Journal of Surgery. 2008;95:183-90.
  • Fenwick E, Claxton K, Sculpher M. The value of implementation and the value of information: combined and uneven development. Medical Decision Making. 2008;28:21-32. Download from Sage Journals Online
  • Grant A, Wileman S, Ramsay C, Bojke L, Epstein D, Sculpher M, et al. The effectiveness and cost-effectiveness of minimal access surgery amongst people with gastro-oesophageal reflux disease - a UK collaborative study. The REFLUX trial. Health Technology Assessment. 2008;12(31):1-204.
  • Griffin S, Claxton K, Sculpher M. Decision analysis for resource allocation in health care. Journal of Health Services Research and Policy. 2008;13:23-30. Download from RSM Press
  • Griffin S, Weatherly H, Richardson G, Drummond M. Methodological issues in undertaking independant cost-effectiveness analysis for NICE: the case of therapies for ADHD. The European Journal of Health Economics. 2008;9(2):137-45
  • Henriksson M, Epstein D, Palmer SJ, Sculpher MJ, Clayton TC, Pocock SJ, et al. The cost-effectiveness of an early interventional strategy in non-ST-elevation acute coronary syndrome based on the RITA 3 trial. Heart. 2008;94:717-23. Download from BMJ
  • Hicks L, Gibbs I, Weatherly H, Byford S. Management, leadership and resources in children's homes: what influences outcomes in residential child-care settings? British Journal of Social Work. 2008;doi:10.1093/bjsw/bcn013. Download from Oxford Journals
  • Manca A, Kumar K, Taylor RS, Jacques L, Eldabe S, Meglio M, Molet J, Thomson S, O'Callaghan J, Eisenberg E, Milbouw G, Buchser E, Fortini G, Richardson J, Taylor RJ, Goeree R, Sculpher MJ. Quality of life, resource consumption and costs of spinal cord simulation versus conventional medical management in neuropathic pain patients with failed back surgery syndrome (PROCESS trial). European Journal of Pain. 2008;12:1047-58.
  • Mason A, Walker S, Claxton K, Cookson R, Fenwick E, Sculpher M. The GMS quality and outcomes framework: Are the quality and outcomes framework (QOF) indicators a cost-effective use of NHS resources? In: Quality and Outcomes Framework. Joint executive summary: Reports to the Department of Health from the University of East Anglia and the University of York.  ‌
  • McCabe C, Claxton K, O'Hagan A. Why licensing authorities need to consider the net value of new drugs - addressing the tension between licensing and reimbursement. International Journal of Technology Assessment in Health Care. 2008;24:140-5. Download from Cambridge Journals
  • McCabe C, Culyer A, Claxton K. The NICE cost-effectiveness threshold: what it is and what it means. Pharmacoeconomics. 2008;9:733-44.
  • McKenna C, Bojke L, Manca A, et al. Shoulder acute pain in primary healthcare: Is retraining GP's effective (SAPPHIRE) randomised trial - cost effectiveness analysis. Rheumatology. 2008;Forthcoming.
  • McKenna C, Chalabi Z, Epstein D, Claxton K. Budgetary policies and available actions: a generalisation of decision rules for allocation and research decisions. Centre for Health Economics, University of York; 2008.
  • McKenna C, Palmer S, Rodgers M, et al. Cost-effectiveness of radiofrequency catheter ablation for the treatment of atrial fibrillation in the UK. Heart. 2008;Forthcoming.
  • Olry de Labry Lima A, Sordo del Castillo L, Garcia Mochon L, Epstein D, Bermudez C, Villegas R. Evaluacion economica de la prueba genetica de la poliposis adenomatosa familiar. Rev Esp Enfirm Dig. 2008;100(8):470-5.
  • Phillips Z, Claxton K, Palmer S. The half-life of truth? what is the appropriate time horizons for research decisions? Medical Decision Making. 2008;28:287-99. Download from Sage Journals Online
  • Reeves D, Kennedy A, Fullwood C, Bower P, Gardner C, Gately C, Lee V, Richardson G, Rogers A. Predicting who will benefit from an expert patients programme self-management course. British Journal of General Practice. 2008;58(548):198-203
  • Rodgers M, McKenna C, Palmer S, et al. Curative catheter ablation in atrial fibrillation and typical atrial flutter: systematic review and economic evaluation. Health Technology Assessment. 2008;12(34). Download from HTA
  • Rogers A, Kennedy A, Reeves D, Bower P, Lee V, Gardner C, Gately C, Richardson G. The UK Expert Patients Programme: Results and Implications from a National Evaluation. Medical Journal of Australia. 2008;Nov17:189(10 Suppl):S21-4.
  • Ryan M, Griffin S, Chitah B, Walker SA, Mulenga V, Kalolo D, Hawkins N, Sculpher MJ, et al. The cost-effectiveness of cotrimoxazole prophylaxis in HIV-infected children in Zambia. Aids. 2008;22:749-57.
  • Sculpher MJ. NICE's 2008 methods guide: sensible consolidation or opportunities missed? Pharmacoeconomics. 2008;26:721-4.
  • Sculpher MJ. Subgroups and heterogeneity in cost-effectiveness analysis. Pharmacoeconomics. 2008;26:799-806.
  • Soares M, Dumville JC. Critical appraisal of cost-effectiveness and cost-utility studies in health care. Evidence Based Nursing 2008;11(4):99-102. Download from BMJ
  • Soares M, Dumville JC. Economic evaluation of healthcare technologies using primary research. Evidence Based Nursing 2008;11(3):67-71. Download from BMJ
  • Spiby H and the ELSA team. Improving care at the primary/secondary interface: a trial of community-based support in early labour (ELSA). Report for the National Co-ordinating Centre for NHS Service Delivery and Organisation R&D (NCCSDO). November 2008. Download from SDO

2007 and previous

2007 

  • Asseburg C, Bravo Vergel Y, Palmer S, Fenwick E, de Belder M, Abrams A, Sculpher M. Assessing the effectiveness of primary angioplasty compared to thrombolysis and its relationship to time delay: a Bayesian evidence synthesis. Heart. 2007;93:1244-50. Download from BMJ
  • Bansback N, Maetzel A, Drummond MF, et al. Considerations and preliminary proposals for defining a reference case for economic evaluations in ankylosing spondylitis. The Journal of Rheumatology 2007;34:1178-83.
  • Bojke L, Hornby E, Sculpher M; on behalf of the REFLUX Trial Team. A Comparison of the Cost Effectiveness of Pharmacotherapy or Surgery (Laporoscopic Fundoplication) in the Treatment of GORD. Pharmacoeconomics. 2007;25(10):829-41.
  • Bravo Vergal Y, Hawkins N, Claxton K, Asseburg C, Palmer S, Woolacoot N, Bruce IN, Sculpher MJ. The cost-effectiveness of etanercept and infliximab for the treatment of patients with psoriatic arthritis. Rheumatology. 2007;46:1729-35. Download from Oxford Journals
  • Bravo Vergel Y, Palmer S, Asseburg C, Fenwick E, De Belder M, Abrams A, Sculpher M. Is primary angioplasty cost effective in the UK? Results of a comprehensive decision analysis. Heart. 2007;93:1238-43. Download from BMJ
  • Briggs A, Mihaylova B, Sculpher M, et al. The cost-effectiveness of perindopril in reducing cardiovascular events in patients with stable coronary artery disease using data from the EUROPA study. Heart. 2007;93:1081-6. Download from BMJ
  • Claxton K. OFT,VBP:QED? Health Economics. 2007;16:545-58. Download Wiley InterScience
  • Claxton K. The irrelevance of inference: a decision making approach to the stochastic evaluation of health care technologies. Reprinted in: Culyer A, editor. Health Economics: critical perspectives on the world economy. London: Routledge; 2007(0-415-35235-5).
  • Claxton K, Culyer A. Rights, responsibilities and NICE: a rejoinder to Harris. Journal of Medical Ethics. 2007;33:462-4. 
  • Claxton K, Sculpher M, Culyer A. Mark versus Luke? Appropriate methods for the evaluation of public health interventions. Centre for Health Economics, University of York; ‌‎‌‎ 2007.
  • Colbourn T, Asseburg C, Bojke L, Phillips Z, Claxton K, Ades A, et al. Prenatal screening and treatment strategies to prevent group B streptococcal and other bacterial infections in early infancy: cost-effectiveness and expected value of information analyses  Health Technology Assessment. 2007;11(29):1-208. Download from HTA
  • Colbourn T, Asseburg C, Bojke L, Philips Z, Welton N, Claxton K, et al. Preventive Strategies for Group B Streptococcal and other Bacterial Infections in Early Infancy: Cost Effectiveness and Value of Information Analyses. British Medical Journal. 2007;Sept 29;335(7621):655.
  • Culyer AJ. Resource allocation in health care: Alan Williams’ decision maker, the authority and Pareto. In: Mason A, Towse A, editors. The Ideas and Influence of Alan Williams: Be Reasonable -Do it My Way! Oxford: Radcliffe Publishing; 2007. p. 57-74.
  • Culyer A, McCabe C, Briggs A, Claxton K, Buxton M, Akehurst R, Sculpher M, et al. Searching for a threshold, not setting one: the role of the National Institute for Health and Clinical Excellence. Journal of Health Services Research and Policy. 2007;12:56-8. 
  • Drummond MF. Evidence for coverage decisions: the need for a reality check. Value in Health. 2007;10(5):321.
  • Drummond MF. NICE: A nightmare worth having? Health Economics, Policy and Law. 2007;2(2):203-8.
  • Epstein D. The health related quality of life of patients with acute coronary syndrome: a comparison of early intervention versus conservative management. Revista Espanola de Economia de la Salud. 2007;6:380-5.
  • Epstein D, Sculpher M, Manca A, et al. Endovascular repair versus open repair in patients with abdominal aortic aneurysm: a modelling study to estimate long term cost-effectiveness. British Journal of Surgery 2007 (In press).
  • Epstein D, Chalabi Z, Claxton KSculpher M. Efficiency, equity and budgetary policies: informing decisions using mathematical programming. Medical Decision Making. 2007;27:128-37. Download from Sage Journals Online
  • Fenwick E, Claxton K, Sculpher MJ. Representing uncertainty: the role of cost-effectiveness acceptability curves. Reprinted in: Culyer A, editor. Health Economics: critical perspectives on the world economy. London: Routledge; 2007 (0415-35235-5).
  • Fleurence RL, Iglesias C, Johnson JM. The cost effectiveness of bisphosphonates for the prevention and treatment of osteoporosis: a structured review of the literature. Pharmacoeconomics 2007;25(11):913-33.
  • Goeree R, Burke N, O'Reilly D, Manca A, et al. Transferability of economic evaluations: approaches and factors to consider when using results from one geographic area for another. Current Medical Research and Opinion. 2007;23(4):671-82. 
  • Griffin SC, Barber JA, Manca A, Sculpher M, et al. Cost effectiveness of clinically appropriate decisions on alternative treatments for angina. British Medical Journal. 2007;334(7594):624. Download from BMJ
  • Griffin S, Claxton K, Hawkins N, Sculpher M. Decision models need to be fit for purpose for decision making: response to Caro et al. Value in Health. 2007;10(4):319. Download Wiley InterScience
  • Hanratty B, Craig D, Nixon J, Rice S, Christie J, Drummond MF. Are the best available clinical effectiveness data used in economic evaluations of drug therapies? Journal of Health Services Research and Policy. 2007;12:(3):138-41
  • Hicks L, Gibbs I, Weatherly H, Byford S. Managing Children's Homes. Developing effective leadership in small organisations. London: Jessica Kingsley Publications 2007. Details from Jessica Kingsley Publishers
  • Kennedy A, Reeves D, Bower P, Lee V, Middleton E, Richardson G, et al. The effectiveness and cost effectiveness of a national lay led self care support programme for patients with long-term conditions: a pragmatic randomised controlled trial. Journal of Epidemiology and Community Health. 2007;61:254-61. 
  • Keen J, Deeming C, Moore J, Weatherly H. New labour, equity and public services: a Rawlsian perspective. Policy and Politics. 2007;35(2):197-214.
  • Manca A, Dumville J, Torgerson DJ, Klaber Moffett JA, et al. Randomised trail of two physiotherapy interventions for primary care back and neck pain patients: cost-effectiveness analysis. Rheumatology. 2007;in press
  • Manca A, Lambert PC, Sculpher M, Rice N. Cost-effectiveness analysis using data from multinational trials: the use of bivariate hierarchical modelling. Medical Decision Making. 2007;27:471-90. Download from Sage Journals Online
  • Mason A, Weatherly H, Spilsbury K, Golder S, et al. The effectiveness and cost-effectiveness of respite for caregivers of frail older people: a systematic review. J Am Geriatr Soc. 2007;55(2):290-9.
  • Mason AWeatherly H, Spilsbury K, Golder S, et al. A systematic review of the effectiveness and cost-effectiveness of different models of community-based care for frail older people and their carers. Health Technology Assessment ; April 2007;11(15):1-176. Download from HTA
  • McCabe C, Claxton K, Tsuchiya A, Raftery J. Assessing the economics challenges posed by orphan drugs: a comment on Drummond et al. International Journal of Technology Assessment in Health Care. 2007;23:397-401.
  • McDaid C, Griffin S, Weatherly H. The Continuous Positive Airway Pressure for the Treatment of Obstructive Sleep Apnoea-Hypopnoea Syndrome: a Systematic Review and Economic Analysis: Assessment report for the National Institute for Health and Clinical Excellance; September 2007.  Download from NICE
  • Olry de Labry Lima A, Epstein D, Garcia Mochon L, et al. Comparacion de costes y supervivencia en pacientes intervenidos quirurgicamente de cancer colorrectal segun diferentes modelos organizativos. Rev Esp Enfirm Dig. 2007;99(11):643-7.
  • Ossa DF, Briggs A, McIntosh E, Cowell W, Littlewood T, Sculpher M. Recombinant erythropoietin for chemotherapy-related anaemia. Pharmacoeconomics. 2007;25:223-37.
  • Richardson G, Kennedy A, Reeves D, Bower P, et al. Cost-effectiveness of the expert patient programme (EPP) for patients with chronic conditions. Journal of Epidemiology and Community Health. 2007;In press. 10.1136/jech.2006.057430.accepted Jun2007
  • Sculpher M, Fenwick E, Claxton K. Assessing quality in decision analytical cost-effectiveness models: a suggested framework and example of application. Reprinted in: Culyer A, editor. Health Economics: critical perspectives on the world economy. London: Routledge; 2007 (0415-35235-5).
  • Spilsbury K, Nelson A, Cullum N, Iglesias C, Nixon J, Mason S. Pressure ulcers and their treatment and effects on quality of life: hospital inpatient perspectives. Journal of Advanced Nursing 2007;Mar 57(5):494-504.
  • Suresh Punekar Y, Rodriguez-Roisin R, Sculpher M, Jones P, Spencer M, . Implications of chronic obstructive pulmonary disease (COPD) on patients health status: a western view Respiratory Medicine 2007;101:661-69. Download from Elsevier
  • Walker S, Palmer S, Sculpher M. The role of NICE technology appraisal in NHS rationing.British Medical Bulletin. 2007:1-14. Download from Oxford Journals

2006 

Decision Modelling for Health Economic Evaluation  

 

Decision Modelling for Health Economic Evaluation
  • Ades A, Claxton K, Sculpher M. Evidence synthesis, parameter correlation and probablistic sensitivity analysis. Health Economics. 2006;15:373-82. Download from Wiley InterScience
  • Ades AE, Sculpher MJ, Sutton A, Abrams A, Cooper N, Welton N, et al. Bayesian methods for evidence synthesis in cost-effectiveness analysis. Pharmacoeconomics 2006;24:2-29.
  • Bojke L, Claxton K, Palmer S, Sculpher M. Defining and characterising structural uncertainty in decision analytic models. Centre for Health Economics, University of York; 2006.
  • Bravo Vergel Y, Chilcott J, Kaltenthaler E, Walters SJ, Blakeborough A, Thomas S. ‌ compared to endoscopic retrograde cholaniopancreatography for the investigation of biliary tree obstruction. International Journal of Surgery 2006;4(1):12-19. 
  • Bravo Vergel Y, Ferguson B. Difficult commissioning choices. A proposed framework for priority setting and a comparative analysis of rationing policies across West Yorkshire & NEYNL PCTs. Journal of Health Services Research and Policy 2006;11(3):150-155. 
  • Bravo Vergel Y, Sculpher M. Making decisions under uncertainty– The role of probabilistic decision modeling. Family Practice 2006; 23(4):391-392.
  • Briggs A, Claxton K, Sculpher M. Decision Modelling for Health Economic Evaluation. Oxford: Oxford University Press 2006. Download from OUP
  • Claxton K, Culyer AJ. Wickedness or folly? The ethics of NICE’s decisions. Journal of Medical Ethics 2006;32: 373-377. 
  • Claxton K, Culyer AJ, Sculpher M, McCabe C, Briggs A, Akehurst R, Brazier J, Buxton M. Discounting and cost-effectiveness in NICE - stepping back to sort out a confusion (Editorial). Health Economics 2006;15:1-4.
  • Claxton K, Sculpher M. Using value of information analysis to prioritise health research: some lessons from recent UK experience. Pharmacoeconomics. 2006;24:1055-68.
  • Claxton K, Sculpher M, Fenwick E. Decision making with uncertainty. In: Jones AM, editor. Companion to Health Economics: Edward Elgar; 2006.
  • Dumville J, Manca A, Kitchener H, Smith R, Nelson L, Torgerson D. On behalf of the COLPO study group. Cost-effectiveness analysis of open colposuspension versus laparoscopic colposuspension in the treatment of urodynamic stress incontinence. BJOG: An International Journal of Obstetrics and Gynaecology 2006;113:1014-22. Download from Wiley InterScience
  • Drummond M, Sculpher M, Better analysis for better decisions: has pharmoeconomics come of age? Pharmacoeconomics 2006;24:107-108.
  • Drummond M, Sculpher M. Better analysis for better decisions: facing up to the challenges. Pharmacoeconomics. 2006;24:1039-42.
  • Fenwick E, Palmer S, Claxton K, Sculpher M, Abrams K, Sutton A. An iterative Bayesian approach to Health Technology Assessment: application to a policy of preoperative optimisation for patients undergoing major elective surgery. Medical Decision Making. 2006;26:480-96. Download from Sage Journals Online
  • Griffin S, Bojke L, Main C, Palmer S. Incorporating direct and indirect evidence using bayesian methods: an applied case study in ovarian cancer. Value in Health. 2006;9(2):123-31. Download from Wiley InterScience
  • Griffin S, Claxton K, Hawkins N, Sculpher MJ (2006). Probabilistic analysis and computationally expensive models: necessary and required? Value in Health 2006:9;244-252. Download from Wiley InterScience
  • Iglesias C, Claxton K. Comprehensive decision analytic modelling and Baysesian value of information analysis: the case of pentoxifylline in the treatment of chronic venous leg ulcers Pharmacoeconomics. 2006;24(5):465-78.
  • Iglesias C, Nixon J, Cranny G, Nelson EA, Hawkins K, Phillips A, Torgerson DJ, Mason S, Cullum N. PRESSURE Trial Group. Pressure relieving support surfaces (PRESSURE) trial: cost effectiveness analysis BMJ 2006;Jun 17;332(7555):1416. Epub 2006 Jun 1. Erratum in: BMJ. 2006 Aug 12;333(7563):339.
  • King S, Griffin S, Hodges Z, Weatherly H, Asseburg C, Richardson G, et al. A systematic review and economic model of the effectiveness and cost-effectiveness of methylphenidate, dexamfetamine and atomoxetine for the treatment of attention deficit hyperactivity disorder in children and adolescents. Winchester, England: Health Technology Assessment 2006:10(23);iii+146. Download from HTA
  • Main C, Ginnelly L, Griffin S, Norman G, Barbieri M, Mather L, et al. A systematic review of the clinical effectiveness and cost effectiveness of topotecan, pegylated liposomal doxorubicin hydrochloride and paclitaxel for second-line or subsequent treatment of advanced ovarian cancer (update). Health Technology Assessment 2006:10(9). 
  • Manca A, Epstein D, Torgerson D, Klaber Moffett J, Coulton S, Farrin A, et al. Randomised trial of a brief physiotherapy intervention compared with usual physiotherapy for neck pain patients: a cost-effectiveness analysis. International Journal of Technology Assessment in Health Care. 2006;22(1):67-75.
  • Manca A, Willan A. "Lost in translation": accounting for between-country differences in the analysis of multinational cost-effectiveness data. Pharmacoeconomics. 2006;24(11):1101-19.
  • McCabe C, Claxton K, Tsuchiya A, Raftery J. Orphan drugs revisited. Quarterly Journal of Medicine. 2006; 99:341-345. Download from Oxford Journals
  • Nelson E, O'Meara S, Craig D, Iglesias C, Golder S, Dalton J, Claxton K. A series of systematic reviews to inform a decision analysis for sampling and treating infected diabetic foot ulcers. Health Technology Assessment. 2006;10(12):1-238. Download from HTA
  • Nelson EA, O'Meara S, Golder S, Dalton J, Craig D, Iglesias C. DASIDU Steering Group. Systematic review of antimicrobial treatments for diabetic foot ulcers Diabet Med 2006;Apr;23(4) 348-59.
  • Nixon J, Nelson EA, Cranny G, Iglesias CP, Hawkins K, Cullum N, Phillips A, Spilsbury K, Torgerson DJ, Mason S. PRESSURE Trial Group. Pressure relieving support surfaces: a randomised evaluation. Health Technology Assessment. 2006 Jul;10(22):iii-iv, ix-x, 1-163.
  • Nixon J, Cranny G, Iglesias C, Nelson EA, Hawkins K, Phillips A, Torgerson DJ, Mason S, Cullum N. Randomised, controlled trial of alternating pressure mattresses compared with alternating pressure overlays for the prevention of pressure ulcers: PRESSURE (pressure relieving support surfaces) trial. BMJ 2006 Jun 17;332(7555):1413. Epub 2006 Jun 1. Erratum in: BMJ. 2006 Jul 1;333(7557):30.
  • O'Meara S, Nelson EA, Golder S, Dalton J, Craig D, Iglesias C. DASIDU Steering Group. Systematic review of methods to diagnose infection in foot ulcers in diabetes Diabet Med 2006;Apr;23(4) 341-47.
  • Petherick ES, O'Meara S, Spilsbury K, Iglesias CP, Nelson EA, Torgerson DJ. Patient acceptability of larval therapy for leg ulcer treatment: a randomised survey to inform the sample size calculation of a randomised trial. BMC Med Res Methodol 2006;Sep 1:6:43.
  • Philips Z, Bojke L, Sculpher M, Claxton K, Golder S. Good practice guidelines for decision-analytic modelling in health technology assessment: a review and consolidation of quality of assessment. Pharmacoeconomics. 2006;24:355-71.
  • Philips Z, Claxton KP, Palmer S, Bojke L, Sculpher MJ. Priority setting for research in health care: an application of value of information analysis to glycoprotein IIb/IIIa antagonists in non-ST elevation acute coronary syndrome. International Journal of Technology Assessment in Health Care 2006;22(3):379-387. Download from Cambridge Journals.
  • Richardson G, Hawkins N, McCarthy JC, Mills PM, Pullen R, Roberts C, et al. Cost-effectiveness of a supplementary class-based exercise program in the treatment of knee osteoarthritis. International Journal of Technology Assessment in Health Care 2006;22(1):84-89.
  • Richardson G, Sculpher M, Kennedy A, Nelson E, Reeves D, Roberts C, et al. Is self-care a cost-effective use of resources? evidence from a randomised trial in inflammatory bowel disease. Journal of Health Services Research and Policy 2006;11(4):225-30. 
  • Sculpher MJ, Claxton K, Drummond M, McCabe C. Whither trial-based economic evaluation for health care decision making. Health Economics, 2006;15:677-687. Download Wiley InterScience
  • Sculpher MJ, Drummond MF. Analysis sans frontiers: can we ever make economic evaluations generalisable across jurisdictions? Pharmacoeconomics. 2006;24(11):1087-99.
  • Urdahl H, Manca A, Sculpher M. Assessing generalisability in model-based economic evaluation studies. A structured review in osteoporosis. Pharmacoeconomics. 2006;24(12):1181-97. Download from Ingenta Connect
  • Wearden AJ, Riste L, Dowrick C, Chew-Graham C, Bentall RP, Morriss RK, Peters S, Dunn G, Richardson G, Powell P. Fatigue intervention by nurses evaluation - The FINE trial. A randomised controlled trial of nurse led self-help treatment for patients in primary care with chronic fatigue syndrome. Biomed Central Medicine. 2006;4(9). Download from BMC
  • Whiting P, Westwood M, Bojke L, Palmer S, Richardson G, Cooper J, Watt I, Glanville J, Sculpher M, Kleijnen J. Clinical effectiveness and cost-effectiveness of tests for the diagnosis and investigation of urinary tract infection in children: a systematic review and economic model. Health Technology Assessment 2006;10(36). 
  • Williams J, Russell I, Durai D, Cheung W-Y, Farrin A, Bloor K, Coulton S, Richardson G. What are the clinical outcomes and cost-effectivenss of endoscopy undertaken by nurses when compared with doctors? A multi institution nurse endoscopy trial (MINuET). Health Technology Assessment 2006;10(40). Download from HTA
  • Woolacott N, Bravo Vergel Y, Hawkins N, Khadjesari Z, Kaith A, Misso K, Light K, Asseburg C, Palmer S, Claxton K, Chalmers R, Bruce I, Sculpher M, Riemsma R Etanercept and infliximab for the treatment of psoriatic arthritis: a systematic review and economic evaluation. Health Technology Assessment 2006; 10(31):1-258. 
  • Woolacoot N, Hawkins N, Mason A, Kainth A, Khadjesari Z, Bravo Vergel Y, Misso K, Light K, Chalmers R,Sculpher M, Riemsma R. Etanercept and Efalizumab for the treatment of psoriasis: a systematic review. Health Technology  Assessment 2006;10(46):1-252. 

2005 

 

 

Methods for the Economic Evaluation of Health Care Programmes (third edition)

  • Anderson GM, Bronskill S, Mustard CA, Culyer AJ, Alter DA, Manuel DG. Both clinical epidemiology and population health perspectives can define the role of health care in reducing health disparities. Journal of Clinical Epidemiology 2005;58:757-62.
  • Barbieri M, Drummond M, Willke R, Chancellor J, Jolain B, Towse A. Variability of cost-effectiveness estimates for pharmaceuticals in Western Europe: lessons for inferring generalizability. Value in Health 2005;8(1):10-23.
  • Brazier J, Akehurst R, Brennan A, Dolan P, Claxton K, McCabe C, et al. Should patients have a greater role in valuing health states? Applied Health Economics and Health Policy. 2005;4:201-8. Download from IngentaConnect
  • Claxton K, Cohen JT, Neumann PJ. When is evidence sufficient? A framework for making use of all available information in medical decision making and for deciding whether more is needed. Health Affairs 2005;24. Download from Health Affairs
  • Claxton K, Eggington S, Ginnelly L, Griffin S, McCabe C, Philips Z, et al. A pilot study of value of information analysis to support research recommendations for the National Institute for Health and Clinical Excellence. Centre for Health Economics, University of York; CHE Research Paper 4 (PDF , 1,149kb)2005.
  • Claxton K, Sculpher M, McCabe C, Briggs A, Akehurst R, Buxton M, Brazier J, O'Hagan T. Probabilistic sensitivity analysis for NICE technology assessment: not an optional extra. Health Economics 2005;14(4):339-347. Download from Wiley InterScience
  • Cooke J, Mason A, Drummond MF, Towse AK. Medication management in English National Health Service hospitals. American Journal of Health-System Pharmacy 2005;62:189-195. Download from Pub Med
  • Cullum N, Spilsbury K, Richardson G. Nurse led care: determining long term effects is harder than measuring short term costs. BMJ 2005;330:682-683. Download from BMJ
  • Culyer AJ. The dictionary of health economics. Cheltenham: Edward Elgar, 2005.
  • Culyer AJ. Involving stakeholders in healthcare decisions - the experience of the National Institute for Health and Clinical Excellence (NICE) in England and Wales. Healthcare Quarterly 2005;8:56-60.
  • Culyer AJ. Egészség-gazdaságtan, egészségügyi közgazdászok, és az egészségpolitikai döntéshozás politikája (Health economics, health economists and the politics of policy making). In: Gulácsi L, editor. Egészég-Gazdaságtan. Budapest: Medicina Könyvkiadó Rt; 2005. p. 35-44.
  • Dawson D, Drummond M, Towse A. European integration and the economics of health care. In: Smith P, Ginnelly L, Sculpher M, editors. Health policy and economics: opportunities and challenges: Maidenhead: Open University Press; 2005. pp. 248-271.
  • Drummond MF, Manca A, Sculpher MJ. Increasing the generalisability of economic evaluations: recommendations for the design, analysis and reporting of studies. International Journal of Technology Assessment in Health Care 2005;21(2):165-171.
  • Drummond MF, Sculpher MJ. Common methodological flaws in economic evaluations. Medical Care 2005;43(7 Suppl):115-14. Download from Pub Med
  • Drummond MF, Sculpher MJ, Torrance GW, O'Brien BJ, Stoddart GL. Methods for the economic evaluation of health care programme. Third edition: Oxford: Oxford University Press; 2005. Download from OUP
  • Epps H, Ginnelly L, Utley M, Southwood T, Gallivan S, Sculpher M, et al. Is hydrotherapy cost-effective? A randomised controlled trial of combined hydrotherapy programmes compared with physiotherapy land techniques in children with juvenile idiopathic arthritis. Health Technology Assessment 2005;9(39):1-76. 
  • EVAR Trial Participants. Endovascular aneurysm repair versus open repair in patients with abdominal aortic aneurism (EVAR trial 1): randomised controlled trial. Lancet. 2005;365(9478):2179-86.
  • EVAR Trial Participants. Endovascular aneurysm repair and outcome in patients unfit for open repair of abdominal aortic aneurism (EVAR trial 2): randomised controlled trial. Lancet. 2005;365(9478):2187-92.
  • Fenwick E, Claxton K, Sculpher M. The value of implementation and the value of information: combined and uneven development. Centre for Health Economics, University of York; CHE Research Paper 5 (PDF , 251kb)2005.
  • Fleurence RL, Iglesias CP, Torgerson DJ. Economic evaluations of interventions for the prevention and treatment of osteoporosis: a structured review of the literature Osteoporos Int 2006;Jan 17(1) 29-40. Epub 2005 Jun 25.
  • Ginnelly L, Claxton K, Sculpher MJ, Golder S. Using value of information analysis to inform publicly funded research priorities. Applied Health Economics and Health Policy. 2005;4:37-46. Download from IngentaConnect
  • Ginnelly L, Sculpher M, Bojke C, DiGuseppi C, Roberts I, Wade A. Determining the cost effectiveness of a smoke alarm give-away program using data from a randomised controlled trial. European Journal of Public Health 2005;15:448-453. Download from Oxford Journals
  • Godfrey C, Parrott S, Eaton G, Culyer A, McDougall C. Can we model the impact of increased treatment expenditure on the UK drug market. In: Lindgren B, Grossman M, editors. Substance use: individual behaviour, social interactions, markets and politics. Advances in health economics and health services research. Volume 16. New York: Elsevier; 2005. p. 265-84.
  • Hawkins N, Sculpher M, Rothman M. Modelling the cost-effectiveness of cardiac interventions: the case of sirolimus-eluting stents. British Journal of Cardiology. 2005;12:AIC83-AIC91. 
  • Hawkins N, Epstein D, Drummond M, Wilby J, Kainth A, Chadwick DM, et al. Assessing the cost-effectiveness of new pharmaceuticals in epilepsy in adults: the results of a probabilistic decision model. Medical Decision Making 2005;25:493-510. Download from Sage Journals Online
  • Hawkins N, Sculpher M, Epstein D. Cost-effectiveness analysis of treaments for chronic disease: using R to incorporate time dependency of treatment response. Medical Decision Making 2005;25:511-519.
  • Iglesias C, Birks Y, Nelson EA, Scanlon E, Cullum N. Quality of life of people with venous leg ulcers: a comparison of the discriminative and responsive characteristics of two generic and a disease specific instruments. Qual Life Res 2005;Sep 14 (7):1705-18.
  • Iglesias CP, Drummond MF, Rovira J, for the Nevalat Project Group. Health-care decision-making processes in Latin America: problems and prospects for the use of economic evaluation. International Journal of Technology Assessment in Health Care 2005;21(1):1-14.
  • Kim J, Henderson RA, Pocock SJ, Clayton T, Sculpher MJ, Fox KAA, for the RITA-3 Trial Investigators. Health-related quality of life after interventional or conservative strategy in patients with unstable angina or non-ST-segment elevation myocardial infarction: One-year results of the third randomized intervention trial of unstable angina (RITA-3). Journal of the American College of Cardiology 2005;45(2):221-228. Download from JACC
  • Klaber Moffett JA, Jackson DA, Richmond S, Hahn S, Coulton S, Farrin A, Manca A, Torgerson DJ. Randomised trial of a brief physiotherapy intervention compared with usual physiotherapy for neck pain patients: outcomes and patients' preference. BMJ 2005;330(7482):75-80. Download from BMJ
  • Lomas J, Culyer AJ, McCutcheon C, McAuley L, Law S. Conceptualizing and combining evidence for health system guidance. Ottawa: Canadian Health Services Research Foundation; 2005.
  • Longworth L, Buxton MJ, Sculpher MJ, Smith DH. Estimating utility data from clinical indicators for patients with stable angina. The European Journal of Health Economics 2005;6:347-353. Download from Pub Med
  • Manca A, Hawkins N, Sculpher MJ. Estimating mean QALYs in trial-based cost-effectiveness analysis: the importance of controlling for baseline utility. Health Economics 2005;14(5):487-496. Download from Wiley InterScience
  • Manca A, Palmer S. Handling missing data in patient-level cost-effectiveness analysis alongside randomised clinical trials. Applied Health Economics and Health Policy. 2005;4(2):65-75. Download from Ingenta Connect
  • Manca A, Rice N, Sculpher MJ, Briggs AH. Assessing generalisability by location in trial based cost effectiveness analysis: the use of multilevel models. Health Economics 2005;14(5):471-485. Download from Wiley InterScience
  • McCabe C, Claxton K, Tsuchiya A. Special status for orphan drugs in health care decision making processes: a wise move? . British Medical Journal. 2005;331:1016-9. Download from BMJ
  • Miller PSJ, Drummond MF, Langkilde LK, McMurray JJV, Ogren M. Economic factors assoicated with antithrombotic treaments for stroke prevention in patients with atrial fibrillation. Forthcoming in: European Heart Journal 2005. Download from Oxford Journals
  • O'Hagan A, McCabe C, Akehurst R, Brennan A, Briggs A, Claxton K, Fenwick E, Fryback D, Sculpher M, Spiegelhalter D, Willan A. Incorporation of uncertainty in health economic modelling studies. Pharmacoeconomics 2005;23:529-36.
  • O'Sullivan AK, Thompson D, Drummond MF. Collection of health-economic data alongside clinical trials: is there a future for piggyback evaluations? Value in Health 2005;8(1):67-79.
  • Palmer S, Sculpher M, Philips Z, Robinson M, Ginnelly L, Bakhai A, et al. Management of non-ST-elevation acute coronary syndromes: how cost-effective are glycoprotein IIb/IIIa antagonists in the UK National Health Service? International Journal of Cardiology 2005;100(2):229-240. Download from ScienceDirect
  • Porthouse J, Cockayne S, King C, Saxon L, Steele E, Aspray T, Baverstock M, Birks Y, Dumville JC, Francis R, Iglesias C, Puffer S, Sutcliffe A, Watt I, Torgerson DJ. Randomised controlled trial of calcium and supplementation with cholecalciferol (vitamin D3) for prevention of fractures in primary care BMJ 2005;Apr 30;330(7498):1003.
  • Richardson G, Gravelle H, Weatherly H, Ritchie G. Cost-effectiveness of interventions to support self-care: a systematic review. International Journal of Technology Assessment in Health Care. 2005;21(4):423-32. Download from Pub Med
  • Robson L, Clarke J, Cullen K, Bielecky A, Severin C, Bigelow P, Irvine E, Culyer AJ, Mahood Q. The effectiveness of occupational health and safety management systems: a systematic review (full report). Toronto: Institute for Work & Health; 2005.
  • Robson L, Clarke J, Cullen K, Bielecky A, Severin C, Bigelow P, Irvine E, Culyer AJ, Mahood Q. The effectiveness of occupational health and safety management systems: a systematic review (summary). Toronto: Institute for Work & Health; 2005.
  • Schultz G, Mozingo D, Romanelli M, Claxton K. Wound healing and TIME; new concepts and scientific applications. Wound Repair and Regeneration. 2005;4((Suppl)):S1-S11. Download from Wiley InterScience
  • Sculpher M, Claxton K. Establishing the cost-effectiveness of new pharmaceuticals under conditions of uncertainty - when is there sufficient eveidence Value in Health. 2005;8:433-46. Download from Wiley InterScience
  • Sculpher M, Claxton K, Akehurst R. It's just evaluation for decision-making: recent developments in, and challenges for, cost-effectiveness research. In: Smith PC, Ginnelly L, Sculpher M, editors. Health policy and economics: opportunities and challenges: Maidenhead: Open University Press; 2005. p. 8-41.
  • Smith PC, Ginnelly L, Sculpher M. (eds) Health policy and economics. Opportunities and challenges. Maidenhead: Open University Press; 2004.
  • Woolacott N, Hawkins N, Mason A, Kainth A, Khadjesari Z, Bravo Vergel Y, Misso K, Light K, Chalmers R, Sculpher M, Riemsma R. Etanercept and Infliximab for the treatment of psoriasis. Health Technology Assessment 2005.
  • Wilby J, Kainth A, Hawkins N, Epstein D, McIntosh H, McDaid C, Mason A, Golder S, O'Meara S, Sculpher M, Drummond M, Forbes C. A rapid and systematic review of the clinical effectiveness, tolerability and cost effectiveness of newer drugs for epilepsy in adults. Health Technology Assessment 2005;9(15):1-172. 
  • Willan AR, Lin DY, Manca A. Regression methods for cost-effectiveness analysis with censored data. Statistics in Medicine. 2005;24(1):131-45.

 2004 

  • Ades AE, Lu G, Claxton K. Expected value of sample information calculations in medical decision modelling. Medical Decision Making 2004;24:207-27. Download from Sage Journals Online
  • Arksey H, Jackson K, Mason A, Wallace A, Weatherly H. Support services for carers: methodological issues in evaluating the literature. Research Works 2004. Download from SPRU
  • Arksey H, Weatherly H. Respite care and short breaks: what works and at what cost? Journal of Demential Care 2004;12:33-37. Download from SPRU
  • Barbieri M, Wong JB, Drummond MF. The cost-effectiveness of infliximab for treatment of severe rheumatoid arthritis in the united Kingdom. Forthcoming in: PharmacoEonomics 2004.
  • Bridle C, Palmer S, Bagnall AM, Darba J, Duffy S, Sculpher M, Riemsma R. A rapid and systematic review and economic evaluation of the clinical and cost-effectiveness of newer drugs for treatment of mania associated with bipolar affective disorder. Health Technology Assessment 2004;8(19):1-200. 
  • Briggs A, Buxton M, Drummond M, Goeree R, Sculpher MJ, Willan A. Unfinished symphony: a tribute to the life and career of Bernie O'Brien (1959-2004). Medical Decision Making 2004;24(5):538-544. Download Sage Journals Online
  • Brown LC, Epstein D, Manca A, Beard JD, Powell JT, Greenhalgh RM. The UK Endovascular Aneurysm Repair (EVAR) Trials: design, methodology and progress. European Journal of Vascular and Endovascular Surgery 2004;27(4):372-381. Download from Pub Med
  • Claxton K, Fenwick E, Palmer S, Sculpher M, Abrams K, Sutton A. Building a reference case for Bayesian applications to health economics and outcome research. CHE Technical Paper 35 (PDF , 5,325kb)‌: York: Centre for Health Economics; 2004. 
  • Claxton K, Ginnelly L, Sculpher MJ, Philips Z, Palmer S. A pilot study on the use of decision theory and value of information analysis as part of the National Health Service Health Technology Assessment Programme. Health Technology Assessment 2004;8(31):1-118. 
  • Cook J, Drummond M, Heyse JF. Economic endpoints in clinical trials. Statistical Methods in Medical Research 2004;13:157-176. 
  • Cook JR, Yin D, Alemao E, Drummond M. Development and validation of a model to project the long-term benefit and cost of alternative lipid-lowering strategies in patients with hypercholesterolaemia. Pharmacoeconomics 2004;22(Suppl 3):37-48. Download from Pub Med
  • Drummond M. Bridging the credibility gap in company-sponsored outcomes research. Spectrum: Pharmacoeconomics, Pricing, and Reimbursement (Paper): Waltham MA: Decision Resources; 2004 May.
  • Drummond M, Chancellor J, Duprat-Lomon I, Sagnier PP, Barbieri M, Martin M. Moxifloxacin in hospital treatment of community-acquired pneumonia: a cost-effectiveness analysis across four European countries. European Journal of Hospital Pharmacy 2004;2:67-75.
  • Drummond M. Economic evaluation in health care: is it really useful or are we just kidding ourselves? Australian Economic Review 2004;37(1):3-11. Download from Wiley InterScience
  • Drummond M. Cost effectiveness of lipid-lowering therapy: let's get real. Pharmacoeconomics 2004;22(Suppl 3).
  • Fenwick E, O'Brien B, Briggs A. Cost-effectiveness acceptability curves: facts, fallacies and FAQ. Health Economics 2004;13:405-415. Download from Wiley InterScience
  • Garry R, Fountain J, Brown J, Manca A, Mason S, Sculpher M, Napp V, Bridgman S, Gray J, Lilford R. EVALUATE hysterectomy trial: a multicentre randomised trial comparing abdominal, vaginal and laparoscopic methods of hysterectomy. Health Technology Assessment 2004;8(26):1-154.
  • Ginnelly L, Sculpher M, Bojke C, DiGuseppi C, Roberts I, Wade A. Determining the cost effectiveness of a smoke alarm give-away program using data from a randomised controlled trial. European Journal of Public Health 2004. Download from Oxford Journals
  • Godfrey M, Keen J, Moore J, Ware P, Hardy R, West R, Weatherly H, Henderson K. An evaluation of intermediate care for older people: A report prepared for the Department of Health 2004;pp508. Download from University of Leeds
  • Gulacsi L, Boncz I, Drummond M. Issues for countries considering introducing the "fourth hurdle": the case of Hungary. International Journal of Technology Assessment in Health Care 2004;20(3):337-41.
  • Heslop P, Byford S, Weatherly H, Jones V. Better rewards.  The costs and effectiveness of employing salaried support carers to reduce waiting lists for short-term care.: York Publishing Services: York 2004. Download from SCIE
  • Hicks L, Gibbs I, Byford S, Weatherly H. Cost information on local authority and non-statutory sector community homes for children. In: Netten A, Curtis L, editors. Unit costs of health and social care. Canterbury: Personal Social Services Research Unit, University of Kent at Canterbury; 2004.
  • Jones L, Griffin S, Palmer S, Main C, Orton V, Sculpher M, Sudlow C, Henderson R, Hawkins N, Riemsma R. Clinical effectiveness and cost-effectiveness of clopidogrel and modified-release dipyridamole in the secondary prevention of occlusive vascular events: a systematic review and economic evaluation. Health Technology Assessment 2004;8(38):1-210. 
  • Jones L, Hawkins N, Westwood M, Wright K, Richardson G, Riemsma R. Systematic review of the clinical effectiveness and cost-effectiveness of capecitabine (Xeloda) for locally advanced and/or metastatic breast cancer. Health Technology Assessment 2004;8(5):1-143. 
  • Kennedy A, Nelson E, Reeves D, Richardson G, Roberts C, Robinson A, Rogers A, Sculpher M, Thompson D. A randomised controlled trial to assess effectiveness and cost of a patient orientated self-management approach to chronic inflammatory bowel disease. Gut 2004;53:1639-1645. Download from BMJ
  • Kaltenthaler E, Bravo Vergel Y, Chilcott J, Thomas S, Blakeborough T, Walters S, Boucher H. A systematic review and economic evaluation of magnetic resonance cholangiopancreatography compared to diagnostic endoscopic retrograde cholangiopancreatography. Health Technology Assessment 2004;8. 
  • Main C, Palmer S, Griffin S, Jones L, Orton V, Sculpher M, Henderson R, Sudlow C, Hawkins N, Riemsma R. Clopidogrel used in combination with aspirin alone in the treatment of non-ST-segment-elevation acute coronary syndromes: a systematic review and economic evaluation. Health Technology Assessment 2004;8(40):1-176. 
  • Mauskopf J, Drummond M. Publication of pharmacoeconomic data submitted to reimbursement or clinical guidelines agencies. Value in Health 2004;7(5):515-516.
  • Mason A, Drummond M, Towse A, Cooke J. Influencing prescribing in English primary care: the views of primary care organisations. Journal of Health Services Research and Policy 2004;9(3):153-158. 
  • McCarthy JC, Mills PM, Pullen R, Richardson G, Hawkins N, Roberts C, Silman A, Oldham J.Supplementation of a home-based exercise programme with a class-based programme for people with osteoarthritis of the knees: a randomised controlled trial and health economic analysis. Health Technology Assessment 2004;8 (46)1-76. 
  • McGuire A, Drummond M, Rutten F. Reimbursement of pharmaceuticals in the European Union. In: Mossialos E MM, Walley T, editor. Regulating pharmaceuticals in Europe: striving for efficiency, equity and quality: Maidenhead: Open University Press; 2004. pp. 130-143.
  • Nixon J, Duffy S, Armstrong N, Craig D, Glanville JM, Christie J, Drummond MF, Kleijnen J. The usefulness of the NHS Economic Evaluation Database to researchers undertaking technology assessment reviews. International Journal of Technology Assessment in Health Care 2004;20(3):249-257.
  • Nixon J, Ulmann P, Glanville J, Boulenger S, Drummond MF, de Pouvourville G. The European Network of Health Economic Evaluation Databases (EURO NHEED) Project. European Journal of Health Economics 2004;5:183-187. Download from Pub Med
  • Philips Z, Ginnelly L, Sculpher M, Claxton K, Golder S, Riemsma R, Woolacoot N, Glanville J. Review of guidelines for good practice in decision-analytic modelling in health technology assessment. Health Technology Assessment 2004;8(36):1-172. 
  • Rascati K, Drummond MF, Annemans L, Davey PG. Education in pharmacoeconomics: an international multidisciplinary view. Pharmacoeconomics 2004;22(3):139-147. Download from Ingenta Connect
  • Richardson G, Godfrey L, Gravelle H, Watt I. Cost-effectiveness of implementing new guidelines for treatment of hypertension in general practice. British Journal of General Practice 2004;54(507):765-771. Download from Ingenta Connect
  • Richardson G, Manca A. Calculation of quality adjusted life years in the published literature: a review of methodology and transparency. Health Economics 2004;13(12):1203-1210. Download from Wiley InterScience
  • Richardson G, Wonderling D, Simon J, Wailoo A, Douglas HR, Culyer AJ, Tsuchiya A, Roberts J, Drummond MF, on behalf of Health Economists in Guidelines. Incorporating health economics in guidelines and assessing resource impact. In: Developing clinical guidelines: technical manual. London: NICE; 2004.
  • Sculpher MJ, Pang FS, Manca A, Drummond MF, Golder S, Urdahl H, Davies LM, Eastwood A. Generalisability in economic evaluation studies in healthcare: a review and case studies. Health Technology Assessment 2004;8(49):1-206. 
  • Sculpher MJ, Bryan S, Fry P, de Winter P, Payne H, Emberton M. Patients' preferences for the management of non-metastatic prostate cancer: a discrete choice experiment. BMJ 2004;328:382-384. Downlaod from BMJ
  • Sculpher M, Manca A, Abbott J, Fountain J, Mason S, Garry R. Cost effectiveness analysis of laparoscopic hysterectomy compared with standard hysterectomy: results from a randomised trial. BMJ 2004;328(7432):134-139. Download from BMJ
  • Smith DH, Fenn P, Drummond M. Cost effectiveness of photodynamic therapy with verteporfin for age related macular degeneration: the UK case. British Journal of Ophthalmology 2004;88(9):1107-12. Download from BMJ
  • Smith PC, Ginnelly L, Sculpher M. Health policy and economics. Opportunities and challenges. Maidenhead: Open University Press; 2004. Download from Open University Press
  • Wright J, Clarke M, Donlan C, Lister C, Weatherly H, Newton C, Cherguit J, Newton E. Evaluation of the Communication Aids Project. Research Report (and Research Brief) Number 580. Department for Education and Skills. 2004. Download from DCFS
  • UK Beam Trial Team, Russell I, Underwood M, Brealey S, Burton K, Coulton S, Farrin A, Garratt A, Harvey E, Letley L, Manca A, Martin J, Klaber Moffett J, Morton V, Torgerson D, Vickers M, Whyte K, Williams M. United Kingdom back pain exercise and manipulation (UK BEAM) randomised trial: effectiveness of physical treatments for back pain in primary care. BMJ 2004;329:1377-1384. Download from BMJ
  • UK Beam Trial Team, Russell I, Underwood M, Brealey S, Burton K, Coulton S, Farrin A, Garratt A, Harvey E, Letley L, Manca A, Martin J, Klaber Moffett J, Morton V, Torgerson D, Vickers M, Whyte K, Williams M. United Kingdom back pain exercise and manipulation (UK BEAM) randomised trial: cost effectiveness of physical treatments for back pain in primary care. BMJ 2004;329:1381-1386. Download from BMJ

2003 

  • Asplund K, Ashburner S, Cargill K, Hux M, Lees K, Drummond M, for the Gain International Investigators. Healthcare resource use and stroke outcome: multinational comparisons within the GAIN international trial. International Journal of Health Technology Assessment in Health Care 2003;19(2):267-277.
  • Bagnall A-M, Jones L, Ginnelly L, Lewis R, Glanville J, Gilbody S, Davies L, Torgerson D. A systematic review of atypical antipsychotic drugs in schizophrenia. Health Technology Assessment 2003;7(13):1-502. 
  • Bagnall A-M, Jones L, Richardson G, Duffy S, Riemsma R. Effectiveness and cost-effectiveness of acute hospital-based spinal cord injuries services: systematic review. Health Technology Assessment 2003;7(19):1-304. 
  • Bravo Vergel Y, Ferguson B. Difficult commissioning choices. A proposed framework for priority setting and a comparative analysis of rationing policies across West Yorkshire & NEYNL PCTs.: Nuffield Institute for Health, University of Leeds; 2003.
  • Chilcott J, McCabe C, Tappenden P, O'Hagan A, Cooper NJ, Abrams K, Claxton K. Modelling the cost-effectiveness of interferon beta and glatiramer acetate in the management of multiple sclerosis. British Medical Journal. 2003;326:522-6. Download from BMJ
  • Cook J, Drummond MF, Heyse J. Economic endpoints in clinical trials. Statistical Methods in Medical Research 2003;22:1955-1976. Download from Sage Journals Online
  • Cook JR, Drummond MF, GLick H, Heyse JF. Assessing the appropriateness of combining economic data from multinational clinical trials. Statistics in Medicine 2003;22:1955-1976 Download from Wiley InterScience
  • Craig D, Nixon J, Armstrong N, Glanville J, Kleijnen J, Drummond M. New BMJ policy on economic evaluation: response of NHS Economic Evaluation Database research team (letter). BMJ 2003;326:445. Download from BMJ
  • Cunningham SJ, Sculpher M, Sassi F, Manca A. A cost-utility analysis of patients undergoing orthognathic treatment for the management of dentofacial disharmony. British Journal of Oral and Maxillofacial Surgery 2003;41(1):32-35. Download from Pub Med
  • Dowie J, Claxton K, Sculpher M, Drummond M. NICE (and the NHS) - quo vadis. In: Oliver A, editor. Health care priority setting: implications for health inequalities Proceedings from a meeting of the Health Equity Network: London: The Nuffield Trust; 2003. p. 9-15.
  • Drummond MF, Becker DL, Hux M, Chancellor JV, Duprat-Lomon I, Kubin R, Sagnier PP. An economic evaluation of sequential i.v./po moxifloxacin therapy compared to i.v./po co-amoxiclav with or without clarithromycin in the treatment of community-acquired pneumonia. Chest 2003;124(2):526-35. Download from CHEST
  • Drummond M, Donaldson C. In the land of blind decision making, is one-eyed economics the king? Applied Health Economics and Health Policy 2003;2(2):73-76.
  • Drummond M. Making economic evaluations more accessible to health care decision-makers. European Journal of Health Economics 2003;4(4):246-247. Download from SpringerLink
  • Drummond MF. Will there ever be a European drug price and reimbursement agency? European Journal of Health Economics 2003;2(4):67-69. Download from SpringerLink
  • Drummond M. Methodological issues in pharmacoeconomic submissions. Spectrum: Pharmacoeconomics, Pricing, and Reimbursement (Paper): Waltham MA: Decision Resources; 2003 June.
  • Drummond M, Brown R, Fendrick M, Fullerton P, Neuman P, Taylor R, Barbieri M. Use of pharmacoeconomics information: report of the ISPOR task force on use of parmacoeconomics/health economic information in health-care decision making. Value in Health 2003;6(4):407-416.
  • Gabriel S, Drummond M, Maetzel A, Boers M, Coyle D, Welch V, Tugwell P. OMERACT 6 Economics Working Group report: a proposal for a reference case for economic evaluation in rheumatoid arthritis. Journal of Rheumatology 2003;30(4):886-90. Download from Pub Med
  • Ginnelly L, Manca A. The use of decision models in mental health economic evaluation: challenges and opportunities. Applied Health Economics and Health Policy 2003;2(3):157-64.
  • Kennedy A, Nelson E, Reeves D, Richardson G, Roberts C, Robinson A, Rogers A, Sculpher M, Thompson D. A randomised controlled trial to assess the impact of a package comprising a patient-orientated, evidence-based self-help guidebook and patient-centred consultations on disease management and satisfaction in inflammatory bowel disease. Health Technology Assessment 2003;7(28). 
  • Kennedy ADM, Sculpher MJ, Coulter A, et al. A multicentre randomised controlled trial assessing the costs and benefits of using structured information and analysis of women's preferences in the management of menorrhagia. Health Technology Assessment 2003;7(8):86. 
  • Kremers HM, Gabriel SE, Drummond MF. Principles of health economics and application to rheumatic disorders. In: Hochberg M C SAJ, Smolen J S, Weinblatt M E, Weisman M H, editor. Rheumatology. 3rd ed: London: Mosby Publishing; 2003.
  • Macran S, Weatherly H, Kind P. Measuring population health: a comparison of three generic health status measures. Medical Care 2003;41(2):218-231. Download from Medical Care
  • Maetzel A, Tugwell P, Boers M, Guillemin F, Coyle D, Drummond M, Wong JB, Gabriel SE. Economic evaluation of programs or interventions in the management of rheumatoid arthritis: defining a consensus-based reference case. Journal of Rheumatology 2003;30(4):891-6. Download from Pub Med
  • Manca A, Sculpher MJ, Ward K, Hilton P. A cost-utility analysis of tension-free vaginal tape versus colposuspension for primary urodynamic stress incontinence. BJOG: An International Journal of Obstetrics and Gynaecology 2003;110:255-262. 
  • Mohr P, Cheng M, Claxton K, Conley R, Feldman A, Hargreaves W, et al. Capturing the heterogeneity of schizophrenia in economic models. Schizophrenia Research. 2003;71(1):83-95.
  • Nixon J, Duffy SB, Craig D, Armstrong N, Christie J, Glanville JM, Drummond MF, Kleijnen J. Improving outcomes through access to critiqued economic evaluations: the NHS Economic Evaluation Database within the HTA review process. Value in Health 2003;6(3):211.
  • Stearns SC, Drummond M. Grading systems for cost-effectiveness studies: is the whole greater than the sum of the parts? (editorial). Medical Care 2003;41(1):1-3. Download from Pub Med
  • Torrance GW, Drummond MF, Walker V. Switching therapy in health economic trials: confronting the confusion. Medical Decision making 2003;23:335-340. Download from Sage Journals Online
  • Wells N, Hettiarachchi J, Drummond M, Carter D, Parpia T, Pang F. A cost-effectiveness analysis of eletriptan 40 and 80 mg versus sumatriptan 50 and 100 mg in the acute treatment of migraine. Value in Health 2003;6(4):438-447.

2002 

  • Armstrong N, Drummond M, Nixon J, Craig D, Glanville J. How do we judge the quality of economic evaluations? Journal of Clinical Excellence 2002;4(3):345-7. Download from Ingenta Connect
  • Busse R, Orvain J, Velasco M, Perleth M, Drummond M, Gurtner F, et al. Best practice in undertaking and reporting health technology assessments: Working Group 4 report. International Journal of Technology Assessment in Health Care 2002;18(2):361-422.
  • Claxton K, Manca A, Sculpher M. Advanced topics in economic evaluation. Module workbook: York: University of York; 2002.
  • Claxton K, Sculpher M, Drummond M. A rational framework for decision making by the National Institute for Clinical Excellence. Lancet 2002;360:711-715. Download from Pub Med
  • Currie GR, Donaldson C, O'Brien BJ, Stoddart GL, Torrance GW, Drummond MF. Willingness to pay for what? a note on alternative definitions of health care program benefits for contingent valuation studies. Medical Decision Making 2002;22:493-7. Download from Sage Journals Online
  • DiGuiseppi C, Roberts I, Wade A, Sculpher M, Edwards P, Godward C, Pan H, Slater S. Incidence of fires and related injuries after giving out free smoke alarms: cluster-randomised controlled trial. BMJ 2002;325:995-7. Download from BMJ
  • Drummond M. Time for a change in drug licensing requirements? European Journal of Health Economics 2002;3:137-8. Download from SpringerLink
  • Drummond M. Nasty or NICE? The formal requirements for economic evaluation of pharmaceuticals in England and Wales. Pharmaceutical News 2002;9:57-62.
  • Drummond M. Should commercial-in-confidence data be used by decision makers when making assessments of cost-effectiveness? Applied Health Economics and Health Policy 2002;1(2):53-4. Download from Pub Med
  • Drummond M. The relevance of health economic evaluation to health care decision makers: Waltham MA: Decision Resources; 2002.
  • Drummond MF. Method without madness. Expert Review of Pharmacoeconomics & Outcomes Research 2002;1(2):305-7. Download from Expert Reviews
  • Drummond MF. Evidence-based medicine meets economic evaluation: an agenda for research. In: Donaldson C, Mugford M, Vale L, editors. Evidence-based health economics: London: BMJ Books; 2002.
  • Fenwick E, Wilson J, Sculpher M, Claxton K. Pre-operative optimisation employing dopexamine or adrenaline for patients undergoing major elective surgery: a cost-effectiveness analysis. Intensive Care Medicine 2002;28:599-608. Download from Pub Med
  • Forbes C, Wilby J, Richardson G, Mather L, Sculpher M, Riemsma R. A rapid and systematic review of the clinical effectiveness and cost effectiveness of pegylated liposomal doxorubicin hydrochloride (Caelyx UK, Doxil, USA) for ovarian cancer. Health Technology Assessment 2002;6(23):1-119.
  • Fukuhara S, Ikegami N, Torrance GW, Nishimura S, Drummond M, Schubert F. The development and use of quality-of-life measures to evaluate health outcomes in Japan. Pharmacoeconomics 2002;20 (Suppl 2):17-23. Download from Pub Med
  • Heyse JF, Cook JR, Drummond MF. Pharmacoeconomics. In: Encyclopedia of biopharmaceutical statistics: New York: Mercel Dekker; 2002.
  • Hoffmann C, Stoykova B, Nixon J, Glanville J, Misso K, Drummond M. Letters to the editor. Value in Health 2002;5(2):114.
  • Hoffmann C, Stoykova BA, Nixon J, Glanville JM, Misso K, Drummond MF. Do health-care decision makers find economic evaluations useful? The findings of focus group research in UK health authorities. Value in Health 2002;5(2):71-78. 
  • Ikegami N, Drummond M, Fukuhara S, et al. Why has the use of health economic evaluation in Japan lagged behind that in other developed countries? Pharmacoeconomics 2002;20 (Supp 2):1-7. Download from Pub Med
  • Kennedy ADM, Sculpher MJ, Coulter A, et al. Effects of decision aids for menorrhagia on treatment choices, health outcomes, and costs: a randomized controlled trial. JAMA 2002;288(21):2701-2708. Download from JAMA
  • Laking GR, Price PM, Sculpher MJ. Assessment of the technology for functional imaging in cancer. European Journal of Cancer 2002;38:2194-2199. Download from Ingenta Connect
  • Levine M, Taylor R, Ryan M, Sculpher M. Decision-making by healthcare payers. Respiratory Medicine 2002;96 Suppl C:S31-S38. Download from Pub Med
  • Manca A, Sculpher MJ. Levonorgestrel-releasing intrauterine system for menorrhagia improved quality of life but cost less than hysterectomy. Commentary. Evidence-Based Obstetrics and Gynaecology 2002;4:24-5.
  • Mason A, Towse A, Drummond M, Cooke J. Influencing prescribing in a primary care led NHS: London: Office of Health Economics; 2002.
  • Nishimura S, Torrance GW, Ikegami N, Fukuhara S, Drummond M, Schubert F. Information barriers to the implementation of economic evaluations in Japan. Pharmacoeconomics 2002;20(Suppl 2):9-15.
  • Nixon J, Phipps K, Glanville J, Mugford M, Drummond M. Using economic evidence to support decision making: a case study of assertive community treatment with the UK National Service Framework for Mental Health. Applied Health Economics and Health Policy 2002;1(4):179-90.
  • Richards DA, Meakins J, Tawfik J, Godfrey L, Dutton E, Richardson G, Russell D. Nurse telephone triage for same day appointments in general practice: multiple interrupted time series trial of effect on workload and costs. BMJ 2002;325:1214-7. Download from BMJ
  • Robinson M, Ginnelly L, Sculpher M, Jones L, Riemsma R, Palmer S, et al. A systematic review update of the clinical effectiveness and cost-effectiveness of glycoprotein IIb/IIIa antagonists. Health Technology Assessment 2002;6(25):1-160. 
  • Robinson M, Manning R, Petticrew M, Rice N, Sculpher MJ, Sheldon T. Technological change in heart attack care in England. In: McClellan M KD, editor. Technological change in health care: a global analysis of heart attack: Ann Arbor: University of Michigan Press; 2002.
  • Rowland D, DiGuiseppi C, Roberts I, Curtis K, Roberts H, Ginnelly L, Sculpher M, Wade A. Prevalence of working smoke alarms in local authority inner city housing: randomised controlled trial. BMJ 2002;325:998-1001. Download from BMJ
  • Sculpher M, Gafni A, Watt I. Shared treatment decision making in a collectively funded health care system: possible conflicts and some potential solutions. Social Science and Medicine 2002;54:1369-1377. Download here
  • Sculpher M, Millson D, Meddis D, Poole L. Cost-effectiveness analysis of stratified versus stepped care strategies for acute treatment of migraine. The Disability in Strategies for Care (DISC) study. Pharmacoeconomics 2002;20(2):91-100. Download here
  • Sculpher MJ, Gafni A. Recognising diversity in public preferences: the use of preference sub-groups in cost-effectiveness analysis. (Authors' reply). Health Economics 2002;11:653-654. Download here
  • Sculpher MJ, Smith DH, Clayton T, et al. Coronary angioplasty versus medical therapy for angina: health service costs based on the Second Randomised Intervention Treatment of Angina (RITA-2) trial. European Heart Journal 2002;23:1291-1300. Download here
  • Smith DH, Fenn P, Drummond MF. Modelling the long-term benefits of photodynamic therapy (PDT) with verteporfin for age-related macular degeneration (AMD). CHE Discussion Paper 187 (PDF , 79kb)‌: York: Centre for Health Economics; 2002.
  • Weatherly H, Drummond MF, Smith D. Using evidence in the design of health improvement programmes: report to the Department of Health. CHE Occasional Paper 42 (PDF , 257kb)‌: York: Centre for Health Economics; 2002.
  • Weatherly H, Drummond M, Smith D. Using evidence in the development of local health policies: Some Evidence from the United Kingdom. International Journal of Technology Assessment in Health Care. 2002;18(4):771-81. Download from Cambridge Journals
  • Weatherly H, Jones V, Byford S, et al. Breakthrough. Community Care 2002;1447:34-5.
  • Weaver N, Williams JL, Weightman AL, Kitcher HN, Temple JMF, Jones P, Palmer S. Taking STOX: developing a cross disciplinary methodology for systematic reviews of research on the built environment and the health of the public. Journal of Epidemiology and Community Health 2002;56:48-55.